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Abstract 
About 60-80% of nursing home patients with dementia have neuropsychiatric 
symptoms such as depression, agitation, and sleep disturbances. These may be 
debilitating and detrimental to the person’s quality of life. Both neuropsychiatric 
symptoms and pain become more frequent in people with advanced dementia. Because 
they have reduced ability to verbally express their symptoms, undiagnosed and 
untreated pain may trigger neuropsychiatric symptoms in these individuals.   
Depression is one of the most prevalent neuropsychiatric symptoms in dementia, 
affecting approximately one of two persons in the course of dementia. Cross-sectional 
studies have found that about 20% of nursing home patients with dementia have 
clinically significant depressive symptoms which often persist over time, and many 
receive antidepressants. However, recent randomised placebo-controlled trials and 
meta-analyses have shown absence of benefit from antidepressant treatment and 
increased risk of adverse events in this population. 
Our research group has previously conducted a randomised controlled trial to 
investigate whether a stepwise protocol for treating pain reduced agitation in nursing 
home patients with dementia and agitation. Secondary analyses suggest that analgesic 
treatment may also reduce mood symptoms such as depression and apathy. However, 
the trial was not placebo-controlled, depression was not the primary outcome, and 
many participants did not have depression. Therefore, this project was planned in order 
to follow-up previous results with a placebo-controlled design including people with 
dementia and depression. 
The relationship between pain and depression has been called the pain-depression 
dyad, implying that the conditions often coexist and exacerbate each other. This 
relationship is even more complex in people with dementia and reduced ability to 
communicate. Many also have multimorbidity, and polypharmacy is a common 
problem which poses an additional risk for drug interactions and drug related harm. 
Therefore, pain treatment must be individually tailored in order to the patient’s needs. 
While it is clearly inappropriate to treat all people with dementia and depression with a 
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single type and dose of analgesic drug to relieve possible pain, we have aimed to 
identify participants who may benefit from a stepwise protocol for treating pain while 
attempting to minimise the risk of harm. 
This thesis consists of three papers, and aims to investigate the impact of pain on the 
severity and progression of depressive symptoms over time in nursing home patients at 
different stages of dementia, and to evaluate the efficacy and tolerability of analgesic 
treatment for depression in people with moderate to severe dementia and depression. 
Data from three different studies constitute the source material for this thesis. Paper I 
combines prospective observational data from two cohorts: the REDIC (Resource Use 
and Disease Course in Dementia) population was followed for 6 months after nursing 
home admission. The COSMOS (COmmunication, Systematic pain assessment and 
treatment, Medication review, Organised activities and Safety) population includes 
people with varying lengths of nursing home stay who were followed for 4 months 
after inclusion. Paper II and Paper III use data from DEP.PAIN.DEM (Efficacy of pain 
treatment on depression in people with dementia), a randomised, placebo-controlled 
trial which assessed the efficacy of analgesic treatment for depressive symptoms in 
nursing home patients with advanced dementia and depression.  
Aims 
Paper I aims to determine whether the severity of pain and depressive symptoms were 
associated in people at different stages of dementia, and whether having pain at 
baseline was associated with future worsening of depression. 
Paper II aims to determine the efficacy of a stepwise increase in analgesic treatment 
for depressive symptoms in nursing home patients with moderate to severe dementia 
and depression. 
Paper III aims to assess the tolerability and adverse events of transdermally 
administered buprenorphine in nursing home patients with moderate to severe 
dementia and depression, and whether tolerability is affected by cognitive function and 
concomitant drug use. 
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Methods 
In Paper I, we used data from one prospective cohort study (REDIC) including 684 
people aged ≥65 with assessments at baseline and after 6 months, and one randomised 
controlled trial (COSMOS) including 67 units (clusters) that were randomised to 
receive a complex intervention or care as usual. From the latter group, 248 participants 
aged ≥65 years with assessments at baseline and after 4 months were included in the 
analyses. In both studies, pain was assessed using the Mobilisation-Observation-
Behaviour-Intensity-Dementia-2 (MOBID-2) Pain Scale, depression with the Cornell 
Scale for Depression in Dementia (CSDD), and cognitive function with the Mini-
Mental State Examination (MMSE). 
Paper II and Paper III present the primary and secondary analyses, respectively, from a 
randomised, placebo-controlled trial (DEP.PAIN.DEM) including 162 nursing home 
patients aged ≥60 years with moderate to severe dementia (MMSE ≤20) and 
depression (CSDD ≥8). Participants were prescribed an individual increase in 
analgesic treatment (paracetamol or buprenorphine), and were randomised to receive 
either active treatment or identical, inert placebo for 13 weeks with assessments at 
baseline, 6 and 13 weeks. In Paper II, the primary outcome was treatment effect on 
change in depressive symptoms (CSDD); secondary outcomes were treatment effect 
on change in pain (MOBID-2), and adverse events. Paper III included the 89 
participants who were prescribed buprenorphine (active/placebo). The primary 
outcome was time to discontinuation of active treatment compared to placebo, 
controlling for cognitive function and concomitant drug use. Secondary outcomes 
were adverse events associated with discontinuation, and treatment effect on daytime 
activity during the first week of treatment, measured by continuous actigraphy 
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In Paper I, we found that pain was significantly associated with depressive symptoms 
(regression coefficient (RC) .48, p<0.001). The association was replicated in 
subgroups with mild, moderate, and severe cognitive impairment. In the group 
followed from admission, depressive symptoms decreased over time, and having less 
pain at follow-up was associated with a decrease in depressive symptoms (within-
subject effect; p=0.042). 
In Paper II, we found that active analgesic treatment was associated with more 
persistent depressive symptoms compared to placebo. While depressive symptoms did 
not decrease significantly during active treatment from 0-13 weeks (mean change -
0.66, 95% CI -2.27; 0.94), the placebo group had a significant improvement in the 
same period (mean change -3.30, 95% CI -4.68; -1.92). The estimated treatment effect 
on depressive symptoms from 0-13 weeks was significant in favour of placebo (RC 
2.64, p=0.013). Paracetamol reduced pain significantly from 6-13 weeks (RC -1.11, 
p=0.037), but depressive symptoms did not improve secondary to reduced pain (RC 
1.58, p=0.313). 23 of 44 participants (52.3%) who received active buprenorphine were 
withdrawn from the trial due to adverse events (p<0.001). 
In Paper III, we found that those who received buprenorphine had 4.7 times increased 
risk of discontinuation compared to the placebo group (p=0.004). Adjusting for 
concomitant drug use, we found that the risk was further increased in those who used 
antidepressants. Use of antidepressants and buprenorphine (n=14) was associated with 
21.6 times increased risk of discontinuation compared to antidepressants and placebo 
(p=0.003). 9 participants in active treatment (20.5%) and 2 in the placebo group 
(4.4%) were excluded due to sedation or somnolence (p=0.022). Those who received 
buprenorphine had a significant 21% reduction in daytime activity on the second day 
of treatment (p=0.005), and mean daytime activity decreased by 13% during the first 





Despite observing that pain reduction was associated with less depressive symptoms in 
people with dementia, we were unable to detect a beneficial effect of an intervention 
with analgesic treatment on depressive symptoms compared to placebo. Contrarily, 
active treatment was associated with more persistent depressive symptoms compared 
to placebo, possibly due to adverse effects. In more than half of those who received 
buprenorphine, adverse events were reported. Known adverse effects of buprenorphine 
include somnolence, agitation, and anorexia, which may easily be mistaken for 
symptoms of depression or dementia in a clinical setting. Buprenorphine appears to be 
poorly tolerated in people with dementia. The risk and benefit of prescribing 
buprenorphine, and other opioid analgesics, to people with dementia and pain warrants 
further investigation. 
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Sammendrag 
Rundt 60-80 % av sykehjemspasienter med demens har nevropsykiatriske symptomer 
som depresjon, agitasjon og søvnforstyrrelser. Disse kan være svært hemmende og 
redusere individets livskvalitet betraktelig. Både nevropsykiatriske symptomer og 
smerter forekommer hyppigere hos personer med langtkommen demens. Fordi de har 
redusert evne til å uttrykke symptomer verbalt, kan udiagnostisert og ubehandlet 
smerte utløse nevropsykiatriske symptomer hos disse personene. 
Depresjon er ett av de vanligste nevropsykiatriske symptomene ved demens, og 
rammer omkring en av to personer gjennom demensforløpet. Tverrsnittstudier har 
funnet at omtrent 20 % av sykehjemspasienter med demens har klinisk relevante 
depresjonssymptomer som ofte vedvarer over tid, og mange behandles med 
antidepressiva. Imidlertid har flere større studier og metaanalyser av nyere dato funnet 
manglende effekt av antidepressiv behandling og økt risiko for bivirkninger i denne 
populasjonen. 
Vår forskningsgruppe har tidligere gjennomført en randomisert placebokontrollert 
studie for å undersøke om en trinnvis protokoll for behandling av smerte reduserte 
agitasjon hos sykehjemspasienter med demens og agitasjon. Sekundære analyser tyder 
på at smertebehandling også kan redusere stemningssymptomer som depresjon og 
apati. Denne studien var ikke placebokontrollert, depresjon var ikke det primære 
utfallsmålet, og mange deltakere hadde ikke depresjon. Dette prosjektet ble derfor 
planlagt for å undersøke om tidligere resultater kan gjenfinnes i en placebokontrollert 
studie som inkluderer personer med demens og depresjon. 
Forholdet mellom smerte og depresjon har blitt kalt smerte-depresjonsdyaden, dette 
innebærer at tilstandene ofte forekommer samtidig og virker gjensidig forverrende. 
Dette forholdet er enda mer komplekst hos personer med demens og redusert evne til å 
kommunisere. Mange har også multimorbiditet, og polyfarmasi er et vanlig problem 
som utgjør en tilleggsrisiko for legemiddelinteraksjoner og legemiddelrelaterte skader. 
Derfor må smertebehandling tilpasses personens individuelle behov. Det ville være 
uhensiktsmessig å behandle alle personer med demens og depresjon med ett enkelt 
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legemiddel for å lindre mulig smerte. Vi har forsøkt å identifisere personer som kan ha 
nytte av en trinnvis økning i smertebehandling, med minimal risiko for skade. 
Denne avhandlingen består av tre artikler, og har som mål å undersøke effekten av 
smerte på alvorlighetsgraden og utviklingen av depresjonssymptomer over tid hos 
sykehjemspasienter med ulike grader av demens, og å evaluere effekten og 
tolerabiliteten av behandling med analgetika mot depresjonssymptomer hos personer 
med moderat til alvorlig demens og depresjon. 
Data fra tre ulike studier utgjør kildematerialet til denne avhandlingen. Artikkel I 
kombinerer prospektive observasjonsdata fra to kohorter: REDIC-populasjonen 
(Ressursbruk og sykdomsforløp ved demens) ble fulgt i 6 måneder fra innleggelse på 
sykehjem. KOSMOS-populasjonen (KOmmunikasjon, Systematisk smertevurdering 
og -behandling, Medikamentgjennomgang, Organiserte aktiviteter og Sikkerhet) 
inkluderer pasienter med varierende lengde på sykehjemsoppholdet som ble fulgt i 4 
måneder fra inklusjon i studien. Artikkel II og Artikkel III bruker data fra 
DEP.PAIN.DEM-studien (Effekten av smertebehandling på depresjon hos personer 
med demens), en randomisert, placebokontrollert studie som undersøker effekten av 
smertebehandling på depressive symptomer hos sykehjemspasienter med 
langtkommen demens og depresjon. 
Mål 
I Artikkel I undersøker vi om alvorlighetsgraden av smerte og depresjonssymptomer er 
assosiert hos personer med ulik grad av demens, og hvorvidt det å ha smerte ved 
oppstart er assosiert med fremtidig forverring av depresjon. 
I Artikkel II undersøker vi effekten av en trinnvis økning av smertebehandling mot 
depressive symptomer hos sykehjemspasienter med moderat til alvorlig demens og 
depresjon. 
I Artikkel III undersøker vi tolerabilitet og bivirkninger av transdermalt administrert 
buprenorfin hos sykehjemspasienter med moderat til alvorlig demens og depresjon, og 
hvorvidt tolerabiliteten påvirkes av kognitiv funksjon og samtidig legemiddelbruk. 
  XIX 
Metode 
I Artikkel I brukte vi data fra en prospektiv kohortstudie (REDIC) som inkluderte 684 
pasienter ≥65 år med målinger ved oppstart og etter 6 måneder, og en randomisert 
kontrollert studie (KOSMOS) som inkluderte 67 enheter (klynger) som ble 
randomisert til å motta en kompleks intervensjon eller fortsette behandling som før. 
Fra sistnevnte gruppe inkluderte vi data fra 248 pasienter ≥65 år med målinger ved 
oppstart og etter 4 måneder. I begge studier ble smerte målt med MOBID-2 
(Mobilisation-Observation-Behaviour-Intensity-Dementia-2) smerteskala, depresjon 
med CSDD (Cornell skala for depresjon ved demens), og kognitiv funksjon med 
MMSE (Mini-Mental Status Evaluering).  
Artikkel II og Artikkel III presenterer henholdsvis primære og sekundære analyser fra 
en randomisert, placebokontrollert studie (DEP.PAIN.DEM) som inkluderte 162 
sykehjemspasienter ≥60 år med moderat til alvorlig demens (MMSE ≤20) og 
depresjon (CSDD ≥8). Pasientene fikk forskrevet en individualisert økning i 
smertebehandling (paracetamol eller buprenorfin), og ble randomisert til å motta enten 
aktiv behandling eller identisk, inaktiv placebo i 13 uker med målinger ved oppstart og 
etter 6 og 13 uker. I Artikkel II var hovedutfallsmålet effekten på endring i depressive 
symptomer (CSDD); sekundære utfallsmål var behandlingseffekten på endring i 
smerte (MOBID-2), og uønskede effekter. Artikkel III inkluderte de 89 pasientene som 
fikk forskrevet buprenorfin (aktiv/placebo). Hovedutfallsmålet var tid til seponering av 
aktiv behandling sammenlignet med placebo, kontrollert for kognitiv funksjon og 
samtidig legemiddelbruk. Sekundære utfallsmål var bivirkninger assosiert med 
seponering, og behandlingseffekten på dagtidsaktivitet under den første 
behandlingsuken, målt gjennom kontinuerlig aktigrafiregistrering fra 7 dager før til 7 
dager etter behandlingsoppstart. 
 
Resultater 
I Artikkel I fant vi at smerte var signifikant assosiert med depressive symptomer (RK 
(regresjonskoeffisient) .48, p<0.001). Assosiasjonen ble gjenfunnet i undergrupper 
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med mild, moderat og alvorlig demens. I gruppen av pasienter som ble fulgt fra 
sykehjemsinnleggelse falt depressive symptomer over tid, og redusert smerte ved 
oppfølging var assosiert med en samtidig reduksjon av depressive symptomer 
(individeffekt; p=0.042). 
I Artikkel II fant vi at aktiv smertebehandling var assosiert med mer vedvarende 
depressive symptomer sammenlignet med placebo. Mens depressive symptomer ikke 
falt hos gruppen som mottok aktiv behandling fra 0-13 uker (gjennomsnittlig endring -
0,66; 95 % KI (konfidensintervall): -2,27; 0,94), hadde placebogruppen en signifikant 
bedring i den samme perioden (-3,30; 95 % KI: -4,68; -1,92). Den beregnede 
behandlingseffekten viste signifikant bedring i placebogruppen (RK 2,64, p=0,013). 
Paracetamol ga signifikant redusert smerte fra 6-13 uker (RK -1,11, p= 0,037), men 
depressive symptomer viste ingen bedring sekundært til denne smertereduksjonen (RK 
1,58, p=0,313). 23 av 44 pasienter (52,3%) som mottok buprenorfin ble trukket fra 
studien på grunn av uønskede hendelser (p<0,001). 
I Artikkel III fant vi at pasienter som mottok buprenorfin hadde 4,7 ganger økt risiko 
for seponering sammenlignet med pasienter i placebogruppen (p=0,004). Justert for 
legemiddelbruk fant vi at risikoen var ytterligere økt hos pasienter som brukte 
antidepressiva. Bruk av antidepressiva og buprenorfin (n=14) var assosiert med 21,6 
ganger økt risiko for seponering sammenlignet med antidepressiva og placebo 
(p=0,003). 9 pasienter i buprenorfingruppen (20,5 %) og 2 pasienter i placebogruppen 
(4,4 %) ble ekskludert på grunn av sedasjon eller somnolens (p=0,022). Pasienter som 
mottok buprenorfin hadde en signifikant 21 % reduksjon i dagtidsaktivitet på 2. 
behandlingsdag (p=0,005), og gjennomsnittlig dagtidsaktivitet ble redusert med 13 % i 




Til tross for at vi fant at smertereduksjon var assosiert med reduserte depressive 
symptomer hos personer med demens, kunne vi ikke påvise noen bedring av 
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depressive symptomer ved behandling med analgetika sammenlignet med placebo. Vi 
fant det motsatte, nemlig at aktiv behandling var assosiert med mer vedvarende 
depressive symptomer sammenlignet med placebo, muligens på grunn av bivirkninger. 
Hos mer enn halvparten av pasientene som mottok buprenorfin ble det rapportert om 
uønskede hendelser. Kjente bivirkninger av buprenorfin inkluderer somnolens, 
agitasjon og anoreksi, disse kan lett forveksles med symptomer på depresjon eller 
demens i klinikken. Buprenorfin ser ut til å tolereres dårlig hos personer med demens. 
Risiko og nytte ved bruk av buprenorfin og andre opioidanalgetika hos personer med 
demens og smerter bør undersøkes videre. 
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1. Introduction 
1.1 Dementia 
Dementia is characterized by progressive neurodegenerative and/or vascular damage 
to the central nervous system, which causes impairment of memory and executive 
function. Neurodegeneration is a part of the normal aging process, and it is still 
unclear what causes these changes to develop to dementia in some individuals. As the 
amount of neurodegeneration increases with age, so does the incidence of dementia. 
In Western Europe, the prevalence of dementia in people aged 65-74 years is 4.6%, 
rising to 12.5% in those aged 75-84 years and 36.3% in those aged 85 years or more.1 
Thus, while dementia or “senility” is no longer regarded as a part of normal aging, it 
is inherently linked to old age, and the number of people living with dementia is 
expected to rise in the near future as a result of increased life expectancy and lower 
birth rates.1,2 
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition 
(DSM-5) criteria, dementia, or ‘major neurocognitive disorder’, can be diagnosed 
when a person experiences significant decline relative to previous performance in one 
or more cognitive domains such as language, learning and memory, or executive 
function, when these deficits interfere with their ability to function independently, 
and they cannot be explained by other causes like delirium or depression. The 
International Classification of Diseases, 10th revision (ICD-10) lists similar criteria 
for the dementia diagnosis. In addition, the ICD-10 requires a duration of minimum 6 
months, combined with a decline in emotional control or motivation or a change in 
social behaviour. The latter criterion requires the presence of at least one of the 
following symptoms: emotional lability, irritability, apathy, or coarsening of social 
behaviour. 
As reflected in these criteria, the progression of dementia leads to loss of 
independence – in fact, dementia is the leading cause of disability and need for 
chronic care in old age.3 In 2015, the estimated annual global cost of dementia was 
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818 billion US$, and approximately 47 million people were living with dementia 
worldwide.4 This number is expected to nearly double every 20 years, and pass 131 
million by 2050.1 Much effort has been invested in research on potential drugs that 
can slow or cure the progression of dementia, but none have been successful. 
Acetylcholinesterase inhibitors or memantine may improve symptoms in mild to 
moderate dementia, but have no effect on disease progression.5 
Being diagnosed with dementia is the strongest predictor of future admission to long-
term nursing home care, and half of individuals with dementia are institutionalized 
after 5-6 years – generally because of a combination of impaired cognitive function, 
behavioural disturbances, and physical impairment.6-10 In 2015, just short of 40 000 
nursing home beds were registered in Norway, and 33 547 people were registered 
with long-term nursing home placement.11 Recent estimates suggest that 84% of 
nursing home patients in Norway have dementia.12,13 
Ongoing research and recent developments 
Work on this thesis started in January 2014. From 2014 to the present day of writing, 
966 clinical trials related to the MeSH keyword ‘dementia’ were published in 
PubMed (MEDLINE) alone. A corresponding search for the combination ‘dementia’ 
and ‘depression’ retrieved 84 clinical trials, and the combination ‘dementia’ and 
‘pain’ retrieved 14 clinical trials. This illustrates the rapid development of the 
evidence base. Although the rationale for the DEP.PAIN.DEM trial was well 
established based on existing literature at the time this work was commenced, the 
publications that are included in this thesis were influenced by more recently 
published works. The last literature search for this thesis was conducted in July, 2018. 
1.1.1 Types of dementia 
While general diagnostic criteria can identify people who are likely to have dementia, 
a definitive diagnosis of dementia can only be made through post mortem 
examination. Dementia is classified according to the process leading to loss of 
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neuronal function, which may be neurodegenerative, vascular, or secondary to other 
disease or injury.  
Neurodegenerative dementia 
The most common cause of dementia in old age is Alzheimer’s disease, which 
accounts for approximately 60% of all dementia cases.14 The prevalence in nursing 
home patients may be higher, as a recent study found that 71% of people with 
dementia had Alzheimer’s disease at admission to nursing home placement.13 
Although the pathogenesis is still unclear, Alzheimer’s disease is characterized by 
deposition and accumulation of amyloid-β peptide into extracellular plaques, and 
formation of intracellular neurofibrillary tangles due to hyperphosphorylation and 
aggregation of the tau protein.15 These changes develop gradually over decades, 
starting long before any clinical symptoms become evident. The first region of the 
brain to be affected is the hippocampus, which is involved in the consolidation of 
new memories and in spatial orientation. The severity and rate of hippocampal 
atrophy can be used as a measure of the severity of Alzheimer’s disease.16 The next 
regions to be affected are the limbic system, which regulates functions such as 
emotion, pain processing, behaviour, motivation, and long-term memory, and the 
neocortex, which is involved in higher cognitive functions such as perception, spatial 
reasoning, conscious thought, and language.17-19 The severity of damage to these 
regions is also closely correlated to cognitive impairment.20  
Dementia with Lewy bodies is the second most common cause of neurodegenerative 
dementia, and accounts for approximately 20% of all recently diagnosed dementia 
cases according to updated diagnostic criteria.21,22 However, the prevalence in nursing 
home patients may be lower, as a recent study found that only 4% of nursing home 
patients with dementia admitted to nursing home placement had Lewy body 
dementia.13 The most prominent early symptoms are deficits in attention and 
executive function, with characteristic fluctuating alertness and cognitive 
performance, as well as impaired visuospatial ability.21 Visual hallucinations and 
psychiatric symptoms such as depression, anxiety, and psychosis are common. 
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Parkinsonism may also be a feature of dementia with Lewy bodies, which is 
distinguished from dementia in Parkinson’s disease by the temporal presentation of 
cognitive and motor impairment. 
Other causes of neurodegenerative dementia include frontotemporal dementia and 
Huntington’s disease, which – along with Alzheimer’s disease – are leading causes of 
early-onset dementia. Early-onset dementia is associated with accelerated disease 
progression and high mortality. Frontotemporal dementia and Huntington’s disease 
appear to follow a particularly malignant course.23 
Vascular dementia 
Vascular damage is considered the second most common cause of dementia in elderly 
people, and has been estimated to account for 26% of all dementia cases.24,25 In 
vascular dementia, neuronal damage is caused by a disruption in the blood vessels to 
the brain, which may be either haemorrhagic or ischemic due to infarction.26 The 
clinical presentation of vascular dementia depends on the type, severity, and 
localization of vascular damage, as well as the presence of any other 
neurodegenerative damage. Although memory often is more preserved in vascular 
dementia compared to Alzheimer’s dementia, the functional impairment may be more 
severe in vascular dementia because concurrent motor disability and mood symptoms 
are more frequent.26 
Most people with late-onset Alzheimer’s disease also have cerebrovascular lesions, 
and vascular damage is associated with more rapid progression of Alzheimer’s 
dementia.27 Vascular burden thus appears to play a part in the aetiopathogenesis of 
Alzheimer’s pathology, and Alzheimer’s dementia is not always clinically 
distinguishable from vascular dementia. Therefore, “mixed dementia” with 
Alzheimer’s and vascular pathology has been suggested to be the most common type 
of dementia, representing the middle ground in a continuous spectrum from pure 
Alzheimer’s to pure vascular pathology.14 
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Secondary dementia 
Dementia may less commonly develop as a secondary symptom of a pre-existing 
injury or disease process. Examples include Wernicke-Korsakoff syndrome, which is 
caused by thiamine deficiency and usually secondary to alcohol abuse.28 Infections, 
such as human immunodeficiency virus (HIV), or traumatic or toxic brain injury are 
other less common causes of dementia. 
1.1.2 Neuropsychiatric symptoms 
In addition to progressive cognitive impairment, neuropsychiatric symptoms (NPS) or 
behavioural and psychological symptoms of dementia (BPSD) are a core component 
of the dementia syndrome, regardless of the cause of dementia. The terms NPS and 
BPSD can be used interchangeably, but while NPS is the preferred term in the United 
States, BPSD is used by the International Psychogeriatrics Association.29 To clarify 
the similarities and differences between NPS and BPSD, the definitions are presented 
in Box 1. 
Neuropsychiatric symptoms will be used here as an umbrella term which includes the 
following 12 individual symptoms: delusions, hallucinations, depression/dysphoria, 
anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, 
aberrant motor activity, sleep disturbances, and appetite changes.30,31 Nearly all 
people with dementia have clinically significant neuropsychiatric symptoms at some 
stage of the disease; these symptoms are often troublesome and are strong predictors 







Box 1. Taxonomy for non-cognitive symptoms of dementia. 
Behavioural and psychiatric symptoms of dementia (BPSD) 
“…the term behavioural disturbances (should) be replaced by the term behavioural 
and psychiatric symptoms of dementia, defined as follows: Signs and symptoms of 
disturbed perception, thought content, mood, or behaviour that frequently occur in 
patients with dementia.”29 Although the following simple grouping of symptoms 
was suggested in 1996, the symptoms and symptom clusters have not been 
exhaustively described and multiple assessment scales are recommended for 
measuring individual symptoms and symptom clusters. 
- Behavioural symptoms: Usually identified on the basis of observation of 
the patient, including aggression, screaming, restlessness, agitation, 
wandering, culturally inappropriate behaviours, sexual disinhibition, 
hoarding, cursing and shadowing. 
- Psychological symptoms: Usually and mainly assessed on the basis of 
interviews with patients and relatives; these symptoms include anxiety, 
depressive mood, hallucinations and delusions. 
Neuropsychiatric symptoms (NPS) 
“This taxonomy chooses an empirically based syndromic approach to taxonomy 
rather than the identification of individual `target' symptoms (e.g., dysphoria or 
delusion) (…) This method begins by identifying individual symptoms in large 
populations of persons with Alzheimer’s disease, proceeds to analyse their inter-
relationships, and then defines clusters of disturbance.”33 Suggested diagnostic 
criteria for an ‘affective’ and a ‘psychotic’ disturbance in Alzheimer’s disease 
were based on the co-occurrence and relative severity of 
- Affective symptoms: depression; irritability; anxiety; euphoria. 
- Associated symptoms: aggression; psychomotor agitation; delusions; 
hallucinations; sleep disturbance; appetite disturbance. 
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Neuropsychiatric symptoms occur in more than 80% of people with any type of 
dementia at some stage of the disease.34 However, the prevalence and severity of 
individual neuropsychiatric symptoms may differ in accordance with the progression 
and underlying cause of dementia (i.e. the areas of the brain that are most affected). 
Environmental factors may also modulate the presentation of neuropsychiatric 
symptoms. For instance, in nursing home units that have a higher number of staff per 
patient and spend more time on patient care, there is a lower prevalence of apathy 
compared with units that have a lower care capacity.35 
Person-centred care for neuropsychiatric symptoms in dementia 
Person-centred care is based on the assumption that the person with dementia has 
unique needs which are shaped in relation to their physical and psychosocial 
surroundings and the care provided.36 The carer aims to identify unmet needs in order 
to improve quality of life for the person with dementia. Unmet psychosocial needs in 
nursing home patients with dementia may include aspects such as emotional distress, 
lack of emotional support, insufficient social interactions, loneliness, or need for day-
time activities.36 Physical and practical needs may include aspects of physical health, 
physical ability such as mobility, senses such as vision and hearing, self-care, 
accommodation, and so forth.36 In the perspective of person-centred care, 
neuropsychiatric symptoms are viewed as expressions of unmet needs which 
consequently may be treated by successfully identifying and meeting the person’s 
needs. For instance, while one person with dementia may thrive in a crowded 
environment, another person may experience confusion, anxiety or agitation due to 
sensory overstimulation in the same environment. A potential strategy to treat these 
symptoms may therefore be a change of environment to a quieter zone with one-to-
one contact. Similarly, symptoms of agitation, aggression or depression in people 
with dementia may be exacerbated by untreated pain.37-39 
The effectiveness of person-centred care for people with dementia has recently been 
investigated in a meta-analysis of nineteen interventional studies, which found 
 32
significant beneficial effects of the interventions on neuropsychiatric symptoms, 
agitation, depression, and quality of life.40 
1.2 Depression 
According to DSM-5 criteria, major depressive disorder is characterized by the core 
symptoms depressed mood (note: may be irritable mood in children/adolescents) 
and/or loss of interest or pleasure. In addition, changes in appetite or body weight, 
sleep pattern (insomnia or hypersomnia), psychomotor activity (agitation or 
retardation), fatigue or loss of energy, feelings of worthlessness or guilt, reduced 
ability to think, concentrate, or make decisions, and recurrent thoughts of death or 
suicidal ideation are listed as possible symptoms of depression. To fulfil the DSM-5 
diagnostic criteria, five or more symptoms including at least one of the core 
symptoms must have been present during the same two-week period, and represent a 
change from previous functioning. Furthermore, the symptoms must cause clinically 
significant distress or reduced ability to function, and cannot be attributed to other 
physical or mental disease. 
ICD-10 criteria describe similar symptoms typical of a depressive episode: lowered 
mood, reduced energy, decreased activity, impaired capacity for enjoyment, interest, 
and concentration, marked tiredness after even small efforts, disturbed sleep and 
diminished appetite, reduced self-esteem and self-confidence, and ideas of guilt and 
worthlessness. Furthermore, lowered mood in depression is described as fairly 
constant from day to day, unresponsive to circumstances, and may be accompanied 
by “somatic” symptoms such as: loss of interest and pleasurable feelings, waking in 
the morning several hours before the usual time, depression worst in the morning, 
marked psychomotor retardation, agitation, loss of appetite, weight loss, and loss of 
libido. Depending on the number of symptoms present and their severity, depression 
may be classified as mild, moderate, or severe. 
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1.2.1 Depression and dementia 
Depression is highly prevalent in all types of dementia, it is commonly one of the first 
presenting symptoms, and may even precede cognitive impairment as a prodromal or 
early symptom of a dementing disorder. In the most common dementia types, the 
patterns of neurodegenerative damage originate from the limbic system. Depression 
can be difficult to differentiate from early stages of dementia because the conditions 
share many core symptoms, such as lack of initiative, and impairment of memory and 
executive function.41 In late-life depression, defined as a major depressive episode 
occurring in an elderly person (60 years or older), it has been estimated that as many 
as 20-50% present with reduced cognitive function compared to non-depressed 
controls with comparable age and education level.42-44 While cognitive decline is 
progressive and irreversible in dementia, it should resolve completely upon 
successful treatment and remission of a depressive disorder. The now outdated term 
“depressive pseudodementia” has been used to describe such transient cognitive 
impairment caused by depression.44 Large longitudinal studies have shown that 
although elderly people with depression show improvement of cognitive function 
when depression is successfully treated, they may not return to the level of function 
they previously had, and furthermore they are at higher risk of future conversion to 
mild cognitive impairment and dementia compared to elderly people without a 
history of depression.45,46 Those who are older at depression onset, with lower 
baseline cognitive function and greater vascular burden, show less improvement in 
cognitive function upon remission.44,47 
Due to differences in study design, assessment and definition of depression, estimates 
of depression prevalence vary widely between studies. A recent meta-analysis of 
neuropsychiatric symptoms in people with Alzheimer’s disease found a pooled 
depression prevalence of 42%, while estimates from single studies ranged from 19-
78%.48 Although fewer studies have assessed depression in other dementia types, 
available data suggest that depression is even more prevalent in vascular dementia 
and dementia with Lewy bodies compared to Alzheimer’s dementia.49  
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In 2002, Olin et al. suggested provisional diagnostic criteria for depression in 
Alzheimer’s disease (Box 2).50 The criteria were adapted from the DSM-4 diagnostic 
criteria for major depressive disorder, which were deemed unsuitable for direct 
application in people with Alzheimer’s disease because they have been developed for 
patients with idiopathic psychiatric conditions, and greatly depend on the patient’s 
ability to verbally report subjective depressive symptoms.50 Furthermore, the authors 
described diagnostic challenges related to changes in behaviour such as loss of 
interest, withdrawal or social isolation which are not specific to depressed individuals 
with Alzheimer’s disease, as these behaviours may also be observed in people with 
dementia but no apparent mood disturbance.50  
Depression is often persistent or follows a fluctuating course in people with 
dementia.51-53 Irrespective of dementia diagnosis, depression becomes more prevalent 
with increasing dementia severity,54 causing increased suffering and reduced quality 
of life.55 Comorbid dementia and depression is associated with a more accelerated 
decline in daily functioning and cognition, and may thus contribute to earlier loss of 
independence and need for nursing home placement.7,56,57 Some evidence indicates 
that people with dementia and depression may be at risk of worse outcomes of 
medical treatment, such as rehabilitation after hip fracture, and increased mortality 
compared to those without depression.58-62 In order to mitigate these effects, treatment 
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Box 2. Provisional diagnostic criteria for depression in Alzheimer’s disease. Olin et 
al., 2002 (excerpt)50 
 
 
1.2.2 Treatment of depression in people with dementia 
The Norwegian Directorate of Health published updated guidelines for diagnosing 
and treating dementia in 2017, which include recommendations for treatment of 
depression in dementia.63 For people with mild cognitive impairment or dementia and 
mild/mild-to-moderate depression, environmental, psychosocial, and/or 
psychotherapeutic interventions are recommended as first-line treatment. 
Antidepressant treatment with a selective serotonin reuptake inhibitor (SSRI) should 
be offered as a supplement when needed, but only when individually tailored non-
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pharmacological interventions have been attempted without the desired effect. For 
treating people with moderate/severe depression, non-pharmacological interventions 
are recommended in combination with offering treatment with an antidepressant of 
the SSRI class. These recommendations are graded as weak, meaning that benefits 
outweigh harms for the majority, but not for everyone.63 In general, the guideline 
states that a weak recommendation could be based on unclear evidence for efficacy, 
or a finely balanced consideration of risk versus benefit. Therefore, the decision to 
start treatment will be influenced by other factors such as patient preference, 
comorbidity, polypharmacy, or burden of medical care.63 
The Norwegian national guideline for treating depression in dementia corresponds to 
recommendations from other national guidelines, as presented in a recent review.64 
Although most guidelines recommend use of an SSRI, e.g. citalopram or sertraline, 
when antidepressant treatment is indicated, some suggest that other classes such as 
noradrenergic and specific serotonergic antidepressants (NaSSAs), e.g. mirtazapine, 
may also be of benefit.64 SSRIs and NaSSAs are currently the most commonly used 
antidepressants in people with dementia and depression.64,65 The efficacy of SSRIs 
for treating depression in people with dementia has been assessed in five placebo-
controlled trials, while only one placebo-controlled trial has tested a NaSSA in this 
group (Table 1).  
Lyketsos et al. included 44 patients with moderate to severe Alzheimer’s disease and 
depression, and found a significant reduction in CSDD depression after 12 weeks of 
sertraline treatment compared to placebo (weighted mean difference -6.70, 95% CI -
11.50; -1.90).66 Contrary to this result, the four other studies did not find benefit of 
SSRI therapy. In a larger study by the same group, Rosenberg et al. included 131 
memory clinic patients with mild to moderate Alzheimer’s disease and depression, 
and found no improvement in CSDD after 12 weeks of sertraline treatment compared 
to placebo.67 The largest study by Banerjee et al. included 326 patients from old-age 
psychiatry services with moderate dementia and depression. Participants were 
randomised in 1:1:1 ratio to receive treatment with sertraline, mirtazapine, or placebo 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































improved significantly in all three groups, and was unchanged from 13 to 39-week 
follow-up. No significant between-group differences on CSDD were found.74 
Systematic reviews and meta-analyses have concluded that there is no robust 
evidence to support the efficacy of antidepressants for depression in people with 
dementia.75-77 
As expected from previous trials, Banerjee et al. found that the placebo group had 
significantly fewer adverse events compared to sertraline (p=0.010) and mirtazapine 
(p=0.031).74 Although the number of deaths or serious adverse events did not differ 
significantly between active treatment and placebo, the risk of serious adverse events 
being rated as severe was higher in participants who received active treatment 
(p=0.003).74 Other trials have found that antidepressant use is associated with 
increased risk of adverse events such as falls, hip fracture, stroke, or death in elderly 
patients and people with dementia.78-81  
Despite the apparently unfavourable risk-benefit ratio for antidepressants in people 
with dementia, 39% of nursing home patients with dementia in Norway currently use 
one or more antidepressants.82,83 A review including studies of antidepressant or 
antipsychotic drug use in nursing home patients in Western Europe from 2009-2015 
found that antidepressant use in people with dementia ranged from 20% (Italy) to 
47% (Sweden).83 The widespread use of antidepressants in people with dementia, 
despite unclear efficacy, demonstrates a clear need for better and safer treatment 
options for depression in this group. 
1.2.3 Non-pharmacological treatment of depression in dementia 
Several non-pharmacological interventions such as psychological therapy, 
reminiscence therapy and personalized pleasant activities have been shown to reduce 
depressive symptoms in people with dementia.84-86 As stated in national guidelines,  
non-pharmacological interventions are currently recommended as first-line treatment 
for mild-to-moderate depression in people with dementia.63,64 Unfortunately, these 
interventions are not suitable for all individuals, and are not systematically 
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implemented in nursing home care, possibly due to barriers such as lack of staff 
training or time.87 
In the framework of person-centred care, unmet needs such as pain, isolation or lack 
of meaningful activity may cause or exacerbate neuropsychiatric symptoms in 
dementia. Therefore, it may be assumed that symptoms such as depression may be 
treated by identifying and applying strategies to reduce unmet needs.40,88 
1.3 Pain 
The International Association for the Study of Pain (IASP) has defined pain as “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage.”89,90 Furthermore, the 
definition explicitly states that “pain is always subjective. Each individual learns the 
application of the word through experiences related to injury in early life. (…) It is 
unquestionably a sensation in a part or parts of the body but it is also always 
unpleasant and therefore also an emotional experience.”89,90 
Pain intensity and quality is multidimensional, affected by complex conscious and 
subconscious processes in the peripheral and central pain processing network. 
Because pain has sensory, cognitive, and affective aspects, the same pain stimulus 
may be experienced very differently in the same individual and between individuals 
depending on factors such as the individual’s expectations and experience of context 
for the pain. For these reasons, self-reported pain intensity is usually regarded as the 
gold standard in pain research.91 Different quantitative scales including verbal or 
pictorial aids, e.g. pain faces or colour changes from green to red, have been 
developed to aid self-report of pain even in children or people with cognitive 
impairment. However, studies have found that in severe dementia, the ability to 
comprehend pain assessment scales and report pain reliably is affected. 
The IASP definition of pain was criticized for relying on the verbal expression of 
pain, thus excluding those who were unable to describe their experience of pain.92 In 
2001, IASP added the following note to the definition in response to these concerns: 
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“The inability to communicate in no way negates the possibility that an individual is 
experiencing pain and is in need of appropriate pain relieving treatment.”93 
1.3.1 Pain and dementia 
In moderate-to-severe dementia, the ability to verbally express pain becomes 
progressively impaired. Pautex et al. included 129 participants with severe dementia 
(CDR≥3) and found that 69% were able to comprehend and use at least one of three 
pain assessment scales.94 However, in the 50th percentile with most impaired 
cognitive function (MMSE≤6) less than half had ability to self-report pain using any 
scale.94 This shows that people with dementia may experience pain but lack the 
ability to understand, remember, and/or verbally describe the intensity, location, or 
quality of pain. Therefore, observational pain assessment scales are required to 
identify pain in people with advanced dementia who lack the ability to self-report 
pain reliably.95 
As for depression, the estimated prevalence of moderate to severe pain in nursing 
home patients with dementia varies considerably between different studies due to 
methodological differences. Studies from nursing homes in Norway have found that 
approximately 50% or more of people with dementia suffer from moderate to severe 
pain, and up to 80% suffer from pain of any severity including mild pain.96-98 
Because pain is difficult to identify in people with dementia, untreated pain is 
recognized as a major clinical concern in this group. Systematic reviews have found 
that nursing home patients with dementia receive significantly less analgesics 
compared to nursing home patients without dementia,99 the same systematic 
difference has been found in acute care, e.g. after hip fracture.100 
Dementia may impact the cognitive component of pain processing in several different 
ways. In severe dementia, the ability to anticipate painful stimuli, e.g. after injury or 
during medical procedures, is impaired. Reduced autonomic activation (e.g. heart rate 
elevation) has been shown in people with dementia compared to cognitively intact 
controls during experimentally inflicted pain.101-103  
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In Alzheimer’s disease, the sensory cortex is unaffected until the very late stages of 
the disease, and there is no evidence for impaired perception of pain.91 However, the 
regions of the brain that are affected are involved in pain processing. Some 
neurodegenerative damage may increase the sensitivity to pain. This includes 
decreased activity in the descending inhibitory pathways, and vascular pathology 
such as white matter lesions.104 Damage to the limbic system may impair motivation 
for pain avoidance or lead to reduced understanding of pain, even though the 
detection of painful stimuli may still be intact.91,104 
Although neurodegeneration in dementia may impact pain processing pathways, 
current evidence has not shown any consistent differences in pain thresholds or 
tolerance for different pain stimuli in people with dementia compared to controls.91,105 
1.3.2 Treatment of pain in people with dementia 
As mentioned previously, systematic reviews have found significantly lower rates of 
analgesic use in people with dementia compared to those without dementia. However, 
several recent studies have reported similar rates of analgesic use in nursing home 
patients with and without dementia, with an overall increase in total analgesic use 
irrespective of cognitive state, and a shift towards increased use of opioid 
analgesics.106,107 In Norway, the use of opioid analgesics in nursing home patients 
increased from 11% in 2000 to 24% in 2011, with a substantial increase in the use of 
strong opioids from 1.9% to 17.9%.106 Furthermore, in the 2011 cohort, the same 
study found that the odds ratio for use of strong opioids in nursing home patients with 
dementia did not differ significantly compared to those without dementia.106 A study 
including the entire population of Denmark in 2010 reported that nursing home 
patients with dementia were significantly more likely to receive opioid analgesics 
compared to nursing home patients without dementia (43 and 38%, respectively).108 
Reports from other countries have found that untreated pain remains a significant 
clinical problem in people with dementia. A study including 425 patients from 12 
nursing homes in Austria in 2011-2012 found that despite having more pain, fewer of 
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the participants with cognitive impairment received scheduled analgesic prescriptions 
compared to those without cognitive impairment (36% and 58%, respectively).109 
Paracetamol is the most widely used non-opioid analgesic in nursing home patients 
and people with dementia. In Norway, regularly scheduled paracetamol treatment 
among nursing home patients has risen from 23% in 2000 to 48% in 2011 
(p<0.001).106 This does not include doses administered pro re nata (PRN; “as 
needed”). In a sample of 383 patients from six nursing homes in Australia, 69% 
received paracetamol within the last 24 hours (regularly scheduled or PRN), and there 
was no significant difference in paracetamol use among patients with and without 
dementia (71.0% and 67.3%, respectively, p=0.44).107 
Non-opioid analgesics 
Paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) are classified as 
non-opioid analgesics, meaning that they do not exert their analgesic effects on the 
opioidergic system. NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin 
synthesis, thereby reducing vasodilation, inflammation, and pain. In elderly patients, 
NSAID use is associated with increased risk of gastrointestinal bleeding, 
cardiovascular events, and acute renal failure, and NSAIDs have clinically relevant 
interactions with many drugs that are commonly used in elderly patients.110 NSAIDs 
are therefore not recommended for use in elderly patients according to consensus-
based criteria for appropriate prescribing.111 Paracetamol has a different mechanism 
of action, which has not yet been fully described, but involves activation of 
descending serotonergic pathways.112,113 As a weak cyclooxygenase inhibitor, 
paracetamol also reduces prostaglandin synthesis.113 Therefore it resembles NSAIDs 
in activity, and is preferred in elderly patients due to its more favourable adverse 
effect profile, although it is a weaker analgesic.113 
Opioid analgesics 
Opioid analgesics are indicated for the treatment of acute and chronic malignant or 
non-malignant pain, and are considered the mainstay for treating severe nociceptive 
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pain. Opioids act by activation of μ, κ, and δ opioid receptors which are distributed in 
the brain, spinal cord, and gastrointestinal tract. Activation of the μ-receptor is the 
primary mechanism for dose-related analgesic effects as well as respiratory depression, 
while κ-activation is associated with other adverse effects such as hallucinations and 
dysphoria.114  
Adverse effects of individual opioids are determined by their pattern of receptor 
selectivity and activation, but many unwanted effects are common to all analgesics in 
the opioid class. For example, opioids increase the muscular tone and reduce motility 
in the gastrointestinal system; this causes constipation which may be severe.115 
Furthermore, stimulation of the chemoreceptor trigger zone in the area postrema causes 
nausea and activates the vomiting centre.116 Upon repeated use, tolerance is developed 
for many of the central adverse effects of opioids such as sedation and euphoria, as 
well as for the intended analgesic effect.117 This may lead to demand for a gradual dose 
increase, and to risk of dependence. Withdrawal symptoms such as hyperalgesia, 
restlessness, hyperhidrosis, anxiety, convulsions, and interrupted sleep may occur if an 
opioid is discontinued abruptly after prolonged use.117 
Respiratory depression is an adverse effect of μ-receptor activation, caused by 
decreased pCO2 sensitivity of the respiratory centre on the surface of the medulla 
oblongata.118 Respiratory depression is dose-dependent, but may occur in therapeutic 
doses. The development of tolerance to respiratory depression is lower than tolerance 
to analgesic effects. This leads to risk of respiratory arrest and death, particularly at 
high doses and/or in combination with other drugs that cause respiratory depression, 
such as barbiturates. 
Buprenorphine 
Buprenorphine is a semi-synthetic opioid which acts as a partial agonist on the μ-
receptor and an antagonist on the κ-receptor.119,120 Partial activation of the μ-receptor 
exerts analgesic effects, while limiting the dose-related risk of respiratory 
depression.121,122 The risk of opioid tolerance and addiction is also less than for full 
agonists; dependence is unusual and withdrawal symptoms are reported as mild when 
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buprenorphine TDS is used to treat pain.122,123 Buprenorphine has high lipid solubility, 
and is more potent with a longer-lasting analgesic effect compared to morphine; 
therefore it has been formulated for continuous transdermal application which provides 
stable serum concentrations with administration every 7 days.122,124 Buprenorphine 
transdermal system (TDS) is indicated for the treatment of chronic moderate to severe 
pain, and is available in Norway in doses from 5 µg/hour which is approximately 
equivalent to 10 mg morphine per 24 hours. In contrast, fentanyl TDS, which is the 
only alternative transdermal opioid, has a starting dose of 12 µg/hour – corresponding 
to approximately 20-35 mg morphine per 24 hours. Due to mainly hepatic metabolism 
and clearance, buprenorphine does not require dose adjustment in patients with renal 
impairment.125 This has, along with the possibility of a low starting dose and gradual 
dose increase with relatively low risk of respiratory depression and dependence, 
positioned buprenorphine TDS as a an appropriate choice of opioid analgesic in elderly 
patients, including those with dementia. 
Efficacy and safety of analgesics in dementia 
Despite the high prevalence of painful conditions and increasing use of analgesics in 
people with dementia, few studies have tested the efficacy and safety of different 
classes of analgesic drugs in people with dementia.126 Age-related physiological 
changes in combination with dementing illness, as well as comorbid disease burden, 
lead to a particularly complex clinical situation where adequate pain relief may be 
difficult to achieve without unacceptable adverse effects. Furthermore, the 
assessment of both pain intensity and adverse effects may be difficult in people with 
reduced ability to communicate verbally. Due to lack of clinical evidence, no 
guidelines for the treatment of pain in dementia currently exist.  
To date, only three placebo-controlled trials have tested the efficacy of analgesic 
treatment for pain or other distressing symptoms in people with dementia, two of 
which tested paracetamol versus placebo. The first trial by Buffum et al. tested the 
comparative efficacy of paracetamol 650 mg administered in scheduled doses four 
times daily in combination with PRN placebo versus placebo in scheduled doses in 
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combination with PRN paracetamol 650 up to four times daily.127 Pain was the 
primary outcome, assessed using the Discomfort Scale – Dementia of Alzheimer 
Type (DS-DAT).128 The trial included 39 patients with severe dementia and diagnosis 
of a painful condition from 3 nursing homes, and had a double-blinded crossover 
design: each patient was treated under one condition for two weeks before switching 
to the other condition without a washout period. Because only four patients received 
PRN paracetamol during placebo treatment, the results can be interpreted as a 
comparison of the efficacy of scheduled paracetamol versus placebo for pain. No 
difference in pain was found between the groups treated with paracetamol 650 mg 
administered four times daily and PRN.127 However, the authors state that the 
administered dose may have been inadequate to treat moderate to severe pain, e.g. 
associated with degenerative joint disease, with which 84% were diagnosed. The 
occurrence of elevated liver function tests was similar between conditions (one 
during active treatment; one during placebo); the study did not report other adverse 
events.127 
The second trial by Chibnall et al. tested the efficacy of paracetamol 1000 mg 
administered three times daily on behaviour and emotional well-being (Dementia 
Care Mapping), agitation (CMAI), and use of as-needed psychotropic drugs in 25 
nursing home patients with dementia.129 The trial had a double-blind placebo-
controlled crossover design; each patient received 4 weeks of active treatment and 4 
weeks of placebo.129 While active treatment significantly increased the time spent in 
activity and socializing with others, no positive effect was found on agitation or 
emotional well-being. Two adverse events were reported during treatment; none of 
which were deemed treatment-related. Use of as-needed psychotropic drugs was also 
unchanged.  
Although the evidence from these two trials is insufficient to determine the efficacy 
of paracetamol for pain and distressing symptoms in people with dementia, 
paracetamol remains the first-line treatment for pain in this population due to its 
favourable safety profile.126  
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Only one previous placebo-controlled trial of opioid analgesics has been conducted in 
people with dementia. Manfredi et al. assessed the efficacy of a long-acting opioid 
(20 mg oxycodone or morphine per 24 hours) for agitation (CMAI) in 47 nursing 
home patients with advanced dementia and agitation.130 The study had a single-blind 
placebo-controlled crossover design. Each patient initially received placebo for 4 
weeks, followed by 4 weeks of active treatment. The patients and study nurses were 
blinded to treatment allocation. Of the 47 patients who were enrolled in the trial, 22 
did not complete the eight-week treatment protocol. Eleven withdrew during the 
initial placebo phase, and 11 during active opioid treatment. The main reasons for 
discontinuation of treatment were unsteady gait (three patients during the placebo 
phase; four patients during opioid treatment), increased agitation (two patients during 
the placebo phase; two patients during opioid treatment) and infection (one patient 
during the placebo phase; two patients during opioid treatment).130 Although the 
withdrawal rate was high, adverse events which caused withdrawal were equally 
frequent during the placebo and active conditions, suggesting that the opioid was well 
tolerated. Mild and transitory adverse events such as sedation and nausea were more 
frequent during active treatment, but the difference was not statistically significant. 
One important limitation to this trial is the substitution of oxycodone 20 mg/day for 
morphine 20 mg/day in participants who could not swallow tablets. Oxycodone is 
1.3-2 times more potent than morphine.131 The authors reported that 13 of the 25 
participants who completed the 8-week treatment protocol received oxycodone, and 
12 received morphine. However, the treatment allocation for those who discontinued 
treatment was not reported. Therefore, the dose-dependent tolerability and relative 
tolerability of oxycodone and morphine in people with dementia remain unknown.130 
Concerns regarding opioid use in people with dementia 
The observed increase of opioid use in people with dementia during the last decades 
may signal that the attention towards assessment and treatment of pain and 
discomfort in dementia has improved. However, this trend may also be a cause for 
concern. While opioid analgesics definitely have their place in the treatment of acute 
severe nociceptive pain in people with dementia, the benefit-risk ratio is more 
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uncertain for long-term use in patients with moderate chronic pain. For example, an 
observational study of home-dwelling elderly patients in the USA has shown a dose-
dependent association between opioid use and risk of hip fracture.132 Available data 
on the safety profile of opioid analgesics in cognitively intact elderly patients may not 
be generalizable to people with dementia.  
Buprenorphine TDS is a relatively new analgesic drug which has been available in 
Norway since 2005, and has quickly become one of the most frequently used opioid 
analgesics in nursing home patients and people with dementia in Scandinavia. In 
2011, a study found that 10.5% of 1542 nursing home patients with dementia were 
prescribed buprenorphine TDS which accounted for 58% of the total use of strong 
opioids in this population.106 A study of the entire population of Denmark in 2010 
confirms this trend, showing that 12.3% of nursing home patients with dementia used 
buprenorphine TDS, while 27.8% used any strong opioid.108 
Use of buprenorphine TDS for chronic moderate to severe non-malignant pain has 
been controversial, as opioids previously have been primarily indicated for cancer 
pain.133 In people with dementia, very little is known about the prevalence of adverse 
effects such as sedation, somnolence, nausea, anorexia, hypotension, urinary 
retention, infection, gait disturbance, falls and hip fracture. Considering how rapidly 
use of buprenorphine TDS has grown in this population, the tolerability and adverse 
effects of buprenorphine in people with dementia warrants further investigation. 
1.3.3 Pain and neuropsychiatric symptoms in dementia 
Chronic pain is associated with numerous adverse outcomes in elderly people, 
including depression, decreased socialization, sleep disturbance, increased healthcare 
utilization and cost, and risk of adverse effects from multiple drug prescriptions.134 
Although the consequences of pain are less well described in people with dementia, 
studies have found higher levels of neuropsychiatric symptoms in those with pain or 
discomfort compared to those without.135-137 
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At the time the DEP.PAIN.DEM trial was planned, three previous randomised 
controlled trials had investigated whether treating pain may reduce neuropsychiatric 
symptoms in nursing home patients with dementia.138-140 Manfredi et al. included 47 
participants in a double-blind placebo-controlled crossover trial of a long-acting 
opioid (oxycodone or morphine, 20 mg/day) for 4 weeks, and found no overall 
improvement in agitation.130 Chibnall et al. included 25 participants in a double-blind 
placebo-controlled crossover trial of paracetamol (3000 mg/day) for 4 weeks, and 
found increased activity and social involvement during active treatment, but no 
decrease in agitation or improvement in emotional well-being.129 Husebo et al. 
included 352 participants with behavioural disturbances in a cluster-randomised 
controlled trial of a stepwise protocol for treating pain, with treatment effect on 
agitation as the primary outcome.38 Pain treatment had a significant beneficial effect 
on agitation and overall severity of neuropsychiatric symptoms compared with the 
control group which received usual treatment (p<0.001).38 Secondary analyses of data 
from the trial suggest that analgesic treatment also reduced depressive symptoms and 
mood disturbances in the same population.39 
1.4 The pain-depression dyad 
The affective networks of the brain overlap with the pain processing network, and the 
subjective experience of pain is partly determined by an emotional component. The 
close relationship between pain and depression is illustrated by studies showing that 
grey matter changes in certain regions of the limbic system (hippocampus, amygdala, 
and cingulate cortex) are associated with multiple conditions that are often comorbid 
with chronic pain, such as depression (Figure 1).141  
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Figure 1. Structural changes in the limbic system associated with chronic pain 
and other related conditions. PgACC/sgACC, pregenual/subgenual anterior cingulate cortex; 
PTSD, post-traumatic stress disorder. Reprinted with permission from Woo and Wager (Pain 2015).141 
 
It is well established that patients with chronic pain are at higher risk of depression, 
and patients with depression are at higher risk of painful somatic complaints.142,143 
Although no clear aetiology has been established, the conditions are known to 
commonly coexist, mutually exacerbate each other, share common signal pathways 
and neurotransmitters, and respond to similar treatments.144 This relationship has 
been called the pain-depression dyad.144  
1.4.1 Pain and depression in people with dementia 
Only four previous studies have explored the association between pain and 
depression in nursing home patients with moderate to severe dementia (Table 2).145-
149 All four studies reported significant associations. However, the results are limited 
by the lack of validated proxy-rated instruments for the assessment of pain and/or 
depression in people with severe dementia. Furthermore, as the studies were all cross-
sectional, we still do not know whether pain is associated with future worsening of 
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The most recent study by Malara et al. included 233 participants at different stages of 
dementia. To assess pain, a combination of self-report (NRS) and proxy rating 
(PAINAD) was used, as well as diagnosis by a physician. However, the authors did 
not specify which of these assessments were used in the subsequent analyses.148  
 
Only the study by Leong et al. reported pain and depression prevalence stratified by 
cognitive function, this study included 358 patients of whom 126 had severe 
cognitive impairment and were able to self-report pain using a numeric rating scale 
(NRS).147 However, as this was primarily a prevalence study, the association reported 
in Table 2 (which has been obtained from a secondary meta-analysis) applies to the 
whole sample, irrespective of cognitive status.152 Therefore we still do not know 
whether a potential causal relationship between pain and depression may be affected 
by the progression of dementia. 
1.4.2 Treating pain to reduce depressive symptoms in dementia 
If pain is associated with worsening of depressive symptoms in people with dementia, 
there may be potential to reduce depression in this group by treating pain. The 
previous cluster randomised trial by Husebo et al. lends some support to this theory.39  
The trial included 352 participants with moderate-to-severe dementia (Functional 
Assessment Staging score >4) and clinically significant agitation (Cohen-Mansfield 
Agitation Inventory (CMAI) score ≥39) from 60 units (clusters) in 18 nursing 
homes.39,153,154 The intervention group (n=175) received an 8-week stepwise protocol 
for treating pain using paracetamol, buprenorphine, morphine, or pregabalin, 
followed by a 4-week wash-out period. The control group (n=177) received usual 
treatment. The study treatment was well tolerated, and only four of 40 participants 
who received an opioid (buprenorphine/morphine) were withdrawn because of 
adverse events.155  
Secondary analyses assessed the impact of analgesic treatment on mood and 
depressive symptoms, and found that the intervention group had a moderate 
improvement in depression assessed by the NPI-NH depression item (SES=0.3, 
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p=0.025). There was also a large improvement in mood, assessed by the NPI-NH 
mood cluster (NPI-NH depression, anxiety, sleep disturbance, apathy, and appetite 
items; SES=0.6, p<0.001).14 However, depression was not an inclusion criterion, and 
the pain intervention was not placebo-controlled. Therefore, the efficacy and safety of 
analgesic treatment for depression in nursing home patients with dementia should be 
investigated further, using a robust placebo-controlled design, including participants 
with clinically significant depressive symptoms. 
Antidepressant effects of buprenorphine 
The opioid κ-receptor is expressed at high levels in the regions of the brain that 
regulate mood, motivation, and reward, such as the limbic system.156 Activation of 
the κ-receptor causes dysphoria, increased anxiety, and aversion.157,158 Although these 
effects may be beneficial during acute stress, prolonged κ-receptor activation during 
conditions such as prolonged or uncontrollable stress may be a contributing factor in 
the aetiology of depression.157 In contrast, κ-receptor antagonists have shown 
anxiolytic and antidepressant effects in rodent models.159,160 Emerging evidence 
suggests that κ-receptor antagonists such as buprenorphine may represent a novel 
strategy for antidepressant treatment.161 Although few trials have been conducted in 
people with depression, some clinical evidence supports this hypothesis.162,163 
Buprenorphine is currently being tested in at least two ongoing phase II trials for 
treatment of depression (ClinicalTrials.gov identifiers NCT02263248 and 
NCT02181231).164 A recent placebo-controlled trial of buprenorphine in combination 
with samidorphan, a μ-receptor antagonist, for treatment-resistant depression has 
shown promising results.165  
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1.5 Rationale for the DEP.PAIN.DEM trial and this 
thesis 
Based on the preexisting evidence-base, as summarized in this introduction, the 
DEP.PAIN.DEM trial and this thesis were based on the following hypotheses:  
(1) The pain-depression dyad exists in people with moderate-to-severe dementia; 
therefore, people with dementia and depression are likely to have more pain. 
(2) Undiagnosed and untreated pain may cause increased depression in nursing 
home patients with dementia. 
(3) A stepwise protocol for treating pain, using paracetamol or buprenorphine 
TDS, may effectively reduce depressive symptoms in nursing home patients 
with dementia and depression with low risk of adverse events. 
(4) Buprenorphine is expected to reduce depression more efficiently compared 
with paracetamol because of its central effects on mood. 
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2. Aims of the thesis 
The overall aims of this thesis were to investigate the impact of pain on the severity 
and progression of depressive symptoms over time in nursing home patients at 
different stages of dementia, and to evaluate the efficacy and tolerability of analgesic 
treatment for depression in people with moderate to severe dementia and depression.  
Each of the three papers contribute to the overall aims of the thesis as described by 
the following specific aims: 
Paper I aims to determine whether the severity of pain and depressive symptoms were 
associated in patients at different stages of dementia, and whether having pain at 
baseline was associated with future worsening of depression. 
Paper II aims to determine the efficacy of a stepwise increase in analgesic treatment 
(using paracetamol or buprenorphine) for depressive symptoms in nursing home 
patients with moderate to severe dementia and depression. 
Paper III aims to assess the tolerability and adverse events of transdermally 
administered buprenorphine in nursing home patients with moderate to severe 
dementia, with particular emphasis on sedation, examining associations with 
cognitive function, age, gender, and concomitant drug use. 
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3. Methods 
3.1 Outline of data sources 
This thesis includes three papers with varying methodology, source material, and 
inclusion and exclusion criteria. Although three different studies have contributed 
data to these three papers, as shown in Table 3, most of the assessment scales that 
were used in the papers were common for all three studies. In the following, the 
assessment scales that were used will be presented first, followed by the methods, 
settings, participants, and ethical considerations in connection with each of the three 
studies that have contributed data to this thesis, and finally a presentation of each of 
the three papers including the design, eligibility criteria, primary and secondary 
outcomes, and statistical analyses that were used. 
Table 3. Sources of data for Papers I-III. 
  REDIC COSMOS DEP.PAIN.DEM 
















  X 
*Control group only. COSMOS; Communication, Systematic pain assessment and treatment, Medication 
review, Organised activities, and Safety, DEP.PAIN.DEM; Efficacy of pain treatment on depression in 
people with dementia, REDIC; Resource Use and Disease Course in Dementia 
3.2 Assessment scales 
This thesis mainly uses data collected from people with moderate to severe dementia. 
In order to ensure comparability between people at all stages of dementia, the 
assessment scales used rely mainly on proxy reports from the patients’ formal 
caregivers. All assessment scales used in the thesis are summarized in Table 4. In the 
following, the most important scales that have been used as outcome measures and/or 
inclusion criteria are discussed in more detail. 
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Table 4. Assessment scales used in Papers I-III (Norwegian versions: Appendix) 
 What does the tool measure? Tool characteristics and psychometric 
properties 
MMSE Staging of cognitive impairment based on 
scores in 11 domains (registration, 
orientation to time and place, short-term 
recall, attention, calculation, long-term 
recall, naming, repetition, comprehension 
(verbal and written), writing, and 
visuospatial construction), questionnaire 
administered directly to the patient by the 
researchers 
30 items assess cognitive function to yield a 
sum score which differentiates level of 
impairment from severe (0-10), moderate 
(11-20), mild (21-25), to no impairment (26-
30).166,167 MMSE is widely used as a 
screening tool, with good reliability and 
validity.167,168 
   
MOBID-2 
Pain Scale 
Pain from the musculoskeletal system 
during standardized, guided movement 
(part 1, current), and internal organs, 
head and skin (part 2, in the last 
days/week), proxy rated by interview 
with NH staff 
Assessment of pain intensity in dementia 
inferred by observable pain behaviours; pain 
from the musculoskeletal system (part 1) 
and pain from internal organs, head, and 
skin (part 2).169,170 Each item is rated on a 
horizontal scale from 0 (no pain) to 10 
(worst pain imaginable). Yields a final 
assessment of total pain (range 0-10). 
Excellent reliability and validity, good 
responsiveness.171 Total pain ≥3 was 
regarded as moderate to severe pain. 
   
CSDD Depressive symptoms in people with 
dementia in 5 domains (mood-related 
signs, behavioural disturbance, physical 
signs, cyclic function, and ideational 
disturbance) in the last week, proxy rated 
by interview with NH staff 
19 items with each symptom score rated 
from 0 (not present) to 2 (severe).172 
Satisfactory interrater reliability and validity 
in the elderly population.173 Sum score ≥8 
defined as depression.54 
   
NPI-NH The frequency and severity of 12 





loss of inhibition, irritability/lability, 
aberrant motor behaviours, sleep and 
appetite and eating disturbances), proxy 
rated by interview with NH staff 
The product of frequency (0-4) x severity 
(1-3) yields a composite score per item from 
0 (not present) to 12 (most frequent and 
severe symptoms), with a cut-off value of 
≥4 for clinically significant symptoms, total 
sum score 0-144.30 The Norwegian version 
has shown good reliability and validity.31 
 
   
Actigraphy A wrist-worn microelectromechanical 
system accelerometer (Philips Actiwatch 
Spectrum PLUS/PRO) provides objective 
recording of interval duration and 
intensity of movement, to yield 24-hour 
activity and rest patterns for 7-14 days  
Total activity counts per day (Total AC) and 
mean intensity of activity per minute 
(AC/min) for daily 12-hour intervals (09:00-
21:00) were extracted from the Respironics 
Actiware 5 software, and mean activity 
counts for Total AC and AC/min were 
calculated for 7-day periods with at least 5 
valid days of recording per week.174,175 
   
CSDD; Cornell Scale for Depression in Dementia, MMSE; Mini-Mental State Examination, MOBID-2; 
Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale, NH; nursing home, NPI-NH: 
Neuropsychiatric Inventory, Nursing Home Version  
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The Mini-Mental State Examination (MMSE) was used as a screening tool to 
group patients according to cognitive state. Although the instrument has shown good 
reliability and validity as a screening tool, the MMSE alone cannot be used to 
diagnose dementia.176 Several important limitations should be acknowledged. As it is 
administered directly to the patient, it is sensitive to daily fluctuations in mood or 
motivation to respond. Cognitive function may be underestimated in people with 
dementia and/or symptoms of depression or apathy, who may lack motivation to 
respond. The MMSE has also been criticized for underestimating mild cognitive 
impairment, particularly in people with high education in whom the MMSE is known 
to overestimate cognitive function.176 Similarly, low education is associated with 
lower MMSE scores and cognitive function may be underestimated in people with 
low education. In addition to education level, the MMSE may also be affected by age 
and gender. However, as a screening tool the MMSE has shown sufficient sensitivity 
and specificity.167,176,177 We have chosen to differentiate between the following four 
stages of dementia; no cognitive impairment (MMSE 26-30), mild cognitive 
impairment (MMSE 21-24), moderate cognitive impairment (MMSE 11-20), and 
severe cognitive impairment (MMSE 0-10). These cut-off values have shown 
substantial agreement with the Clinical Dementia Rating scale, another widely used 
assessment tool, for identifying people with mild, moderate, and severe dementia.167 
Depressive symptoms were assessed using the Cornell Scale for Depression in 
Dementia (CSDD), which has been validated and used in clinical studies including 
people with and without dementia.54 Each of the 19 items is rated from zero (no 
symptom) to two (severe symptoms), or a (not possible to evaluate). The CSDD 
yields a sum score of between zero (no depression) and 38 (most severe depression), 
and has shown optimal sensitivity for depression at scores ≥6 (sensitivity 0.91, 
specificity 0.73), while the specificity is optimal using ≥8 as a cut-off for depression 
(sensitivity 0.78, specificity 0.84) as summarized in a recent systematic review and 
meta-analysis.54 The factor structure of the CSDD scale was recently investigated by 
Barca et al., in a sample of 1682 people with mild to severe dementia recruited from 
nursing homes and memory clinics. Five symptoms clusters were identified: mood; 
physical; cyclic; retardation; and behavioural symptoms. The mood factor included 
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the items suicide, pessimism, poor self-esteem, sadness, mood-congruent delusions, 
and multiple physical complaints.178 Although previous studies have found somewhat 
varying factor structures, the mood factor as well as the cyclic factor that was found 
in this study are quite stable across previous studies, as reviewed by the authors.178 
The physical factor included the symptoms weight loss and appetite loss; the cyclic 
factor included the symptoms multiple awakenings during sleep and difficulty falling 
asleep; the retardation factor included the items loss of interest, lack of joy, lack of 
energy, retardation, and agitation; and finally the behaviour factor included the items 
diurnal variation, anxiety, and irritability.178 Interestingly, the authors found that all 
factors except the mood and cyclic factors increase in severity as dementia 
progresses, suggesting a potential overlap between other CSDD items and dementia 
symptoms.178 
We assessed pain using the Mobilisation-Observation-Behaviour-Intensity-
Dementia-2 (MOBID-2) Pain Scale, a two-part staff-administered behavioural 
instrument to assess pain in older persons with advanced dementia.170,171 The 
evaluation of inferred pain intensity is based on the patient’s pain behaviours during 
standardised, guided movements of different body parts to assess pain from the 
musculoskeletal system (Part 1), and pain behaviours related to internal organs, head 
and skin are registered on pain drawings and monitored over time (Part 2).171 
Excellent interrater and test-retest reliability, internal consistency and validity have 
been reported.170 The tool has also demonstrated responsiveness to treatment, as it is 
able to assess change in the total score (range 0-10) after pain treatment has been 
initiated.171 
The Neuropsychiatric Inventory – Nursing Home version (NPI-NH) was used to 
assess the total presence of neuropsychiatric symptoms, calculated as the sum of 
individual symptom scores (frequency x intensity).30 In addition, the NPI-NH 
depression item was used as a surrogate measure for depression in order to 
investigate whether the effects that were found using the CSDD as an outcome 
measure could be replicated with a different assessment scale.179 The factor structure 
of the NPI-NH items has been investigated by several authors, and the depression 
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item has been found to cluster with symptoms such as anxiety, night-time behavioural 
disturbances, eating and appetite disturbances.180-183 Results are somewhat conflicting 
as to whether apathy should be considered as part of a mood cluster in dementia, or as 
part of a separate symptom cluster.183 Differences between the samples, including 
dementia severity, may explain some of the variability.  
Daytime activity was assessed in a subgroup of patients included in the 
DEP.PAIN.DEM trial, using wrist actigraphy. The actigraphs contain 
accelerometers that record information digitally on intensity and length of movement 
in active periods. They were worn continuously on the patient’s dominant wrist 
during recording. Actigraphy has been shown to provide a reliable and valid measure 
of activity.174,175 Total activity was recorded for 24-hour intervals. To assess daytime 
activity, total activity per day and mean intensity of activity per minute per day from 
09:00 to 21:00 was extracted from the Philips Respironics Actiware 6.0.9 software. 
Daily scheduled use of analgesic, antidepressant, or psychotropic drugs was assessed 
by extracting current prescriptions from the patients’ medical records, and classifying 
each drug according to the Anatomical Therapeutic Chemical (ATC) system as 
shown in Table 5.  
Table 5. Classification of analgesic and psychotropic drugs 
Classification ATC code Drug class 
Analgesics M01A Systemic nonsteroidal anti-inflammatory drugs 
N02 Systemic analgesics 
Psychotropic drugs N03A Antiepileptic drugs 
N05A Antipsychotic drugs 
N05B Anxiolytic drugs 
N05C Hypnotic/sedative drugs 
N06A Antidepressant drugs 
N06D Anti-dementia drugs 
ATC; Anatomical Therapeutic Chemical classification system 
Use of anticholinergic drugs was assessed using the Anticholinergic Cognitive 
Burden (ACB) scale.184,185 Each prescribed drug with mild, moderate, and strong 
anticholinergic properties was assigned 1, 2, and 3 points, respectively, and total 
ACB was calculated as the sum score of all prescribed anticholinergic drugs. 
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3.3 Paper I 
3.3.1 Design 
This was a prospective cohort study including observational data from two 
independent multicentre studies in nursing homes from 6 counties of Norway; the 
REDIC (Resource Use and Disease Course in Dementia) trial and the COSMOS 
(Communication, Systematic pain assessment and treatment, Medication review, 
Organised activities, and Safety) trial control group. 
3.3.2 The REDIC study 
Design 
The REDIC (Resource Use and Disease Course in Dementia) trial was a prospective 
observational study (2012-2017) which included four different cohorts.13 One cohort 
consisted of nursing home patients who were followed from admittance to long-term 
nursing home care (REDIC-NH). The patients were assessed at baseline (within four 
weeks after admittance) and at 6-month intervals for a total follow-up period of three 
years. The study was administrated by the Centre for Old Age Psychiatric Research, 
Innlandet Hospital Trust, and was initiated by the Norwegian Directorate of Health, 
which also provided funding for the data collection. 
Setting and participants 
In total, 182 units from 47 nursing homes in four counties of Norway were included 
(Hedmark, Hordaland, Nord-Trøndelag, and Oppland), and 696 patients joined the 
study from January 2012 to June 2014. Eligible patients were ≥65 years, or younger if 
they had a diagnosis of dementia, and newly admitted to a nursing home with 
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Assessments 
The assessments that were used in this thesis were conducted at baseline and after 6 
months, and included cognition (MMSE), pain (MOBID-2), depression (CSDD), 
neuropsychiatric symptoms (NPI-NH), and use of analgesic and antidepressant drugs. 
Data were collected through structured interviews with the nursing home patients and 
their caregivers. Assessments were conducted by the nursing home staff after a two-
day training program led by 10 research nurses who supervised data collection and 
provided support as needed. The research nurses completed a five-day training 
program to qualify them for educating and supervising the data collectors. 
Demographic information and prescribed drugs were collected through a review of 
the patients’ medical records. 
Ethics 
Verbal and written informed consent was obtained from the patients if they were 
deemed to have medical decision-making capacity. In those with reduced capacity to 
give consent, written consent was obtained from a legally authorised representative in 
accordance with ethics committee requirements and current Norwegian legislation. 
The trial was approved by the Regional Committee for Medical and Health Research 
Ethics (2011/1738) and registered at ClinicalTrials.gov (NCT01920100). 
Contributions 
Access to data was granted by Professor Geir Selbæk, Research Director, the 
Norwegian National Advisory Unit on Ageing and Health. The candidate did not 
contribute to the data collection. 
3.3.3 The COSMOS study 
Design 
The COSMOS (Communication, Systematic pain assessment and treatment, 
Medication review, Organised activities, and Safety) study was a multicentre, cluster 
randomised and controlled effectiveness-implementation hybrid trial (2013-2016) 
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which included nursing home patients living in the included nursing home unit 
(cluster) and randomised clusters to either a complex intervention for 4 months or 
usual care.186 The patients were assessed at baseline and after 4 and 9 months. The 
study was administered by the Centre for Elderly and Nursing Home Medicine, 
University of Bergen, and was funded by the Research Council of Norway (222113). 
Setting and participants 
In total, 67 units from 33 nursing homes in three counties of Norway were included 
(Akershus, Hordaland, and Østfold) from August 2014 to December 2015. Eligible 
participants were ≥65 years and had been living in the participating ward for at least 4 
weeks. Patients with life expectancy ≤6 months or schizophrenia were ineligible for 
inclusion. 36 units with 394 residents were cluster randomised to receive the 
intervention, and 31 units with 329 residents were allocated to the control condition. 
Of these, 297 and 248 participants, respectively, received the allocated intervention.  
Intervention 
The units were randomised to receive a multicomponent intervention that consisted of 
staff education and implementation of structured, evidence-based efforts to increase 
1) communication between staff, patient, and relatives to promote advance care 
planning; 2) systematic assessment and treatment of pain; 3) medication review; 4) 
meaningful activity; 5) patient safety. Units that were randomised to the control 
group did not receive any intervention during the follow-up period, but followed a 
waiting-list strategy with staff education offered after completion of the trial. 
However, all staff received training related to use of the assessment instruments. This 
thesis only uses data from the 248 participants who contributed to clinical 
assessments in the control group. 
Assessments 
The assessments that were used in this thesis were obtained from the control group 
only, and were conducted at baseline and after 4 months. Assessments included 
cognition (MMSE), pain (MOBID-2), depression (CSDD), neuropsychiatric 
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symptoms (NPI-NH), and use of analgesic and antidepressant drugs. Data were 
collected through structured interviews with the nursing home patients and their 
primary caregivers. Prior to participation, the proxy raters received a half-day specific 
training program including the relevant assessment scales. Assessments were 
conducted by research assistants who had completed a two-day training program to 
qualify them for collecting data. Demographic information and prescribed drugs were 
collected through a review of the patients’ medical records.  
Ethics 
Verbal and written informed consent was obtained from the patients if they were 
deemed to have medical decision-making capacity. In those with reduced capacity to 
give consent, written consent was obtained from a legally authorised representative in 
accordance with ethics committee requirements and current Norwegian legislation. 
The trial was approved by the Regional Committee for Medical and Health Research 
Ethics (2013/1765) and registered at ClinicalTrials.gov (NCT02238652). 
Contributions 
Access to data was granted by Professor Bettina Husebø. The candidate made minor 
contributions to the planning of the trial, and participated in obtaining informed 
consent as well as the baseline data collection in the Bergen region, approximately 4 
weeks’ workload in total. 
3.3.4 Trial profile 
The database for Paper I included participants from the REDIC and COSMOS trials, 
aged ≥65 years, in whom pain and depression had been assessed prospectively 
without applying any trial intervention (Figure 2). 
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Figure 2. Trial profile Paper I.  
COSMOS; Communication, Systematic pain assessment and treatment, Medication review, Organised 
activities, and Safety, CSDD; Cornell Scale for Depression in Dementia, MOBID-2; Mobilisation-
Observation-Behaviour-Intensity-Dementia-2 Pain Scale, REDIC; Resource Use and Disease Course in 
Dementia 
 
3.3.5 Outcome variables 
The primary outcomes were the association between pain (MOBID-2) and change in 
depressive symptoms (CSDD), and the association between depressive symptoms 
(CSDD) and change in pain (MOBID-2). Furthermore, we investigated whether the 
observed associations were affected by cognitive state (MMSE), and use of analgesic 
(M01A/N02) or antidepressant (N06A) drugs. In order to investigate whether the 
associations were replicated using a different depression assessment scale, the NPI-
NH depression item was used as a secondary outcome measure. 
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3.3.6 Statistics 
Baseline characteristics were described with mean and standard deviation (SD) for 
continuous variables and with number of participants and percentages of sample size 
for categorical variables. In order to assess whether the REDIC and COSMOS groups 
were different at baseline, we used the independent samples t-test for normally 
distributed continuous variables, Mann-Whitney U-test for non-normal distributed 
continuous variables, and Pearson χ2-test for categorical variables.  
The unadjusted odds ratio (OR) for depression among participants with moderate to 
severe pain was calculated at baseline. Linear regression models were fitted to 
analyse the prospective association between pain at baseline and depression at 
follow-up, and vice versa, adjusted for depression, pain, age, sex, and cognitive 
function at baseline. To account for intra-cluster correlation at the nursing home 
level, we used robust estimators for variance. 
To explore whether increasing pain was associated with increasing depression, and 
vice versa, we used linear mixed effect models with restricted maximum likelihood 
estimation. We conducted several analyses for the outcome variables where we 
included fixed effects for MOBID-2, CSDD, time, antidepressant use, and analgesic 
use (time-varying covariates), and MMSE, age, and sex (time-constant variables). 
Associations at different stages of cognitive functioning were assessed by stratifying 
those with no/questionable, mild, moderate, and severe dementia according to 
MMSE.167 To account for intra-cluster correlation, the models were fitted with 
random intercept for both nursing home and patient-level effects. We included 
random slope for MOBID-2 and CSDD at patient-level, thus allowing the effects of 
these covariates to vary between patients. The covariance structures were specified 
using an independent model for both patients and nursing homes. The regression 
coefficients for the time-varying covariates can be interpreted as a between-patients 
effect and/or a within-patient effect. In order to explore the contributions of between-
patients effects and within-patients effects on the primary outcomes, we included 
both within and between effects in the same model. Mixed model analyses were also 
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conducted using NPI-depression as a dependent variable, with MOBID-2, time, 
MMSE, age, and sex as independent variables, to explore whether any associations 
obtained using the CSDD scale were replicated. We regarded p<0.05 as statistically 
significant. All analyses were conducted with Stata/IC version 14 (StataCorp LP, 
College Station, TX, USA). 
3.4 Papers II-III 
3.4.1 Design 
These papers present the primary and secondary results from the randomised 
controlled trial DEP.PAIN.DEM (Efficacy of pain treatment on depression in people 
with dementia). 
3.4.2 The DEP.PAIN.DEM trial 
DEP.PAIN.DEM was a multicentre, randomised, placebo-controlled trial (2014-
2016) including nursing home patients with advanced dementia and depression. 
Participants were prescribed an individual increase in analgesic treatment 
(paracetamol or buprenorphine), and randomised to receive either active treatment or 
identical, inert placebo for 13 weeks with assessments at baseline, 6 and 13 weeks. 
The trial was administered by the Centre for Elderly and Nursing Home Medicine, 
University of Bergen, and was funded by the Research Council of Norway (221951). 
Setting and participants 
In total, 162 nursing home patients were included from 47 nursing homes in five 
counties of Norway (Akershus, Hordaland, Møre og Romsdal, Oslo, Rogaland). 
Eligible participants were 60 years or older, with moderate to severe dementia 
according to DSM-5 (MMSE ≤20) and depression (CSDD ≥8) of at least 3 weeks’ 
duration. Exclusion criteria were: cognitive impairment related to other diagnoses 
than Alzheimer's disease, frontotemporal dementia, vascular dementia, dementia with 
Lewy bodies, or mixed dementia; life expectancy <6 months; severe pain (MOBID-2 
pain score ≥8), severe aggression (with NPI-NH aggression item ≥8); suicide risk; 
  67 
severe hepatic or renal insufficiency; anaemia (haemoglobin <8.5 mmol/L in men, 
<7.5 mmol/L in women); uncontrolled epilepsy; severe disease that could interfere 
with study participation; contraindication or clinically significant drug interaction to 
the assigned study treatment; and scheduled prescriptions for any opioid analgesic 
other than or exceeding buprenorphine 5 µg/hour. A drug interaction analysis was 
conducted by a pharmacist (the candidate), and potential drug-drug and drug-disease 
interactions were discussed with the nursing home physician who had the final 
responsibility for considering the appropriateness of treatment, prescribing the study 
drug, and making clinical decisions in the case of any adverse events. Study treatment 
was not prescribed to individuals in whom pain was considered likely to be caused by 
an immediately treatable underlying condition, such as cystitis. 
Randomisation and blinding 
The trial was double-blinded, and participants were randomly allocated to each arm 
in a 1:1 ratio according to computer-generated random numbers in blocks of 10 
(paracetamol) and 12 (buprenorphine) with no stratification factors. Statisticians 
generated and sent the randomisation lists directly to the production and packing 
facilities without researcher involvement. Paracetamol and identical, inert placebo 
tablets were purchased from Kragerø Tablettproduksjon AS, Norway. Mundipharma 
Research Limited, UK provided buprenorphine TDS and identical, inert placebo. The 
patients, carers, clinicians, pharmacy, researchers, and study statistician were masked 
to group identity until completion of the protocol. 
Intervention 
Patients were prescribed analgesic treatment according to the stepwise protocol for 
treating pain (Table 6). All participants continued their usual medical treatment after 
inclusion in the study (including any regular or “as needed” (PRN) analgesic). The 
use of PRN analgesics was allowed and monitored during the study, ensuring that all 
patients received adequate pain treatment irrespective of group allocation. Ongoing 
treatment with antidepressants, other psychotropic drugs, and regular analgesics was 
allowed if the dose had remained stable for 4 weeks prior to study inclusion. 
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Clinicians were advised to keep doses of psychotropic and analgesic drugs unchanged 
during the study period if possible. If lasting changes were made to regular analgesic 
treatment or antidepressants, the patient was withdrawn from the study. 
 
Table 6. Stepwise protocol for treating pain. 
Step Regular analgesic treatment Study treatment Dose 
1 No analgesic (1a) or paracetamol ≤1 g/day (1b). Paracetamol tablets Max. 3 g/day 
Placebo tablets Inert placebo 
2 Non-opioid analgesic (paracetamol >1 g/day, 
and/or NSAID), or no analgesic, but with 
difficulty swallowing tablets (2a), or 
buprenorphine 5 µg/hour (2b). 
Buprenorphine TDS 5 µg/hour (max. 10 
µg/hour in 2b) 
Placebo TDS Inert placebo 




Assessments of depression (CSDD), pain (MOBID-2), neuropsychiatric symptoms 
(NPI-NH), and use of analgesic, antidepressant and psychotropic drugs were made at 
baseline and after 6 and 13 weeks. Additionally, cognition was assessed at baseline 
and after 13 weeks, and actigraphy recordings were obtained from a subgroup of 
patients for 14 days at baseline (1 week prior to and 1 week after initiation of study 
treatment), and for 7 days during week 13 (the last week of treatment).  
Adverse events were recorded as reported by nursing home staff, who were provided 
with a comprehensive list of known adverse effects of the study treatment based on 
information from the Summary of Product Characteristics, and instructed to contact 
the researchers by phone immediately if an adverse event was suspected. The 
researchers were available by phone 24 hours a day for the duration of the trial. In 
addition, the raters were asked specifically about whether they had observed any 
suspected adverse event during scheduled data collection (week 0, 6, and 13) and 
spontaneous contacts. Adverse events were registered and grouped according to the 
Medical Dictionary for Regulatory Activities (MedDRA) hierarchy for system organ 
classification.187 All reported adverse events were recorded upon suspicion, 
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regardless of whether or not they were deemed likely to be caused by the study 
treatment. 
Data were collected through structured interviews with the nursing home patients and 
their primary caregivers. Assessments were conducted by research assistants who had 
completed a two-day training program to qualify them for collecting data. 
Demographic information and prescribed drugs were collected through a review of 
the patients’ medical records. 
Ethics 
Verbal and written informed consent was obtained from the patients if they were 
deemed to have medical decision-making capacity. In those with reduced capacity to 
give consent, written consent was obtained from a legally authorised representative in 
accordance with ethics committee requirements and current Norwegian legislation. 
The trial was approved by the Regional Committee for Medical and Health Research 
Ethics (2013/1474) and the Norwegian Medicines Agency (EudraCT 2013-002226-
23), and registered at ClinicalTrials.gov (NCT02267057). Participants were insured 
to cover compensation and treatment in the event of drug-related harm. 
Contributions 
The candidate made major contributions to the planning and conduction of the trial 
from 2014-2016, in cooperation with fellow Ph.D. Candidate Kjersti Marie Blytt 
from 2015-2016. The candidates recruited all of the nursing homes, screened the 
nursing home patients for eligibility, obtained informed consent from all eligible 
patients and their relatives, and conducted baseline and follow-up assessments in 
cooperation with the nursing home staff. As a licensed pharmacist, the candidate 
handled the storage and distribution of study drugs, destruction of unused drugs, and 
participated in the labelling of study drugs – thereby providing major savings on 
pharmacy services for the project. In addition, the candidate contributed to the 
communication with drug manufacturers, the Norwegian Medicines Agency, and the 
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Regional Committee for Medical and Health Research Ethics (REK-Vest) in order to 
finalize the necessary approvals.  
3.4.3 Paper II 
Design 
This paper presents the primary results from the DEP.PAIN.DEM trial, a randomised, 
multicentre, double-blind placebo-controlled trial to assess the efficacy of analgesic 
treatment for depressive symptoms in nursing home patients with dementia and 
depression. 
Trial profile 
All participants in the DEP.PAIN.DEM trial were included in the database for Paper 
II (Figure 3). Participants were long-term nursing home patients (n=162) aged ≥60 
years with dementia (MMSE≤20) and depression (CSDD≥8); for full inclusion and 
exclusion criteria, see section 3.4.2. 
Outcome variables 
The main outcome was treatment effect on change in depression (CSDD) from 
baseline to 13 weeks. In order to assess whether any change in depression was caused 
by decreased pain, change in pain (MOBID-2) was a secondary outcome, as well as 
adverse events and dropouts from treatment. 
Statistics 
Baseline characteristics were presented as mean (SD) for continuous variables and 
number of participants (%) for categorical variables. Treatment effects on both the 
primary outcome (depression assessed by the CSDD) and the secondary outcome 
(pain assessed by the MOBID-2 Pain Scale) were assessed separately using linear 
mixed effects models which incorporated all assessments at baseline, 6, and 13 
weeks. We treated time as a categorical variable, and included fixed effects for time, 
intervention and their interaction in the models. To account for clustering, the models 
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Figure 3. Trial profile Paper II 
CSDD; Cornell Scale for Depression in Dementia, TDS; transdermal system 
 
were fitted with random intercepts for nursing home units and individuals. Treatment 
effects were calculated for active treatment versus placebo, these analyses were 
repeated with use of other analgesics or antidepressants at baseline as covariates to 
control for any impact of concomitant drug use. We also conducted pre-planned 
subgroup analyses for paracetamol tablets compared to placebo tablets, 
buprenorphine TDS compared to placebo TDS, and to investigate treatment effects 
stratified for level of cognitive function and for the presence of moderate to severe 
pain. We regarded p<0.05 as significant. All statistical analyses were conducted with 
STATA/IC 14 (Stata Corp LP, College Station, TX, USA). 
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3.4.4 Paper III 
Design 
This paper presents secondary analyses from the DEP.PAIN.DEM trial, and is the 
first randomised, double-blind placebo-controlled trial to assess the tolerability of 
buprenorphine TDS in people with advanced dementia. 
Trial profile 
The 89 participants who were prescribed buprenorphine (active/placebo) in the 
DEP.PAIN.DEM trial were included in the database for Paper III (Figure 4). 
Outcome variables 
The primary outcome was time to discontinuation of active treatment compared to 
placebo, controlling for cognitive function and concomitant drug use. The secondary 
outcome was treatment effect on activity during the first week of treatment, measured 
by continuous actigraphy recording for 7 days before and 7 days after treatment was 
started. The tolerability of buprenorphine TDS was operationalized by assessing how 
many participants discontinued treatment due to adverse events (defined as suspected 
adverse event, clinical deterioration, or death), and how long treatment lasted before 
such discontinuation. The impact of regularly scheduled drug use (excluding 
prescriptions administered PRN or “as needed”) on tolerability was assessed, 
including total number of prescriptions, ACB, use of analgesic drugs, and the 
individual and total number of prescriptions for psychotropic drugs. 
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Figure 4. Trial profile Paper III 
TDS; transdermal system 
 
Statistics 
We used a Cox regression model to determine whether those who were randomised to 
receive active buprenorphine had a higher risk of discontinuation compared to those 
who received placebo. These analyses were repeated with age, sex, MOBID-2, 
CSDD, MMSE, and use of other analgesics or antidepressants at baseline as 
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covariates. To further assess whether the risk of discontinuation of buprenorphine 
was modified by drug use, we tested the interaction between the treatment effect and 
each of the drug variables on discontinuation, both unadjusted and adjusted for age, 
sex, MOBID-2, CSDD, and MMSE at baseline. To assess immediate changes in 
activity in the first days of treatment, we used linear mixed effect models for Total 
AC and AC/min per day using the mean recording from the 7 days before treatment 
was initiated as baseline. Time was included as a categorical variable, with fixed 
effects for time, intervention, and their interaction in the models. To account for 
clustering, the models were fitted with random intercepts for nursing home units and 
individuals. We regarded p<0.05 as significant. All statistical analyses were 
conducted with STATA/IC 14 (Stata Corp LP, College Station, TX, USA). 
  75 
4. Main results 
Paper I 
Erdal A, Flo E, Selbaek G, Aarsland D, Bergh S, Slettebo DD, Husebo BS. 
Associations between pain and depression in nursing home patients at different stages 
of dementia. J Affect Disord 2017;218:8-14. 
 Many of the included participants had pain and depression. 40% suffered from 
moderate to severe pain (MOBID-2≥3) at baseline (343 of 858 assessed), and 
38% had depression (347 of 924 assessed). 
 Half of those with depression also had pain (19% or 164 of the 856 
participants who completed both assessments), and those with pain had 
increased risk for depression (unadjusted odds ratio 2.35, 95% CI 1.76; 3.12). 
 Pain and depression persisted to follow-up in about half of those diagnosed at 
baseline. Persistent moderate-to-severe pain was found in 22.2% of the sample 
(137 of the 617 participants who completed both pain assessments), and 20.6% 
had persistent depression (144 of the 699 participants who completed both 
depression assessments). 
 Those who had more severe pain had significantly more depressive symptoms; 
a 1-point increase in MOBID-2 pain was associated with a 0.5 increase in 
CSDD (p<0.001; mixed model with adjustment for time from baseline to 
follow-up). Similarly, those with more severe depressive symptoms also had 
significantly more pain; a 1-point increase in CSDD was associated with a 0.1 
increase in MOBID-2 pain (p<0.001; mixed model). These associations were 
not affected by cognitive function (MMSE), and remained unchanged when 
adjusting for age, sex, and number of analgesics and/or antidepressants. 
 This was the first publication to determine that having pain was associated 
with future worsening of depression, and vice versa, in people with dementia.  
 In the COSMOS group, pain intensity at baseline was associated with a 
significantly higher burden of depressive symptoms at 4-month follow-up 
(linear regression, RC .41, p=0.026; adjusted for depression at baseline, 
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MMSE, sex, and age), but not in the REDIC group after 6-month follow-up 
(RC .08, p=0.358). 
 Those who had more severe depressive symptoms at baseline had significantly 
more pain at 6-month follow-up in the REDIC group (linear regression, RC 
.05, p=0.008; adjusted for pain at baseline, MMSE, sex, and age). The same 
association was not significant in the COSMOS group after 4-month follow-up 
(RC .06, p=0.064). 
 In the REDIC population, we found a significant within-subject effect of pain 
on depressive symptoms, i.e. a person who had reduced pain at follow-up had 
significantly less depressive symptoms at follow-up compared to baseline 
(mixed model, between-subject coefficient .62, p<0.001; within-subject 
coefficient .23, p=0.042). In the COSMOS population, only the between-
subject effects were significant (p=0.317 for within-subject effects). 
 We did not find that the obtained association between pain and depression can 
be explained by overlap between pain and CSDD items such as multiple 
physical complaints, as the association was replicated using the NPI-NH 
depression item as an alternative outcome in the mixed model analysis; a 1-
point increase on the MOBID-2 scale was significantly associated with a .11 
increase on the NPI-NH depression subscale (p=0.005). 
Paper II 
Erdal A, Flo E, Aarsland D, Ballard C, Slettebo DD, Husebo BS. Efficacy and Safety 
of Analgesic Treatment for Depression in People with Advanced Dementia: 
Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial 
(DEP.PAIN.DEM). Drugs Aging 2018;35(6):545-558. 
 We did not find that depressive symptoms could be ameliorated by treating 
undiagnosed pain in people with dementia. 
 Depressive symptoms remained unchanged in the group that received active 
treatment (paracetamol/buprenorphine; mean CSDD change -0.66, 95% CI -
2.27; -0.94). 
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 In contrast, the placebo group had a significant improvement in depressive 
symptoms from baseline to 13 weeks (mean CSDD change -3.30; 95% CI -
4.68; -1.92). 
 The estimated effect of active treatment on depressive symptoms from 
baseline to 13 weeks was therefore significant in favour of placebo, as active 
treatment (paracetamol/buprenorphine) was associated with a significant 
increase of 2.64 on the CSDD scale (95% CI 0.55; 4.72, p=0.013) relative to 
placebo. 
 We were unable to detect a significant treatment effect of paracetamol (n=73) 
on depression; active paracetamol was associated with a 1.98 increase in 
CSDD depression relative to placebo tablets (95% CI -0.79; 4.74). 
 Buprenorphine was associated with a near-significant 3.04 increase in CSDD 
depression relative to placebo TDS; however, the trial was not sufficiently 
powered to detect subgroup effects, as reflected by the wide confidence 
interval (95% CI -0.11; 6.19). 
 Overall, there was no significant change in pain from baseline to 13-week 
follow-up. In those who received active treatment, mean MOBID-2 change 
from baseline to 13 weeks was -0.28 (95% CI -0.90; 0.35). The corresponding 
change in the placebo group was -0.09 (95% CI -0.63; 0.46), to yield a non-
significant estimated treatment effect of -0.19 (95% CI -1.02; 0.64). 
 Subgroup analyses show that buprenorphine did not appear to reduce pain; the 
estimated treatment effect was a non-significant increase in MOBID-2 pain of 
0.47 (95% CI -0.77; 1.71) from baseline to 13 weeks. However, paracetamol 
had a near-significant treatment effect on pain estimated to -0.98 (95% CI -
2.00; 0.05) from baseline to 13 weeks, and paracetamol reduced pain 
significantly by -1.11 (95% CI -2.16; -0.06, p=0.037) from week 6 to 13 
compared to placebo tablets. Other subgroup analyses did not show significant 
treatment effects on pain. 
 Of the 162 participants who were enrolled in the trial, 35 were withdrawn due 
to adverse reactions, deterioration, or death: 25 (31.3%) during active 
treatment, and 10 (12.2%) in the placebo group. 
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Paper III 
Erdal A, Flo E, Aarsland D, Ballard C, Slettebo DD, Husebo BS. Tolerability of 
buprenorphine transdermal system in nursing home patients with advanced dementia: 
a randomized, placebo-controlled trial (DEP.PAIN.DEM). Clin Interv Aging 
2018;13:935-46. 
 Of 44 participants who received buprenorphine 5 µg/hour, 52.3% (n=23) 
discontinued treatment due to adverse events compared to 13.3% (6 of 45) in 
the placebo group (p<0.001). Five participants who received buprenorphine 
and three who received placebo died during the study period, this difference 
was not significant (Pearson χ2-test, p=0.439). 
 Mean time to discontinuation was 61 days (SD 36) in the buprenorphine 
group, and 82 days (SD 24) in the placebo group. Within the first 14 days, nine 
participants (20.5%) discontinued buprenorphine, and two (4.4%) discontinued 
placebo treatment. 
 Adverse events which caused discontinuation of active treatment were most 
frequently described as exacerbation of neuropsychiatric symptoms, and of the 
23 participants who discontinued buprenorphine, adverse events classified as 
psychiatric and/or neurological symptoms were reported as the cause in 16 
(69.6%). 
 Sedation/somnolence was the single most frequently reported adverse effect, 
with nine participants (20.5%) affected in the buprenorphine group and two 
(4.4%) in the placebo group (p=0.022). Actigraphy recording of daytime 
activity during the first week of treatment also showed that those who received 
buprenorphine had a 12.9% decrease in mean daytime activity (Total AC), but 
this effect was not statistically significant (mixed model; p=0.053). 
 However, those who received buprenorphine had significantly reduced 
daytime activity on the second day of treatment compared to placebo (mixed 
model; Total AC: -16967, p=0.005). This corresponds to a 21.4% decrease in 
total daytime activity compared with the mean daytime activity recorded 
during the week before treatment was started. 
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 Unadjusted analyses show that those who received buprenorphine had 4.7 
times increased risk of discontinuation due to adverse events compared with 
those who received placebo (Cox proportional hazards model, hazard ratio 
(HR), 95% CI 1.66; 13.3, p=0.004). When adjusted for age, sex, MMSE, 
MOBID-2 and CSDD at baseline, active treatment was associated with 24.0 
times higher risk of discontinuation (p=0.006). 
 When testing the interaction effects between active treatment and variables for 
concomitant drug use on discontinuation risk, we found that only 
antidepressant drugs were associated with increased risk for adverse events 
and discontinuation of treatment. Those who used an antidepressant and 
received buprenorphine (n=14) had 21.6 times increased risk of 
discontinuation compared with those who used an antidepressant and received 
placebo (n=27; unadjusted HR, 95% CI 2.75; 170, p=0.003). Adjusting for 
age, sex, MMSE, MOBID-2, and/or CSDD did not impact the result. 
 In the same analysis, we found that in those who received buprenorphine and 
did not use an antidepressant (n=30) the risk of discontinuation was not 
significantly increased compared with those who received placebo and did not 
use an antidepressant (n=18; unadjusted HR 1.88, 95% CI 0.63; 5.64, 
p=0.257). This shows that a drug-drug interaction between antidepressants and 




5.1 General considerations 
This thesis aims to investigate the relationship between pain and depression in people 
with dementia, and to assess the efficacy and safety of analgesic treatment for 
depressive symptoms in nursing home patients with advanced dementia and 
depression. The interrelationship between pain and depression in elderly nursing 
home patients at all stages of dementia and cognitive impairment was confirmed in 
the cohort study presented in Paper I.  
Although the observational design of Paper I does not allow any conclusion on the 
direction of causality, this result supports the rationale for and main hypothesis 
investigated in Paper II, namely that systematic assessment, identification and 
treatment of undiagnosed pain may ameliorate depressive symptoms in nursing home 
patients with advanced dementia and depression who are unable to verbally 
communicate symptoms of pain and discomfort.  
Based on previous studies, we anticipated that our results would confirm an 
association between untreated pain and depressive symptoms in people with 
dementia, and furthermore that treating pain can reduce depression in this population. 
However, Paper II presented results from a randomised controlled trial to assess the 
efficacy of an individual increase in analgesic treatment on depressive symptoms in 
people with advanced dementia (DEP.PAIN.DEM) and found that, contrary to our 
initial hypothesis, people who received active analgesic treatment had significantly 
more persistent depressive symptoms compared to those who received placebo. 
The DEP.PAIN.DEM trial was designed in order to minimise the risk of harm to the 
included participants, and therefore had very stringent inclusion and exclusion 
criteria. It may seem counter-intuitive that the included participants were not required 
to have a minimum of untreated pain, and even that participants with severe pain 
(MOBID-2 ≥8) were excluded from the trial. The latter was necessary for several 
reasons. Firstly, the placebo-controlled design meant that we could not risk untreated 
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severe pain in those who were randomised to the placebo condition. Secondly, the 
maximum allowed analgesic dose was low in order to reduce risk of adverse effects, 
and may have been insufficient to treat severe pain. Importantly, although MOBID-2 
pain was not an inclusion criterion, this does not mean that we know for certain that 
participants with a MOBID-2 score of zero at baseline did not, in fact, have pain. The 
MOBID-2 score is our best approximation for quantifying pain intensity in this 
population, but does not equate to the persons’ subjective pain experience which 
remains unknown. This is at the core of the rationale for the DEP.PAIN.DEM trial, 
which hypothesized that undiagnosed pain may contribute to depressive symptoms in 
people with moderate to severe dementia.  
In Paper III, adverse events reported during treatment with active buprenorphine TDS 
were investigated. Paper III followed up on preliminary results from Paper II which 
indicated that those who received active analgesic treatment may have had more 
persistent depressive symptoms because of psychiatric adverse effects of 
buprenorphine TDS.  
The following discussion aims to provide a critical appraisal of the methodological 
basis, implications for practice, and external validity of the findings presented in 
Papers I-III, as well as important ethical considerations in relation to the methods, 
results, and wider dissemination of the conclusions presented in this thesis. 
5.2 Discussion of study methods 
5.2.1 Paper I: a cohort study 
To investigate the bidirectional associations between pain and depression in people 
with dementia, we chose a prospective observational study design including two 
different cohorts of nursing home patients. The two cohorts had different inclusion 
criteria, which may impact generalisability of the results. 
The largest cohort (REDIC sample) consisted of people who were recently admitted 
to long-term nursing home care. They were younger, relatively fewer women, had 
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less severe dementia, less pain, less depression and less severe neuropsychiatric 
symptoms compared to the smaller cohort (COSMOS sample) that was recruited 
regardless of length of stay. While the latter sample is likely to be representative of 
the general nursing home population, the former sample may provide findings that 
are more generalizable to nursing home patients with short lengths of nursing home 
stay. Despite this limitation, we chose to merge the two cohorts in the main analyses. 
By this approach, we were able to achieve a more balanced sample in terms of 
cognitive function as shown in Table 7.  









6.6% 4.2% 6.0% 
Mild dementia  
(MMSE 21-25) 
15.2% 9.7% 13.8% 
Moderate dementia  
(MMSE 11-20) 
59.2% 41.7% 54.7% 
Severe dementia  
(MMSE 0-10) 
18.9% 44.4% 25.5% 
COSMOS; Communication, Systematic pain assessment and treatment, Medication review, Organised 
activities, and Safety, MMSE; Mini-Mental State Examination, REDIC; Resource Use and Disease 
Course in Dementia 
 
Although the prospective observational design is well suited to illustrate associations 
between exposure or independent variables and outcome or dependent variables, this 
design cannot generate conclusive data on causal relationships. We have observed 
effects within individuals which indicate that pain reduction was associated with 
reduced depressive symptoms, or similarly that pain exacerbation was associated with 
increased depressive symptoms. Importantly, these associations must be tested in a 
randomised controlled trial in order to determine any direction of causality between 
pain and increased depression, and vice versa. 
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5.2.2 Papers II-III: a randomised placebo-controlled trial 
To test the hypothesis of causality between pain intensity and depressive symptoms, 
we used a randomised, double-blind, placebo-controlled trial design. This design has 
the advantage of controlling the exposure to the independent variable, which in 
contrast to observational trials can facilitate evidence on causality. The placebo-
control has the additional advantage of eliminating many known sources of bias in 
open-label randomised controlled trials, such as expectation effects, to provide strong 
evidence for the intervention effects. Randomised, double-blind placebo-controlled 
trials are therefore regarded as the gold standard for generating evidence on 
causality.188 
However, the quality of the evidence is dependent on the strength of the study design. 
In randomised controlled trials, the aim is to keep all variables except exposure to the 
intervention balanced between the intervention and control groups in order to isolate 
the intervention effect as the difference between groups. Therefore, stringent 
inclusion and exclusion criteria are often applied. This means that the population 
under study may not be generalizable to the real-world population.189 Furthermore, 
the study protocol may differ from real-world clinical decisions in ways that impact 
generalisability. 
In the DEP.PAIN.DEM trial, we were only able to include about 7% of the 2323 
nursing home patients who were screened for eligibility. The majority of excluded 
individuals were ineligible for inclusion due to regular use of opioid analgesics (24% 
of all screened nursing home patients), because they did not have depression (39%), 
or did not have dementia (6%). These combined 69% were not in the target group for 
the intervention, and/or would be unlikely to have any benefit from the intervention 
on the main outcome (depression). This leaves 24% of the screened population, who 
were excluded for various reasons of which renal failure, change of placement, severe 
psychiatric disorder, or short life expectancy/death were most frequent. Note that the 
reason for exclusion was registered based on the first exclusion criterion that was 
fulfilled, after which no further assessments were conducted. In order to reduce 
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unnecessary resource use and patient involvement, MOBID-2 was assessed after the 
medical record review and interview with the primary caregiver was completed. 
Therefore, none of the screened individuals were registered as excluded because of 
severe pain. Only 137 individuals (6% of the 2323 screened; or 46% of the 299 
individuals who were otherwise eligible for inclusion) were excluded because they, or 
most frequently their guardians, declined to participate. Based on these data, the 
results from the DEP.PAIN.DEM trial should have generalisability to the target 
population which is nursing home patients with dementia and depression who do not 
have acknowledged severe pain and do not use opioid analgesics except low-dose 
buprenorphine TDS. 
5.2.3 Use of proxy rating scales 
Proxy rating was a prerequisite for obtaining assessments of the relevant outcomes in 
participants with advanced dementia. This is illustrated by Pautex et al. who found 
that less than half of people with MMSE ≤6 were able to comprehend and use any 
pain assessment scale even after repeated instructions.94 In the DEP.PAIN.DEM trial, 
the participants had a mean MMSE score of 7.8, and the subgroup in Article III had a 
mean score of 7.0. Instead of using a mixture of self-report and proxy-rated 
assessment scales, we decided to use the same assessment scales in all participants 
regardless of cognitive state in order to facilitate between-group comparisons. The 
same procedure has been used in several comparable trials.67,74 However, the use of 
proxy reports for the assessment of subjective outcomes such as pain and depression 
increases the risk of bias because the response will be affected by the rater’s own 
perception, understanding, and judgment.190 Although proxy rating is the best 
available method to gather information about these symptoms in people with 
advanced dementia, it is important to keep in mind that proxy ratings of pain and 
depression are assumed to have only low to moderate agreement with self-reported 
symptom intensity.190 Meanwhile, self-reported pain and depression in people with 
dementia are generally biased toward lower symptom intensity because of decreased 
awareness of and understanding of symptoms, and therefore may not be the 
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appropriate “gold standard” even in people with mild to moderate dementia who are 
still able to describe their symptoms.190 
When family caregivers are asked to rate the health or wellbeing of people with 
dementia, they generally report higher levels of suffering compared to the persons’ 
self-rated symptoms.191 Caregivers with poor psychological well-being and health 
status report more suffering, with a higher discrepancy between proxy-rated and self-
rated symptoms.191 In caregivers who are asked to rate patients’ health-related quality 
of life, their own self-rated quality of life is significantly associated with their 
response on behalf of the patient.192 Caregivers with pain report higher proxy-rated 
pain intensity in people with dementia, and caregivers with depression tend to report 
that patients suffer from higher levels of symptoms or disability.193 While similar 
characteristics of the formal caregivers who provided observations are likely to be 
associated with the rated symptom intensity, we have not attempted to assess or 
control for pain or depression in the proxy raters. 
However, by using the same proxy-rated scales in all included participants, we are 
able to collect the same data for all participants, regardless of dementia severity, and 
control for the effects of dementia progression in our data. Furthermore, whenever 
possible, we attempted to use the same proxy rater at each assessment of the same 
participant in order to minimise the effects of between-rater variability. The screening 
tools that were used to detect depression, pain and dementia were not intended for 
diagnostic use, and no universally accepted cut-off values exist for the CSDD, 
MOBID-2, or MMSE scales.  
Diagnosis and course of depression: impact of dementia severity 
The diagnostic accuracy of the CSDD scale at different cut-off values has recently 
been reviewed in a meta-analysis by Goodarzi et al.54 We intended to include people 
with moderate-to-severe depressive symptoms, and therefore did not apply the CSDD 
cut-off scores that are intended to diagnose major depressive disorder, which are 
typically higher. To ensure that the included participants had persistent depressive 
symptoms of at least 4 weeks’ duration, depression was assessed at screening and re-
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assessed at baseline. To reduce false positives at screening, the inclusion criterion 
was chosen as the cut-off with optimal specificity (≥8).54 As depressive symptoms 
often fluctuate over time, we used the cut-off with optimal sensitivity (≥6) at baseline 
as a criterion for persistent depression.54 While this does not imply that all 
participants had a depressive disorder, they did have sufficient depressive symptoms 
to allow us to detect change in symptom severity during treatment, as shown in the 
sample size analysis for the primary outcome of the DEP.PAIN.DEM trial. 
The accuracy of the CSDD scale may be affected by dementia severity. Studies that 
have assessed the psychometric properties of the CSDD scale have primarily included 
people with mild to moderate dementia.54 In a longitudinal study with 74-month 
follow up of 1158 nursing home residents, dementia severity was associated with 
higher CSDD scores in both mood and non-mood items.53 This corresponds to results 
from a factor analysis of the CSDD scale which found that the total score was 
significantly higher in people with severe dementia compared to those who had mild 
or moderate dementia.178 Several items rated by the CSDD scale may overlap with 
dementia symptoms, such as apathy or agitation, and therefore increase in severity as 
dementia progresses. Barca et al. examined the five-factor structure of the CSDD 
scale (symptom subscales: mood; physical; cyclic; retardation; behaviour) at different 
stages of dementia, and found that mood and cyclic symptoms were not significantly 
associated with dementia severity, while scores for physical and behavioural 
symptoms and retardation were significantly higher in advanced dementia.178 This 
suggests that the latter three factors may not precisely assess depression in severe 
dementia due to overlap with symptoms of dementia, while mood and cyclic function 
may persist as core symptoms of depression in advanced dementia.178 
Although symptoms of dementia and depression as assessed by the CSDD scale 
overlap and may be difficult to distinguish, the follow-up period of the 
DEP.PAIN.DEM trial (13 weeks) is likely too short to expect dementia progression to 
influence our results significantly. This is supported by preliminary analyses of 
change in cognitive function (MMSE) from baseline to follow-up, which do not show 
significant change between or within groups. Furthermore, any effect of dementia 
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progression on the course of CSDD depressive symptoms should be balanced 
between active treatment and placebo. 
The Neuropsychiatric Inventory – Nursing Home Version 
Although the NPI-NH was not used as a primary outcome, the use of the depression 
subscale of the NPI-NH as an alternative measure of depression is supported by 
several validity studies which have shown significant correlation with NPI-NH 
depression and other rating scales for depression in dementia.30,179,194 Selbaek et al. 
found a Spearman’s correlation coefficient of 0.60 between the Norwegian 
translations of the NPI-NH depression item and the CSDD scale (p<0.01).195 
Interestingly, several studies that have investigated the factor structure of the NPI-NH 
scale have found that apathy does not cluster with affective symptoms, suggesting 
that apathy may represent a separate syndrome from depression. Other symptoms that 
are included in the CSDD scale but may not be clustered with NPI-NH affective 
symptoms include agitation, irritability, and appetite and eating disturbances.183 
However, studies of the NPI-NH factor structure have found varying results, and 
items that have been clustered with depression in some studies but not others include 
apathy, anxiety, night-time behaviours and appetite and eating disorders.180,181 
Assessment of pain: the MOBID-2 Pain Scale 
Many assessment scales have been developed to diagnose pain in people with 
dementia, but the extent to which the different scales have been translated, tested and 
validated across different clinical settings varies. Current expert recommendations 
highlight the need to incorporate the following three elements in order to detect and 
assess pain in people with dementia: facial expressions of pain; behavioural changes 
or vocalization related to pain; and observation over time, particularly in relation to 
movement or routines such as daily care.151 The MOBID-2 Pain Scale includes 
detailed assessments of all three elements (see Appendix). MOBID-2 has shown 
excellent interrater and test-retest reliability.171 In a recent systematic review of pain 
assessment scales for people with dementia, MOBID-2 was rated among the highest 
for internal consistency.196 The tool has also demonstrated responsiveness to change, 
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as the total pain intensity score was significantly reduced after analgesic treatment.171 
While no single pain assessment tool has been universally recommended, the 
MOBID-2 Pain Scale has been sufficiently tested and validated to serve as the best-
available instrument to assess pain intensity in the current setting, that is, people with 
dementia residing in long-term nursing home care in Norway.196 
The MOBID-2 scale therefore represents our best available approximation to the pain 
intensity experienced by people with advanced dementia who are unable to 
communicate their symptoms verbally, but no objective standard exists. Furthermore, 
the optimal cut-points for classifying total pain on the 11-point scale have not been 
determined. Even for self-reported pain, there is debate as to which cut-points on an 
11-point scale can be used to accurately diagnose mild, moderate, or severe pain in 
different populations.197,198 Patient characteristics have been found to affect the 
optimal cut-points. One such trait is catastrophizing, which can be defined as the 
tendency to worry about the worst possible outcome from a situation.199 In patients 
with low catastrophizing tendency, pain scores of ≤3 correspond to mild interference 
of pain with functioning, while for patients with high catastrophizing, a cut-point of 
≤5 more accurately reflects mild pain.200  
Traits in both the proxy rater and the patient are likely to affect the obtained MOBID-
2 pain score. Although a cut-point of MOBID-2 ≥3 for clinically relevant pain has 
been established, the optimal cut-points for mild, moderate, and severe pain intensity 
have not yet been investigated.171 While uncertainty remains as to the reliability and 
validity of diagnosing different levels of pain intensity based on cut-points on the 
MOBID-2 Pain Scale, the current evidence-base shows satisfactory psychometric 
properties with regard to monitoring of change in pain intensity.171 Furthermore, we 
have controlled for the impact of interrater variability by ensuring that the same rater 
conducted follow-up assessments whenever possible. 
Dementia diagnosis and staging of cognitive impairment 
The prevalence of undiagnosed dementia is high in nursing home patients.201,202 In 
order to include people with dementia who had not received a diagnosis, we used the 
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MMSE scale to detect individuals with undiagnosed cognitive impairment and to 
perform a screening of cognitive function. In compliance with DSM-5 criteria, we 
excluded those with a history of any other condition which may explain the observed 
cognitive impairment, such as developmental disorders, traumatic head injury, or 
chronic alcohol abuse. No additional assessments were made in order to diagnose 
dementia subtypes. In the late stages of dementia, it can be very difficult to 
distinguish between different types of dementia.203 Although the protocol was 
amended to include plans for data collection that would allow making a diagnosis of 
the most likely dementia type, we were unable to complete the planned interviews 
with the patients’ relatives because of the total workload of the ongoing project. In 
addition, not all participants had a close relative who could have provided 
information about the debut and characteristics of cognitive symptoms. Based on 
previous studies, we assume that most participants had mixed pathology with 
Alzheimer’s disease and vascular lesions.204 It is unlikely that stratification on 
dementia subtype would yield information on differential efficacy or tolerability of 
treatment, given the sample size obtained for the DEP.PAIN.DEM trial. 
While the MMSE scale is not diagnostic and poorly identifies mild cognitive 
impairment, it has shown high accuracy as a screening tool for moderate to severe 
cognitive impairment related to dementia, with good interrater and internal 
reliability.167,205 
However, the MMSE scale has poor responsiveness to change, particularly during 
short follow-up periods, and therefore may not be sensitive to treatment effects.205 
Learning effects upon repeated assessments may cause bias, particularly when the 
intervals between testing are short. Although the MMSE scale was included in the 
DEP.PAIN.DEM protocol as a secondary outcome, the 13-week follow-up is 
probably too short to expect any significant change in cognitive function, and 
therefore any treatment effect. 
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5.2.4 Sources of bias 
Hawthorne effects 
The Hawthorne effect was originally described in a factory setting, where it became 
apparent that workers increased their productivity because of the awareness of being 
studied – rather than as a result of an intervention aimed towards changing their 
behaviour.206 In a wider sense, the Hawthorne effect may be used to describe 
improvement that is observed because the research subjects change their behaviour as 
a result of their participation in trial procedures, and not because of the efficacy of an 
intervention on an outcome.206 In the nursing home setting, with the use of proxy 
raters, it can be argued that a Hawthorne effect plays a part when a similar 
improvement is observed in the control and intervention groups alike. The Hawthorne 
effect shares some similarity with a type of response bias called demand 
characteristics, that describes the tendency of research participants to adapt their 
behaviour or responses to fulfil their purpose in the study, that is, to support what 
they believe is the aim of the study.207 
Subject-expectancy effects 
Another potential source for bias toward improvement may be subject-expectancy 
effects, which describe the effects of the research subjects’ expectation of an effect on 
their reported outcome.208 This type of bias includes placebo and nocebo effects. In 
the DEP.PAIN.DEM trial, subject-expectancy effects may occur in the proxy raters 
who have delivered the intervention. Because they may subconsciously expect the 
intervention to be effective (or to cause harm), they may be biased toward reporting 
an improvement (or worsening) from baseline. 
Sampling bias 
By applying multiple inclusion and exclusion criteria, the percentage of the target 
population that is eligible for inclusion is reduced. Furthermore, the likelihood of 
being included in the trial may differ across the target population, thus introducing 
risk of sampling bias which may limit the external validity or generalisability of the 
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results.209,210 In the DEP.PAIN.DEM trial, strict inclusion and exclusion criteria were 
necessary in order to reduce the risk of harm to frail and multimorbid individuals. 
This means that the results should not be generalised beyond the population that was 
in fact eligible to be included in the trial. Although we were able to include a small 
percentage of all nursing home patients, the obtained results may provide valuable 
information for clinicians who regularly encounter people with advanced dementia 
and depression in whom pain is difficult to diagnose, but cannot be ruled out as a 
potential cause for distressing symptoms.  
5.2.5 Controlling for bias 
Although proxy-rated data have a high risk of bias, the placebo-controlled design of 
the DEP.PAIN.DEM trial ensures that caregiver characteristics which may influence 
our results are balanced between the active and placebo groups, thus minimising the 
effects of any bias introduced from proxy rating. This is one of the most important 
advantages of the DEP.PAIN.DEM trial in comparison with the previous cluster-
randomised controlled trial by Husebo et al. which generated the main hypothesis that 
the DEP.PAIN.DEM trial was designed to test.39 However, due to risk of sampling 
bias, the results should not be generalised beyond the target population: nursing home 
patients with moderate-to-severe cognitive impairment and depressive symptoms who 
do not have diagnosable severe pain, do not use regularly scheduled opioid analgesics 
other than or exceeding buprenorphine 5 µg/hour, and do not fulfil other exclusion 
criteria as listed in section 3.4.2. 
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5.3 Discussion of the results  
Paper I confirmed that pain is associated with increased depressive symptoms in 
people with advanced dementia. This result corresponds to similar findings from 
cross-sectional studies, but our study was the first to show that change in pain 
intensity between baseline and follow-up was associated with a corresponding change 
in depressive symptom burden at individual level.152,211  
In Paper II, we found that despite the relationship between pain and worsening of 
depression, analgesic treatment was not associated with reduced depression scores in 
people with advanced dementia and depression. In contrast, active treatment was 
associated with more persistent depressive symptoms compared to those who 
received placebo. This was mainly driven by a significant decrease in depressive 
symptoms from baseline to follow-up in the placebo group, while depressive 
symptoms in the active treatment group remained unchanged. We suggest that this 
unexpected finding is at least partly explained by adverse effects of analgesic 
treatment. This is supported by the high dropout rate observed in participants treated 
with buprenorphine TDS compared to placebo TDS, which was not observed in those 
who received paracetamol. 
Paper III investigated the tolerability and adverse events reported in the subgroup of 
participants who received buprenorphine or placebo TDS, and found a significantly 
higher hazard ratio for discontinuation due to adverse events in those who received 
buprenorphine compared to placebo. Furthermore, antidepressant use was strongly 
associated with increased risk for discontinuation of active treatment, suggesting a 
clinically significant drug interaction between buprenorphine TDS and 
antidepressants in people with advanced dementia. Other variables investigated, 
including cognitive function, pain intensity, depressive symptoms, and use of other 
psychotropic or anticholinergic drugs, did not impact discontinuation risk. The most 
frequent types of adverse events associated with discontinuation were psychiatric and 
neurological, and sedation was the single most frequently reported adverse symptom. 
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5.3.1 The course of depressive symptoms in dementia 
A large study by Borza et al. including 1158 nursing home residents at baseline (T0) 
with follow-up after 12 (T1), 31 (T2), 53 (T3), and 74 months (T4) found that the mean 
CSDD score decreased from T0 to T1, but returned to baseline level at T2.53 The 
authors suggest that this rebound effect may be caused by a Hawthorne effect, which 
has also been observed in other studies of depressive symptoms in dementia.39,53 In 
Paper I, we observed a similar decrease of CSDD depressive symptoms in the REDIC 
population who had follow-up after 6 months, but not in the COSMOS population 
who were re-assessed after 4 months. This may be due to lower sample size and 
shorter time to follow-up in the latter group.  
In Paper II, we found a significant decrease of depressive symptoms in the placebo 
group after a 13-week follow-up period. While this group was smaller and had even 
shorter time to follow-up compared with the COSMOS group, participants in the 
DEP.PAIN.DEM trial were selected to include people with high initial levels of 
depression, thus making it more likely to observe a change in depressive symptoms 
over time. The apparent decrease of depressive symptoms in the DEP.PAIN.DEM 
control group may therefore be caused by regression toward the mean, which 
describes an effect where extreme measurements tend to normalize upon repeated 
assessments, as well as by a Hawthorne effect similar to that described in previous 
prospective studies.  
5.3.2 The efficacy of analgesic treatment for depression in people 
with dementia 
In the DEP.PAIN.DEM trial, those who received active analgesic treatment had an 
unchanged mean CSDD score from baseline to follow-up, and the treatment effect 
was therefore in the direction of increased depressive symptoms relative to the 
observed improvement in the placebo group. This result directly opposes our initial 
hypothesis which was based on results from a previous trial,39 and other findings 
suggesting that pain may contribute to depression in dementia.145-149,152 
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Husebo et al. conducted the only previous study assessing the effect of analgesic 
treatment on depressive symptoms in people with advanced dementia, and found a 
moderate improvement on depression assessed by the NPI-NH depression item and a 
large improvement in the NPI-NH mood syndrome consisting of the items 
depression, apathy, anxiety, night-time behaviours and appetite and eating 
disorders.39 However, the NPI-NH depression item did not show improvement in the 
DEP.PAIN.DEM trial. Effects on the NPI mood cluster and other NPI items have not 
yet been investigated in the DEP.PAIN.DEM data; this should be a future priority. 
Other methodological differences between the DEP.PAIN.DEM trial and the previous 
trial by Husebo et al. may have contributed to the different results. The latter included 
nursing home patients with advanced dementia and agitation, and like the 
DEP.PAIN.DEM trial, participants were included regardless of presumed pain 
intensity at baseline.39 However, in the trial by Husebo et al., pain intensity assessed 
by MOBID-2 at baseline was higher compared with the DEP.PAIN.DEM trial (mean 
total score approximately 4 and 3, respectively).155 Higher pain intensity may have 
contributed to a greater potential for beneficial treatment effects in the trial by 
Husebo et al. in comparison with our study. Husebo et al. found that over 60% had 
moderate-to-severe pain, defined as a MOBID-2 score of 3 or more at baseline, and 
that pain treatment significantly reduced pain intensity.38,155  
The trial by Husebo et al. also had a larger sample size, with 352 participants in total 
of whom 175 were cluster randomised to receive the intervention, and 177 to the 
control condition which was usual treatment.38 In the intervention group, 63% 
(n=103) were prescribed paracetamol and only 22.6% (n=37) received 
buprenorphine, as opposed to 45.0% (n=36) and 55.0% (n=44) of the 
DEP.PAIN.DEM intervention group. This means that a higher proportion of 
participants in the former trial used either no analgesic or low-dose paracetamol at 
inclusion, and were allocated to receive paracetamol only. The different allocation 
ratio to paracetamol and buprenorphine between the two trials is a possible 
explanation for the apparently opposing results. The stepwise protocol for treating 
pain that was applied by Husebo et al. included the option to use pregabalin for 
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neuropathic pain, and found that this was the major cause of dropouts due to adverse 
events, with two dropouts (17%) among the 12 participants who were prescribed 
pregabalin. Those who received pregabalin also used paracetamol and buprenorphine 
TDS.  
Because the DEP.PAIN.DEM trial was placebo-controlled, and both treatment groups 
were well balanced with regard to demographic and clinical characteristics, the 
increased stability of depressive symptoms in the active treatment group compared to 
the controls is unlikely to be explained by measuring error, proxy bias or expectation 
effects. Therefore the administered analgesic treatment (paracetamol and/or 
buprenorphine) must have had some impact on the symptoms that were assessed and 
interpreted as depression using the CSDD scale. 
Subgroup analyses of the effects of paracetamol and buprenorphine did not show a 
significant effect on change in total CSDD score in any of the treatment groups, 
possibly due to low sample size. There was a trend toward increased depressive 
symptoms from baseline to 13 weeks in both groups, with a treatment effect of 1.98 
(p=0.162) and 3.04 (p=0.059) for paracetamol and buprenorphine, respectively. There 
are many potential factors which may influence the course of depressive symptoms in 
people with advanced dementia, and analgesics may be effective in subgroups of 
patients. Further studies of the association between pain and depression are therefore 
needed, and larger sample sizes with increased statistical power are likely required. 
5.3.3 The DEP.PAIN.DEM trial: Adverse events and safety 
In multimorbid nursing home patients with advanced dementia, a high rate of clinical 
deterioration and death can be expected over a 12-week period.212 Of the thirteen 
participants who were reported to deteriorate and/or died during the trial, none were 
suspected to be related to the study treatment or procedures. In all thirteen reported 
cases, the study treatment was discontinued upon recognition of worsened health and 
none of the participants who died still received treatment with the study drug at the 
time of death. Furthermore, the number of deteriorations and deaths did not differ 
significantly between active treatment and placebo. 
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Although we had a high number of withdrawals from treatment with buprenorphine 
because of adverse events, these were typically mild and all resolved upon 
discontinuation of treatment. The number of drug discontinuations shows that the 
procedures to ensure patient safety were successfully implemented in the nursing 
homes, and illustrates the carers’ and the responsible physicians’ awareness of and 
commitment to patient safety.  
5.3.4 Differentiation between symptoms of dementia, depression, 
and adverse events 
As mentioned previously, the CSDD items can be clustered into five factors, 
comprising one mood factor and four non-mood factors.178 Of these, mood and cyclic 
functions appear to remain stable while other non-mood factors increase in severity 
when dementia progresses and may therefore reflect dementia symptoms rather than 
true depression.178 We have not yet investigated the effects of analgesic treatment on 
the CSDD five factor structure, and cannot conclude as to whether the significant 
difference between participants who received active treatment and the control group 
in the course of CSDD symptoms during the follow-up period can be explained by 
adverse effects of active treatment on mood or non-mood CSDD factors. This will be 
investigated further by our group.  
We suggest that adverse effects of analgesic treatment may have caused worsening of 
single CSDD items such as reduced appetite, agitation, or sedation, which has 
cancelled out the Hawthorne effect that was observed in the placebo group. This is 
supported by preliminary analyses, which do not show any significant worsening of 
the CSDD mood factor during treatment, while several non-mood factors worsened 
significantly (manuscript in preparation). The estimated effect of active treatment 
(paracetamol/buprenorphine) on the CSDD mood factor from baseline to 13 weeks 
was 0.76 (p=0.08), while the effect on the combined non-mood factors was 1.65 
(p=0.03). The non-mood factors behaviour and retardation worsened significantly by 
0,72 (p=0.01) and 1.14 (p=0.01), respectively, while the factors physical and cyclic 
symptoms remained unchanged (p=0.88 and 0.71, respectively). Subgroup analyses 
show that the buprenorphine group, but not the paracetamol group, had a significant 
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worsening of non-mood CSDD factors during treatment. In those who received 
buprenorphine, the treatment caused significant worsening of the factors behaviour 
and retardation by 0.97 (p=0.01) and 1.53 (p=0.01), respectively, from baseline to 13 
weeks. No significant treatment effect on any factor was found in the paracetamol 
group. This supports the hypothesis that adverse effects of buprenorphine on 
dementia symptoms may explain the lack of improvement on depressive symptom in 
the DEP.PAIN.DEM intervention group. 
5.3.5 Adverse effects of buprenorphine in people with dementia 
With the exception of Husebo et al., no previous trial has reported on the safety of 
buprenorphine TDS in people with advanced dementia.38,155 Husebo et al. found that 
buprenorphine was well tolerated, and of the 40 participants who received an opioid 
analgesic in the previous trial (36 of whom received buprenorphine TDS), only four 
were withdrawn because of adverse events which the researchers deemed likely to be 
treatment related. The prevalence and types of adverse events recorded in those who 
received buprenorphine were not reported.38,39,155,213 
The pattern of observed adverse events from buprenorphine treatment as described in 
Paper III differs from previous results from studies that have included elderly people 
without dementia in several important ways. A non-systematic literature search 
identified five trials and one meta-analysis that have reported on the safety of 
buprenorphine for chronic moderate-to-severe pain in cognitively intact elderly 
people, excluding those which exclusively recruited patients with postoperative or 
cancer-related pain.214-219 All five trials had an open-label design. While the minimal 
age of the included participants ranged from 58 years, the mean age was high with a 
range from 72 to 85 years, and the combined number of participants in all five trials 
was 841. The follow-up period ranged from four to 22 weeks, with a median duration 
of 12 weeks. The meta-analysis included some additional trials which did not 
originally report adverse events stratified on age group. However, eight of the 14 
controlled trials included in the meta-analysis had an enriched enrolment design, 
meaning that only participants who tolerated treatment for an open-label run-in 
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period were enrolled in the randomised controlled trial.219 Figure 5 displays the 
observed range of the most frequently self-reported adverse events in the five 
controlled trials, and corresponding results from the meta-analysis of six non-
enriched trials and Paper III.  
Two trials found lower rates of reported adverse events compared with the 
DEP.PAIN.DEM trial (both previous trials found a rate of 47%, compared with 57% 
in the DEP.PAIN.DEM trial),215,218 while the three other trials and meta-analysis 
reported adverse events in 82-93% of the participants.214,216,217,219 However, most 
adverse events were classified as mild-to-moderate, and did not cause withdrawal 
from treatment (Figure 5). Subjectively rated adverse events such as dizziness, 
nausea, constipation, asthenia, and headache were either not reported or had a much 
lower occurrence in the DEP.PAIN.DEM trial compared with trials that included 
elderly people without dementia (Figure 5).  
Methodological differences may have influenced the observed differences in adverse 
events between the DEP.PAIN.DEM trial and the previous studies that have included 
elderly people without dementia (Figure 5). The administered doses ranged from 5-70 
µg/hour in the previous trials, and most included a larger number of participants 
compared to our study.214-219 This increases the likelihood of reports of dose-
dependent or rare adverse events. Furthermore, because the trials did not have a 
double-blinded placebo-controlled design and not all had a control group, there is 
inherent risk of different types of bias such as expectancy or confirmation bias which 
may lead to over-reporting of adverse events and cannot be controlled for in the data 
material. Other participant characteristics such as pain diagnosis and pain intensity 
may also have had an impact on the prevalence and pattern of adverse effects, 
particularly because diagnosable pain was not an inclusion criterion for the 
DEP.PAIN.DEM trial as opposed to the comparator trials. 
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Figure 5. Pattern of observed adverse events during treatment with 
buprenorphine TDS for chronic non-malignant pain in cognitively intact elderly 
people,214-219 compared with results from the DEP.PAIN.DEM trial (Paper III). 
AE; adverse event, DEP.PAIN.DEM; Efficacy of pain treatment on depression in people with dementia, 
TDS; transdermal system 
 
However, the most important difference between our trial and the previous trials 
conducted in elderly people without dementia is arguably our reliance on proxy 
rating. It is unlikely that people with dementia are less affected by adverse events 
than those without dementia. Rather, the proxy raters may not have had the proper 
tools, education, and resources to observe all types of adverse events, symptoms may 
be expressed differently in people with dementia, and/or the observable symptoms 
may have been too subtle to detect by proxy. As an example, it seems possible that 
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dizziness could be interpreted as other symptoms such as confusion or sedation in 
people who cannot communicate verbally. In any case, insufficient ability to detect or 
correctly identify mild-to-moderate adverse events is a likely explanation for the 
discrepancy illustrated in Figure 5. 
Although certain adverse effects may have been interpreted differently or attributed 
to other symptoms by the proxy raters, the high number of treatment discontinuations 
illustrates their commitment to patient safety. This may also have contributed to the 
high rate of treatment discontinuations. Many adverse events of buprenorphine TDS 
are considered transient and may resolve upon continued treatment, but the decision 
to wait and see may be easier to make in patients who do not have communication 
difficulty. 
Interestingly, the patterns of adverse events reported in people with dementia during 
different pharmacological interventions have recently been investigated in a 
systematic review, which found similar results to those reported in Paper III: 
neurological and psychiatric adverse events were among the most frequently reported 
adverse events across different studies; centrally active drugs were among those most 
often implicated in adverse events; and the frequency of reported adverse events was 
generally lower in people with dementia compared to those without dementia.220 
Nevertheless, this does not imply that people with dementia are less exposed to 
adverse effects, as other trials have identified dementia as a risk factor for adverse 
drug reactions.221 
While we were able to detect fewer than expected adverse events of buprenorphine 
TDS in people with dementia in the DEP.PAIN.DEM trial, particularly those of mild-
to-moderate intensity, we found a higher than expected rate of withdrawal due to 
adverse events (Figure 5) and a higher relative frequency of psychiatric and 
neurological adverse events. In 16 of 17 cases, these were deemed mild-to-moderate 
in severity by the responsible physicians, in the sense that continued treatment would 
be inappropriate - only one participant had mild/transient sedation and continued 
treatment. 
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The DEP.PAIN.DEM trial appears to be poorly designed to detect common mild-to-
moderate adverse effects of buprenorphine TDS, such as dizziness, which do not 
necessarily cause any easily observable symptoms. However, the adverse events that 
were recorded differ significantly from the pattern of adverse effects previously 
reported in elderly people without dementia. Most importantly, a higher than 
anticipated proportion of the participants discontinued treatment because of adverse 
events, and psychiatric and neurological adverse events were reported more 
frequently in people with advanced dementia compared with previous trials in 
cognitively intact elderly people. 
5.3.6 Sedation and reduced daytime activity during buprenorphine 
use  
Mild and transient drowsiness or sedation is a common adverse effect of 
buprenorphine TDS, estimated to affect approximately 29% in studies that have 
included people aged 65 or more without dementia.219  Change in daytime activity 
was a secondary outcome in Paper III, with daytime activity arbitrarily defined as the 
total activity output recorded by actigraphy between 09:00 AM and 09:00 PM. We 
found that those who received buprenorphine had significantly reduced daytime 
activity shortly after treatment was started compared with the placebo group which 
had unchanged activity. However, we do not know whether reduced daytime activity 
is transient and may resolve upon continued treatment with buprenorphine in people 
with dementia. Should a reduction in activity level persist during long-term treatment, 
this may contribute to increased risk for functional decline, frailty, and mortality.222-
225 In light of the potential serious consequences of a lasting decrease in daytime 
activity, the long-term effects of buprenorphine TDS on activity and function in 
people with dementia should be investigated further. 
5.3.7 Interaction between buprenorphine TDS and antidepressants 
In Paper II, we found that antidepressant drug use was the only variable for 
concomitant drug use which had an impact on the tolerability of buprenorphine TDS. 
Even though relatively few individuals who received buprenorphine used 
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antidepressants (n=14), we found that those who did were at the highest risk of 
discontinuation of treatment due to adverse events. When analyses were stratified on 
antidepressant use, those who did not use antidepressants did not have significantly 
increased risk of discontinuation during buprenorphine treatment compared with 
placebo, as illustrated in Figure 6. Even though the number of participants who 
received active treatment and did not use antidepressants was higher (n=30), we did 
not find a statistically significant increase in discontinuation risk in this group 
compared with antidepressant nonusers who received placebo (n=18; Figure 6). In 
comparison, the 14 individuals who used antidepressants and received buprenorphine 
had a large, statistically significant risk increase compared with those who used 
antidepressants and received placebo (n=27; Figure 6).  
Although subgroup analyses must be interpreted with caution due to low sample size, 
this highly significant effect suggests that a drug interaction between antidepressants 
and buprenorphine, rather than adverse effects of buprenorphine alone, may be the 
mechanism behind the low tolerability of buprenorphine TDS observed in the 
DEP.PAIN.DEM trial. An interaction between buprenorphine and antidepressant 
drugs has not previously been specifically described in the literature. 
Of those who received buprenorphine and used antidepressants, seven used 
escitalopram, five used mirtazapine, and two used mianserin. Within each 
antidepressant group, four, three, and two participants, respectively, had adverse 
events which led to premature discontinuation of treatment.  
Combinations of drugs with either serotonergic or anticholinergic activity are known 
to cause clinically relevant interactions in frail elderly people. Antidepressants of the 
SSRI class may cause serotonin toxicity, particularly in combination with other drugs 
that cause increased central serotonin levels.226 
Escitalopram is an SSRI with strong serotonergic properties, and the most frequent 
adverse effects include diarrhoea, dizziness, xerostomia, fatigue, headache, nausea, 
sweating, sedation, and tremor.227,228 
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Figure 6. Discontinuation risk stratified by antidepressant use 
Cox regression, adjusted for age and sex. CI, confidence interval. 
 
Mirtazapine and mianserin are tetracyclic antidepressants (TeCAs) which act as 
NaSSAs. Mirtazapine acts as an antagonist on the α2-receptors of the adrenergic 
system, as well as on several 5-HT receptor subtypes, thereby enhancing serotonergic 
activity.229 Dry mouth, sedation, and increases in appetite and body weight are the 
most common adverse effects.229 Mianserin has a similar pattern of activity.230 
A potential mechanism for the observed interaction may be additive or synergistic 
effects of buprenorphine and antidepressants on sedation, as all the types of 
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antidepressants used may cause sedation. This is also supported by reports of 
increased sedation as the most frequent adverse effect of buprenorphine in the 
DEP.PAIN.DEM trial. However, we did not find that sedation or somnolence was 
reported more frequently in those who received buprenorphine and used 
antidepressants compared with those who did not (Pearson χ2-test, p=0.913). 
Another potential explanation for the observed interaction may be the antagonistic 
effects of buprenorphine on the opioid κ-receptor. Activation of the κ-receptor causes 
adverse effects such as hallucination, dysphoria, increased anxiety, and aversion, in 
addition to analgesic effects.114,157,158 In contrast to full opioid agonists such as 
morphine and oxycodone which activate the κ-receptor, buprenorphine acts as a κ-
receptor antagonist and is therefore associated with a lower risk of treatment-induced 
dysphoria. Antidepressants exert their effects on the monoamine neurotransmitter 
systems, and an emerging body of evidence suggests that κ-receptors also modulate 
dopaminergic and serotonergic signalling.231 Although the precise mechanism of 
action is not yet understood, the κ-receptor modulates the regulation of serotonin, 
including the activity of the presynaptic serotonin transporter (SERT).163 SERT 
regulates the synaptic availability of serotonin (5-HT) by transporting released 5-HT 
back from the synaptic cleft into the neuron, and is the primary site of action for 
SSRIs.228 Preclinical trials have shown that activation of the κ-receptor may decrease 
SERT expression and activity, thereby decreasing 5-HT reuptake, in some regions 
where the κ-receptor is expressed.231,232 κ-receptor agonists also increase dopamine 
transporter activity, but have no effect on noradrenergic transporter activity.233  
However, most research on the κ-receptor system has been conducted in rodent 
models. Little evidence exists in support of increased serotonergic activity during 
treatment with buprenorphine, and the effects of buprenorphine on the monoamine 
system have not been investigated in people with dementia.234-236  
Even though buprenorphine has some anticholinergic effects, such as xerostomia and 
urinary retention, it is unlikely that combined anticholinergic effects have caused the 
observed interaction for two reasons: firstly, ACB score did not impact 
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discontinuation risk, and secondly, none of the participants who received 
buprenorphine used TCAs. 
Frailty may also contribute to the increased risk of adverse events in those who used 
antidepressants and received buprenorphine, as frail individuals are characterised by 
impaired homeostasis and reduced resilience which increases their susceptibility to 
adverse drug effects and drug interactions.237 However, this does not explain why 
antidepressants were the only drug class to impact discontinuation risk. 
As shown in Figure 6, the major difference in tolerability of buprenorphine TDS was 
not found between those who received buprenorphine versus placebo, but rather 
between those who used antidepressants and buprenorphine in combination versus 
those who did not. This suggests that buprenorphine TDS should be used with 
particular caution in people with dementia who also use antidepressants. New clinical 
trials with larger sample sizes are needed to fully elucidate the impact of concomitant 
drug use on risk of adverse events of buprenorphine TDS, and also to determine 
whether antidepressant use increases the risk of adverse events during treatment with 
other strong opioids in addition to buprenorphine TDS.  
5.3.8 Challenges concerning research in people with dementia 
Nursing home patients with dementia are among the most difficult groups to include 
in research. Those who are granted long-term residential care in Norway have 
advanced dementia and/or complex comorbidity with severely reduced independence 
and functional ability. While most are being treated for multiple comorbid conditions, 
the individual pharmacological interventions often lack evidence-based efficacy and 
safety when applied in combination to patients with advanced disease and frailty. 
Most randomised controlled trials that compare an intervention with either placebo or 
the best available treatment are conducted in relatively healthy patients who do not 
have clinically significant comorbid conditions, and who are capable of providing 
consent to participate as well as to self-report symptoms and adverse effects during 
treatment.238 
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The DEP.PAIN.DEM trial required screening of a high number of individuals from 
many nursing homes in order to achieve the desired number of included participants. 
Of those who fulfilled all of the inclusion criteria and none of the exclusion criteria, 
51% gave informed consent and were enrolled in the trial. The corresponding 
inclusion rate for a previous large-scale placebo-controlled trial by Banerjee et al. 
which assessed the efficacy of antidepressant treatment versus placebo for depression 
in people with dementia was 53.5%.74 However, the latter trial included participants 
from old-age psychiatry services where only 664 patients were screened for eligibility 
in order to obtain enrolment of the required 326 participants.74 This shows that the 
identification of eligible participants with dementia and depression was more 
resource-intensive in the nursing home setting compared to specialized secondary 
health care services. 
5.4 External validity 
Paper I included a large sample of nursing home patients with dementia of varying 
severity. Data were obtained from two different studies, conducted in a high number 
of nursing homes of varying sized, from a large and varied geographical area. In 
Paper I, we found a strong association between pain intensity and depressive 
symptoms in people with dementia, which we believe has high clinical relevance for 
this population. Based on these findings, pain should be recognized as a risk factor 
for depression, and vice versa, in nursing home patients and people with dementia. 
We recruited participants from nursing homes of varying sizes, located in both urban 
and rural areas, and recruited from a large geographical area. Although a high number 
of nursing home patients were screened to identify eligible participants for the 
DEP.PAIN.DEM trial, this does not mean that the trial had a poor inclusion rate. 
Most of the screened nursing home patients were excluded based on information from 
medical records, such as use of opioid analgesics, short-term placement, no dementia, 
other diagnoses, et cetera. An acceptable ratio of those who were eligible to 
participate were included in the trial. Therefore, the participants are representable for 
the population that was studied: nursing home patients in Norway with dementia and 
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depressive symptoms, who neither had diagnosable severe pain which precluded 
randomisation to active or placebo conditions, nor used other opioid analgesics. We 
expect that the obtained results from the DEP.PAIN.DEM trial and Papers II and III 
have direct clinical applicability for this group.  
However, patterns of analgesic use in people with dementia vary greatly between 
different countries. Both the general prevalence of analgesic use, as well as the choice 
of analgesic agent and doses applied may vary between different countries and 
clinical settings. We excluded 28% of all nursing home patients who were screened 
because they already received non-permitted treatment with an opioid. Therefore, the 
findings may not be applicable to clinical settings where fewer receive analgesic 
treatment, and more individuals are likely to have undiagnosed and untreated pain.  
Additionally, the DEP.PAIN.DEM trial was not designed to investigate whether there 
was any interaction between the obtained treatment effect and type of pain. 
Therefore, the results should not be generalised to populations with specific subtypes 
of pain, such as neuropathic pain or cancer pain, as well as those with severe pain. 
5.5 Ethical considerations 
The DEP.PAIN.DEM trial and this thesis have been planned and conducted in 
accordance with the current Declaration of Helsinki.239 All data material that has been 
used in this thesis originates from trials that have been approved by the Regional 
Committees for Medical and Health Research Ethics. In addition, the 
DEP.PAIN.DEM trial was approved and monitored by the Norwegian Medicines 
Agency. The DEP.PAIN.DEM, COSMOS, and REDIC trials were all registered in a 
clinical trial database (www.ClinicalTrials.gov) prior to enrolment of participants, 
and the data from the trials have been used to test hypotheses stated a priori. These 
results have been disseminated.  
The Declaration of Helsinki states that the rights and interests of individual research 
subjects must be safeguarded in all medical research, that the knowledge that is 
generated by research should be of direct benefit to the participant, and that it must 
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outweigh burden and potential harm.239 For people who are particularly vulnerable, 
and may have increased likelihood of being wrongfully treated or harmed, the 
Declaration calls for specifically considered protection.239 Furthermore, the 
Declaration provides criteria for consent to participate in research. Whenever 
possible, research should be conducted in subjects who are able to give free and 
voluntary informed consent to participation. However, when necessary, people who 
cannot provide informed consent may be included in research as long as informed 
consent is obtained from a legally authorised representative. In such cases, the 
research must either be likely to benefit these participants directly, or to promote the 
health of the group that they represent. For these reasons, the risk-benefit balance 
must be considered particularly carefully when research involves people with 
advanced dementia, many of whom are unable to provide informed consent and have 
difficulty communicating their wishes and needs. 
Regardless of whether the participant had capacity to consent, their ability to provide 
active assent or dissent during trial procedures was respected and no participant was 
forced to take study treatment or complete any assessment against their will. All those 
who were approached received individually adjusted verbal and written information 
about the trial, to ensure as far as possible that they were aware of the aims and 
implications of participating in the trial regardless of whether the participants 
themselves or their next of kin/legal guardian provided informed consent. 
Some important procedures that were implemented in the protocol in order to reduce 
the risk of harm will be discussed here. Firstly, in order to reduce the risk of untreated 
pain in participants who were randomised to receive placebo, the use of as-needed 
analgesics was allowed and encouraged, and the responsible physician had full 
authority to withdraw the patient from participation in the trial if they deemed it 
necessary, for example because of difficulty in managing pain, or clinical changes 
with increased need for pain management, such as falls, injuries or infections. 
Although the control condition was a placebo, no ongoing analgesic treatment was 
removed. Therefore, the placebo condition can be considered current best practice.239 
Secondly, because participants who did not necessarily have diagnosable pain at 
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baseline were prescribed a strong opioid analgesic “off-label” with depressive 
symptoms as the primary indication, they may be exposed to risk for adverse effects 
without direct benefit on pain or other symptoms. In order to minimise the risk of 
harm, the use of buprenorphine TDS was limited to the lowest available dose. No 
participant was prescribed buprenorphine/placebo TDS without the approval of the 
responsible physician who had complete knowledge of the patient’s clinical state, 
usual medical treatment, potential drug interactions, and so forth. Furthermore, the 
nursing homes received thorough information about potential adverse effects, and 
were closely followed by the researchers in order to detect and manage adverse 
events immediately.  
Unfortunately, a breach of protocol was discovered after the DEP.PAIN.DEM trial 
was completed. The Norwegian Medicines Agency approved the use of 
buprenorphine TDS in the stepwise protocol for treating pain, with the condition that 
no participants would receive an opioid analgesic as part of the trial unless they 
already received other scheduled analgesic treatment (e.g. paracetamol). This 
condition was made in order to reduce the risk of opioid dependency in participants 
who did not have pain. However, the stepwise protocol for treating pain was applied 
as described in Table 6 (page 67) which allows for prescribing 
buprenorphine/placebo TDS to participants who did not use any analgesic, but had 
difficulty swallowing tablets. We found that eleven participants were affected by this 
error, seven of whom received buprenorphine, and four received placebo TDS. 
Anonymized details of these participants including the occurrence of adverse events 
as a result of the protocol violation have been shared with the Norwegian Medicines 
Agency and the Regional Committee for Medical and Health Research Ethics. Four 
of the seven participants who received buprenorphine had clinically significant pain 
(MOBID-2 ≥ 3), and therefore the intervention had a clear indication and was 
medically justified. One patient had missing data for pain measurement. The rate of 
adverse effects among the seven affected participants was lower than the overall rate 
observed in the trial, and the reported adverse effects were all mild and transient. 
Because no participants were harmed, the Norwegian Medicines Agency have 
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released a statement to conclude that no additional investigation in this matter is 
deemed necessary based on the current available information. 
Despite the risk of opioid adverse events in the study being higher than anticipated, 
these events were generally mild-to-moderate and resolved upon discontinuation of 
treatment. There was no significant difference in the rate of clinical deterioration or 
death between buprenorphine and placebo TDS, and no deaths were considered likely 
to be related to the treatment. 
The rationale for the DEP.PAIN.DEM trial was based on data from previous research 
which indicated that neuropsychiatric symptoms of dementia, including depression, 
and pain was ameliorated by analgesic treatment with paracetamol or buprenorphine 
TDS, with low risk of adverse effects.38,39,155,213 Therefore we expected that those 
who received the intervention would benefit directly from a reduction of distressing 
symptoms. We also expected that the control group would benefit directly from 
improved care after the staff was trained in the assessment of pain and distressing 
symptoms.  
Although the trial did not find a treatment effect of analgesic treatment on depressive 
symptoms, the knowledge gained from the DEP.PAIN.DEM trial has direct and 
indirect benefit for the participants for two reasons. Firstly, the trial refutes results 
from a previous study which found that opioid analgesics may ameliorate depressive 
symptoms in people with dementia, thus reducing the risk of overprescribing 
analgesic treatment to people with advanced dementia and depression. Secondly, the 
DEP.PAIN.DEM trial found a higher than anticipated risk of neurological and 
psychiatric adverse events in participants treated with buprenorphine, and may 
contribute to improve detection of adverse effects of buprenorphine TDS in this 
population. Therefore, although we failed to achieve the anticipated benefit for the 
participants who received the intervention in the DEP.PAIN.DEM trial, the results 
have had direct implications for increased safety and knowledge-based treatment 
recommendations in nursing home patients with advanced dementia. 
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Conclusions 
This thesis has investigated how pain is related to depressive symptoms in people 
with dementia, and furthermore the efficacy and safety of analgesic treatment for 
depression in nursing home patients with advanced dementia and depressive 
symptoms.  
In Paper I, we found that pain was associated with increased depressive symptoms in 
a cohort of nursing home patients with dementia.  
However, experimental data from Paper II demonstrate that an individualised 
increase in analgesic treatment using paracetamol or buprenorphine TDS did not 
ameliorate depressive symptoms in nursing home patients with moderate to severe 
dementia and depression compared to placebo. Contrary to our initial hypothesis, we 
found that active treatment was associated with more persistent depressive symptoms, 
possibly due to adverse effects of buprenorphine TDS.  
Paper III follows up on these results and investigates more closely the observed 
pattern of adverse events in participants who were prescribed buprenorphine TDS, 
and reports higher than anticipated rates of adverse events resulting in poor 
tolerability and high risk of discontinuation. Main reasons for discontinuation were 
psychiatric and neurological adverse events, which may easily be attributed to 
neuropsychiatric symptoms in dementia. Secondary analyses also show reduced 
daytime activity during the first days of treatment. Concomitant use of 
antidepressants and buprenorphine greatly increased the risk of adverse events, 
suggesting that drug interaction effects may have contributed to the poor tolerability. 
These results may not be generalizable to patients with severe pain, or to countries or 
populations where people with dementia generally receive less analgesics compared 
to Norway. The safety and efficacy of buprenorphine TDS for pain in people with 
dementia should therefore be investigated further, specifically in relation to 
exacerbation of neuropsychiatric symptoms as well as potentially reduced daytime 
activity during long-term treatment which may adversely affect clinical outcomes. 
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Implications and future perspectives 
Currently, the use of both opioid analgesics and antidepressants is at an all-time high 
in nursing home patients and people with dementia. This change in prescribing 
practice has not been followed by increased efforts to investigate the safe and 
effective use of analgesic drugs in frail, multimorbid patients with dementia and high 
rates of polypharmacy and drug-related problems. One reason for the lack of 
evidence may be the challenge of designing high-quality randomised controlled trials 
that are ethically acceptable and feasible in this population. There is also a lack of 
robust evidence for the efficacy of antidepressants in the treatment of depression in 
people with dementia, while studies have shown high risk of adverse effects. This 
indicates the need for better treatment guidelines for both pain and depression in 
people with dementia. 
The DEP.PAIN.DEM trial has provided data for several supplementary analyses 
which should be conducted in order to follow up on the findings presented here. This 
includes planned investigations of: long-term effects of increased sedation during 
treatment with opioid analgesics; effects of buprenorphine TDS on different 
behavioural and psychiatric symptoms of dementia such as the CSDD factor structure 
(including mood versus non-mood factors), NPI-NH items and clusters, and CMAI; 
and effects of paracetamol on daytime activity (actigraphy). 
To date, very few placebo-controlled trials of opioid analgesics have been conducted 
in people with dementia. This thesis has presented important new information about 
the tolerability and adverse events of buprenorphine TDS in people with advanced 
dementia and depression. However, the safety data are based on secondary analyses 
and include a relatively low number of participants. Participants were recruited based 
on symptoms of depression rather than pain intensity, and we were not able to assess 
how pain intensity or type of pain affected tolerability. Insufficient evidence exists to 
determine which opioid analgesics may be superior in terms of tolerability and 
efficacy in people with dementia. Therefore, more research on the efficacy and safety 
of buprenorphine and other opioid analgesics for treating pain in people with 
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advanced dementia is needed. Future research should aim to produce clinically 
relevant information including adverse events, dose recommendations, and drug 
interactions in this population. 
One potential future direction is to conduct a discontinuation trial of opioid analgesics 
in people with advanced dementia and mild/no pain. If adverse effects of opioid 
analgesics can be mistaken for neuropsychiatric symptoms in dementia, and cause 
increased sedation and reduced daytime activity, such symptoms may improve if 
opioid treatment is discontinued when it is no longer indicated, or unnecessarily high 
doses are reduced. Furthermore, if concomitant use of antidepressants causes reduced 
tolerability of buprenorphine TDS, those who also use antidepressants should benefit 
more from dose reduction or discontinuation of buprenorphine. This hypothesis 
should be tested for buprenorphine specifically, and opioids in general. As both 
antidepressants and opioid analgesics are among the most frequently prescribed drugs 
in nursing home patients with dementia, a drug interaction has high clinical relevance 
and wide implications for patient safety. 
Future trials should be designed to overcome the challenges that are inherent to 
research on people with dementia in the nursing home setting; including how to 
achieve an appropriate control condition. Placebo-controlled trials are particularly 
difficult in multimorbid participants with complex treatment needs, and current best 
practice may be preferable to a placebo comparator in many cases. However, for 
many types of interventions, including non-pharmacological or multicomponent 
interventions, blinding is difficult to obtain. Lack of blinding may increase the risk of 
bias, thus reducing the quality of the obtained results. 
There is still a need for high-quality research to inform the safe and effective 
treatment of pain and depressive symptoms, using both pharmacological and non-
pharmacological strategies, to improve clinical outcomes and quality of life for 
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1. Vrangforestillinger     
2. Hallusinasjoner     
3. Agitasjon/aggresjon     
4. Depresjon/dysfori     
5. Angst     
6. Oppstemthet/eufori     
7. Apati/likegyldighet     
8. Manglende hemninger     
9. Irritabilitet/labilitet     
10. Avvikende motorisk adferd     
11. Søvn     
12. Appetitt-/spiseforstyrrelser     
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Hyppighet - hvor ofte skjer adferden? 
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3. Hyppig - flere ganger per uke men sjeldnere enn hver dag  
4. Svært hyppig - daglig eller oftere  
 
Intensitet – hvor ille er det for pasienten? 
1. Mild - medfører liten belastning for beboeren  
2. Moderat - forårsaker uvanlig eller merkelig atferd  
3. Alvorlig - forstyrrende og forårsaker mye uvanlig eller merkelig atferd 
 
Belastning – hvor mye merarbeid er det for pleierne? 
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2. Mild  
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9. Irritabilitet/Labilitet  
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10. Avvikende motorisk atferd  
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inkluder vanlig tremor eller tungebevegelser.)  
 
11. Søvn  
Har beboeren søvnvansker (symptomet er ikke til stede hvis pasienten må opp på toalettet en eller 
to ganger om natten for deretter straks å sovne igjen)? Er han/hun våken om nettene? Vandrer 
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12. Appetitt- eller spiseforstyrrelser  
Har beboeren hatt en ekstremt god eller dårlig matlyst, vektendring, eller uvanlige spisevaner (skår 
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A B S T R A C T
Background: Pain is associated with depression in nursing home patients with dementia. It is, however, unclear
whether pain increases depression. Therefore we evaluated the prospective associations between pain and
depressive symptoms in nursing home patients at different stages of cognitive impairment.
Methods: Two longitudinal studies were combined, including 931 patients (≥65 years) from 65 nursing homes.
One study assessed patients at admission, with 6-month follow-up (2012–2014). The other study assessed
residents with varying lengths of stay, with 4-month follow-up (2014–2015). Patients were assessed with the
Mini-Mental State Examination, the Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale, and
the Cornell Scale for Depression in Dementia.
Results: At baseline, 343 patients (40% of 858 assessed) had moderate to severe pain, and 347 (38% of 924) had
depression. Pain increased the risk of depression (OR 2.35, 95% CI 1.76–3.12). Using mixed model analyses, we
found that a 1-point increase in pain was associated with a .48 increase in depression (p< .001). This
association persisted in mild, moderate, and severe cognitive impairment. In those recently admitted, depressive
symptoms decreased over time, and having less pain at follow-up was associated with a decrease in depressive
symptoms (within-subject effect; p=.042).
Limitations: The two cohorts had different inclusion criteria, which may reduce generalisability. The study
design does not allow conclusions on causality.
Conclusions: Pain and depressive symptoms are associated in patients with dementia. Because reduced pain is
associated with less depressive symptoms, these patients should be assessed regularly for untreated pain. The
benefit of analgesic treatment should be weighed carefully against the potential for adverse effects.
1. Introduction
In Norway, over 80% of nursing home patients have dementia
(Helvik et al., 2015). Symptoms of depression affect up to 50% of
people with dementia, causing increased suffering, reduced quality of
life, and possibly shortened life expectancy (Enache et al., 2011;
Gonzalez-Salvador et al., 2000; Janzing et al., 1999; Todd et al.,
2013). Depression in people with dementia may also accelerate the
decline in daily functioning and cognition, and contribute to the loss of
independence and earlier nursing home placement (Luppa et al., 2008;
Potter and Steffens, 2007; Rapp et al., 2011). Over time, depression
often persists and re-occurs in these individuals (Selbaek and Engedal,
2012; Selbaek et al., 2013), and may be associated with worse outcomes
of medical treatment (Bellelli et al., 2008; Lenze et al., 2007; Smith
et al., 2015).
To manage mild to moderate depression in people with dementia,
nonpharmacological interventions such as psychotherapy, reminiscence
therapy, and personalized pleasant activities are recommended as first-
line treatment (Kales et al., 2015; Orgeta et al., 2015; Testad et al.,
2014). In severe depression, pharmacological treatment with antide-
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pressants is recommended, although updated systematic reviews of the
use of antidepressants for depression in people with dementia did not
find conclusive evidence for efficacy in this population (Leong, 2014;
Nelson and Devanand, 2011).
Thus far, little attention has been paid to potential modifiable causal
factors of depression such as untreated chronic pain. Approximately
40–60% of nursing home patients are suggested to be in daily moderate
to severe pain (Achterberg et al., 2010; Husebo et al., 2011). People
with dementia are at particular risk of untreated pain because their
ability to understand, evaluate, and verbally communicate symptom
severity gradually decreases (Flo et al., 2014). This may trigger
symptoms such as depression, agitation, and sleep problems (Ballard
et al., 2009). The interrelationship between pain and depression,
known as the “pain-depression dyad”, is well documented in people
without dementia (Bair et al., 2003; Goldenberg, 2010). Although no
clear aetiology has been established, the conditions are known to
commonly coexist, mutually exacerbate each other, share common
signal pathways and neurotransmitters, and respond to similar treat-
ments (Chopra and Arora, 2014).
The pain-depression dyad is not sufficiently investigated in people
with dementia (Bair et al., 2003; Goldenberg, 2010). Thus far, four
cross-sectional studies have found a significant association between
pain and depression in nursing home patients with moderate to severe
dementia (Cipher and Clifford, 2004; Leong and Nuo, 2007; Malara
et al., 2016; Williams et al., 2005), including one study which also
reported the prevalence of pain and depression stratified by cognitive
status (Leong and Nuo, 2007). The most recent study by Malara et al.
(2016) included 233 patients at different stages of dementia and found
a significant association between pain and depression as evaluated by a
physician. Although these studies provide important insights, some had
a low sample size, did not assess pain and/or depression with validated
proxy-rated instruments, and all studies lack prospective data to
evaluate whether pain is associated with future worsening of depres-
sion. In the current study, we investigate the prospective associations
between pain and depression in nursing home patients with advanced
dementia to explore whether pain may be an exacerbating factor for
depression, or vice versa. We addressed the following research ques-
tions: i) Is the intensity of pain associated with the severity of
depression? ii) Is change in pain over time associated with change in
depression? iii) How are these associations affected by cognitive
function and use of analgesic or antidepressant drugs?
2. Methods
2.1. Sample
We analysed prospective data from two independent multicentre
studies in 6 counties of Norway. The REDIC (REsource Use and DIsease
Course in Dementia) study included all patients aged ≥65 years (or
younger, if established dementia diagnosis) at admission to nursing
home care with an expected stay of> 4 weeks, and life expectancy> 6
weeks, from January 2012 to June 2014 (Sandvik et al., 2016a). In
total, 696 patients were included from 47 nursing homes. The current
analyses use data collected at month 0 and 6, excluding 12 patients
aged<65 years (Fig. 1). The other study, COSMOS (COmmunication,
Systematic pain treatment, Medication review, Organized activities and
Safety), included all patients aged ≥65 years in long-term nursing
home care, excluding patients with diagnosis of schizophrenia or life
expectancy<6 months, from April 2014 to June 2015 (Husebo et al.,
2015). In total, 545 patients were included from 67 units (clusters) in
31 nursing homes. Clusters were randomised to receive either a
complex intervention or care as usual (Husebo et al., 2015). The
current analyses use data from the control group, comprising 247
patients from 26 units, collected at month 0 and 4 (Fig. 1).
2.2. Data collection
Data collection in both studies was completed in close collaboration
with a staff member who had been familiar with the patients for a
minimum of 4 weeks prior to data collection. The staff received training
in the appropriate use of each outcome measure (Table 1), and had
assistance from the researchers as needed. Demographic information
and scheduled drug prescriptions (excluding prescriptions given “as
needed”) were extracted from the patients’ medical records. Analgesic
use at baseline and follow-up was assessed by counting the number of
prescriptions for drugs classified as systemic analgesics (Anatomical
Therapeutic Chemical (ATC) code N02 or M01A) at each time point.
Similarly, antidepressant use was assessed by counting the number of
prescriptions for drugs classified as antidepressants (ATC code N06A) at
baseline and follow-up. We did not assess the appropriateness of dose;
i.e. a dose adjustment from baseline to follow-up was not registered.
Cognitive function was assessed using the Mini-Mental State
Examination (MMSE), with scores from 26 to 30 defined as no/
questionable, 21–25 as mild, 11–20 as moderate and 0–10 as severe
cognitive impairment (Folstein et al., 1975; Perneczky et al., 2006).
Pain was assessed using the Mobilisation-Observation-Behaviour-Inten-
sity-Dementia-2 (MOBID-2) Pain Scale, with moderate to severe pain
defined as a score of ≥3 (Husebo et al., 2014). Depressive symptoms
were assessed using the Cornell Scale for Depression in Dementia
(CSDD), and depression defined as a score of ≥8 (Alexopoulos et al.,
1988; Burns et al., 2004). The Neuropsychiatric Inventory – Nursing
Home version (NPI-NH) was used to assess neuropsychiatric symptoms
(Cummings et al., 1994; Selbaek et al., 2008), and the NPI-depression
subscale was used as a secondary outcome measure.
2.3. Statistical analysis
Baseline characteristics were described with mean and standard
deviation (SD) for continuous variables and with number of patients
and percentages of sample size for categorical variables. Differences at
baseline between the studies were tested with independent samples t-
tests for normally distributed continuous variables, Mann-Whitney U-
test for non-normal distributed continuous variables and Pearson χ2
tests for categorical variables. The unadjusted odds ratio (OR) for
depression among patients with moderate to severe pain was calculated
at baseline. Linear regression models were fitted to analyse the
prospective association between pain at baseline and depression at
follow-up, and vice versa, adjusted for depression, pain, age, sex, and
cognitive function at baseline. To account for intra-cluster correlation
Fig. 1. Patients included in the final analyses.
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at the nursing home level, we used robust estimators for variance. To
explore whether increasing pain was associated with increasing depres-
sion, and vice versa, we used linear mixed effect models with restricted
maximum likelihood estimation. We conducted several analyses for the
outcome variables where we included fixed effects for MOBID-2, CSDD,
time, antidepressant use, and analgesic use (time-varying covariates),
and MMSE, age, and sex (time-constant variables). Associations at
different stages of cognitive functioning were assessed by stratifying
according to MMSE (Perneczky et al., 2006). To account for intra-
cluster correlation, the models were fitted with random intercept for
both nursing home and patient-level effects. We included random slope
for MOBID-2 and CSDD at patient-level, thus allowing the effects of
these covariates to vary between patients. The covariance structures
were specified using an independent model for both patients and
nursing homes. The regression coefficients for the time-varying covari-
ates can be interpreted as a between-patients effect and/or a within-
patient effect. To investigate this further, we included both within and
between effects in the same model (Rabe-Hesketh and Skrondal, 2012).
Mixed model analyses were also conducted using NPI-depression as a
dependent variable, with MOBID-2, time, MMSE, age, and sex as
independent variables, to explore whether any associations obtained
using the CSDD scale were replicated. We regarded p< .05 as
statistically significant. All analyses were conducted with Stata/IC
version 14 (StataCorp LP, College Station, TX, USA).
2.4. Ethical and legal considerations
Verbal and written informed consent was obtained from the patients
if they had sufficient ability to consent; if not, written presumed consent
was obtained from a legally authorised representative, in accordance
with the ethics committee requirements and current Norwegian legisla-
tion. The REDIC and COSMOS trials were approved by the Regional
Committees for Medical and Health Research Ethics, 2011/1738 and
2013/1765, and registered at clinicaltrials.gov, NCT01920100 and
NCT02238652, respectively.
3. Results
We included 931 patients with a mean age of 85.4 (SD 7.0) and
mean MMSE score of 14.6 (SD 7.1); 622 (66.8%) were women
(Table 2). In total, 703 completed the follow-up assessments, 142 died,
39 moved home or to a different institution/ward, 5 withdrew consent
to participate, and 42 were lost to follow-up for other reasons (Fig. 1).
Compared to the REDIC study, participants included in the COSMOS
trial were older and had a higher ratio of women. They had lower
MMSE scores, more pain and depressive symptoms, neuropsychiatric
symptoms, and used more analgesics and antidepressants. At baseline,
343 of all patients (40.0% of those who completed the assessment) had
moderate to severe pain (MOBID-2≥3), 347 (37.6%) had depression
(CSDD≥8), and 164 (19.2% of 856 patients who completed both
assessments) had both pain and depression. The unadjusted OR of
patients with moderate to severe pain having depression was 2.35 (95%
CI 1.76–3.12). MOBID-2 assessments at baseline and follow-up were
completed by 617 patients, of whom 137 (22.2%) had moderate to
severe pain at both assessments. Mean pain score was unchanged from
baseline to follow-up, and 92 patients (14.9%) had new incidence
moderate to severe pain at follow-up. CSDD assessments at baseline and
follow-up were completed for 699 patients, of whom 144 (20.6%) had
depression at both assessments, and 81 patients (11.6%) had new
incidence depression at follow-up.
Using linear regression, we found that pain at baseline was
significantly associated with depression at follow-up in both the
REDIC and COSMOS groups (coefficients .26 and .70, p=.022 and<
.001, respectively). When adjusting for covariates, this association
remained significant only in the COSMOS group (Table 3). Similarly,
depression at baseline was significantly associated with pain at follow-
up in both groups in the unadjusted analyses (coefficients .06 and .11
for REDIC and COSMOS, respectively, p< .001), but only significantly
in the REDIC group (coefficient .05, p=.008) after adjusting for
covariates.
Using linear mixed model analyses, adjusted for time (months),
MMSE, age, and sex, we found that patients with more pain were
significantly more depressed than those with less pain, and vice versa
(Model 2, Table 4). An increase of 1 on the MOBID-2 scale was
associated with an increase of .48 on the CSDD scale (p< .001) and
with an increase of .11 on the NPI-depression subscale (p=.005). An
increase of 1 on the CSDD scale was associated with an increase of .10
on the MOBID-2 scale (p< .001). When measures of between- and
within-subject effects were included in the model, only the between-
subject effects were significant (p< .001 for between-, and p=.113 for
within-subject effects). Over time, depression scores decreased in
severity (.10 decrease in CSDD scores per month, p=.007), as opposed
to pain which remained unchanged. The severity of pain and depression
was gender independent (coefficients .26, p=.069; −.08, p=.814;
respectively). Older patients had more pain (coefficient .02, p=.014)
but less depression (−.10, p< .001), and those with more severe
cognitive impairment had more depression (1 point less on the MMSE
scale was associated with .12 increase in CSDD, p< .001), but not more
pain (coefficient .00, p=.721). However, the progression of depression
over time (Fig. 2) was not affected by MMSE score (p=.990). The
mixed model analyses were re-calculated separately for the REDIC and
COSMOS groups with unchanged results, except that the COSMOS
Table 1
Assessment scales.
What does the tool measure? Tool characteristics and psychometric properties
MMSE Staging of cognitive impairment based on scores in 8 domains (orientation to
time and place, short-term recall, attention, calculation, long-term recall,
language, repetition, and complex commands), questionnaire administered
directly to the patient
30 items yield a sum score from severe (0–10), moderate (11–20), mild
(21–25), to no cognitive impairment (26–30) (Folstein et al., 1975). Widely




Assessment of pain intensity in dementia inferred by observation of pain
behaviours during standardised, guided movement (part 1 - musculoskeletal
system; current) and previous observations of other pain behaviours (part 2 -
internal organs, head and skin; in the last days), proxy rated
Each item is rated on a horizontal scale from 0 (no pain) to 10 (worst pain
imaginable). Yields a final assessment of total pain (range 0–10) (Husebo
et al., 2007). Excellent reliability and validity, good responsiveness (Husebo
et al., 2014). Total pain ≥3 was defined as moderate to severe pain.
CSDD Depressive symptoms in people with dementia in 5 domains (mood-related
signs, behavioural disturbance, physical signs, cyclic functions, and ideational
disturbance) in the last week, proxy rated
19 items with each symptom score rated from 0 (not present) to 2 (severe)
(Alexopoulos et al., 1988). Satisfactory interrater reliability and validity in the
elderly population (Korner et al., 2006). Sum score ≥8 defined as depression
(Burns et al., 2004).
NPI-NH The frequency and severity of 12 neuropsychiatric items in dementia
(delusions, hallucinations, agitation/aggression, depression/dysphoria,
anxiety, elation/euphoria, apathy/indifference, loss of inhibition, irritability/
lability, aberrant motor behaviours, sleep and appetite and eating
disturbances), proxy rated
The product of frequency (0–4) and severity (1–3) yields a composite score
per item from 0 (not present) to 12 (most frequent and severe symptoms),
with a cut-off value of ≥4 for clinically significant symptoms. Sum score
0–144 (Cummings et al., 1994). The Norwegian version has shown good
reliability and validity (Selbaek et al., 2008).
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population did not have a significant reduction in depressive symptoms
over time (coefficient −.08, p=.474). The REDIC population had a
significant within-subject effect of pain on depressive symptoms, i.e. a
patient who had reduced pain at follow-up had significantly less
depressive symptoms at follow-up compared to baseline (between-
subject coefficient .62, p< .001, within-subject coefficient .23,
p=.042). In the COSMOS population, only the between-subject effects
were significant (p=.317 for individual effects).
The associations between pain and depressive symptoms remained
significant when use of analgesics and/or antidepressants at baseline
and follow-up was included in the mixed models (Model 3–5, Table 4).
Use of analgesics was significantly associated with pain and depression.
A patient who received an increased number of analgesics from baseline
to follow-up had significantly increased pain (coefficient .65, p< .001)
and increased depression (.49, p=.006) in the same period (Model 4,
Table 4). Number of prescribed antidepressants was significantly
associated with depressive symptoms (1.2, p< .001), but not with
pain (−.02, p=.873) (Model 3, Table 4).
When patients were grouped according to cognitive function, pain
was significantly associated with increased depression in people with
mild (coefficient .47, p=.005) and moderate (.62, p< .001) cognitive
impairment, and near-significantly in those with severe cognitive
impairment (.24, p=.050; Table 5), but not significantly associated in
those with no/questionable impairment (.39, p=.232). Correspond-
ingly, depression was associated with pain in mild (.09, p=.008),
moderate (.12, p< .001), and severe (.06, p=.016) cognitive impair-
ment, but not in those with no/questionable impairment (.07, p=.229).
4. Discussion
4.1. Discussion
This study confirms the continued existence of the pain-depression
dyad in nursing home patients irrespective of cognitive status.
Moreover, this study is the first to show that reduced pain intensity is
associated with future reduction of depressive symptoms in this
population. This is the first large-scale multicentre prospective study
investigating the associations between pain and depression over time in
nursing home patients at all stages of cognitive impairment, using
validated proxy-rated instruments with good validity, reliability, and
responsiveness, and controlling for intra-cluster correlation and use of
analgesics and/or antidepressants. The obtained OR of depression in
patients with moderate to severe pain (unadjusted OR 2.35, 95% CI
1.76–3.12) was similar to results from previous nursing home studies
(Cipher and Clifford, 2004; Gruber-Baldini et al., 2005; Leong and Nuo,
2007; Malara et al., 2016; Williams et al., 2005).
Although we found that the association between pain and depres-
sive symptoms was strongest in patients with moderate cognitive
impairment (Table 5), the difference in effect between the four stages
of cognitive impairment was not significant (p=.227). This means that
we did not find evidence to suggest that the association changed with
increasing severity of cognitive impairment. In patients with no/
questionable impairment, the association was nonsignificant, probably
because this group was smaller (n=49). Patients with severe cognitive
impairment appear to have a weaker association than those with
moderate impairment, which did not reach significance despite this
group being relatively large (n=201), but the difference in effect was
not significant with the current sample size.
At baseline, 48% received one or more analgesics, while 40% still
had moderate to severe pain. A previous study found that in 2011, 58%
Table 2
Characteristics of included patients at baseline; total and between groups.
Total
(n=931)
N* REDIC (n=684) N* COSMOS (n=247) N* p
Agea 85.4 (7.0) 84.8 (6.8) 87.0 (7.2) < .001
Femaleb 622 (66.8%) 931 437 (63.9%) 684 185 (74.9%) 247 .002
MMSEa 14.6 (7.1) 15.7 (6.4) 11.4 (7.9) < .001
MMSE≤20b 673 (80.2%) 839 487 (78.2%) 623 186 (86.1%) 216 .012
MOBID-2c 2.3 (2.3) 2.1 (2.1) 2.8 (2.8) .008
MOBID-2≥3b 343 (40.0%) 858 249 (38.0%) 656 94 (46.5%) 202 .030
CSDDc 6.8 (5.6) 6.5 (5.2) 7.8 (6.4) .017
CSDD≥8b 347 (37.6%) 924 243 (35.7%) 681 104 (42.8%) 243 .049
NPI-NH total scorec 14.0 (17.0) 924 12.8 (15.3) 681 17.6 (20.7) 243 .012
NPI-NH depressionc 1.8 (3.1) 909 1.9 (3.1) 675 1.7 (3.1) 234 .448
Analgesicsb 445 (47.8%) 288 (42.1%) 157 (63.6%) < .001
Antidepressantsb 292 (31.4%) 193 (28.2%) 99 (40.1%) .001
Numbers represent mean (SD) or number of patients (%).
MMSE: Mini-Mental State Examination; NPI-NH: Neuropsychiatric Inventory-Nursing Home Version.










REDIC (n=453) COSMOS (n=158)
(follow-up) (baseline) Coef. p Coef. p
CSDD MOBID-2
(unadjusted)
.26 .022* .70 < .001*
CSDD MOBID-2 .08 .358 .41 .026*
CSDD .48 < .001* .49 < .001*
MMSE −.04 .357 −.07 .188
Sex .30 .347 .32 .802
Age −.08 .007* .01 .818
REDIC (n=439) COSMOS (n=138)
Coef. p Coef. p
MOBID-2 CSDD
(unadjusted)
.06 < .001* .11 < .001*
MOBID-2 CSDD .05 .008* .06 .064
MOBID-2 .38 < .001* .38 .005*
MMSE .03 .039* −.01 .849
Sex .13 .531 .37 .435
Age .01 .395 −.01 .800
COSMOS, COmmunication, Systematic pain treatment, Medication review, Organized activities
and Safety Study; CSDD, Cornell Scale for Depression in Dementia; MMSE, Mini-Mental
State Examination; MOBID-2, Mobilisation-Observation-Behaviour-Intensity-Dementia-2
Pain Scale; REDIC, REsource Use and DIsease Course in Dementia Study. Analyses include all
patients with valid assessments at baseline and follow-up, and are adjusted for intra-
cluster effects at the nursing home level.
* Significant association at p< .05 level.
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of nursing home residents in Norway were prescribed analgesics
(Sandvik et al., 2016b). While we found a lower overall prescription
rate, this is probably explained by the large proportion of recently
admitted nursing home patients in our sample. In the COSMOS group,
which is more comparable to the general nursing home population,
64% received analgesics. This may indicate a slight increase in
analgesic use from 2011 to 2014. A higher number of prescribed
analgesics at baseline, or an increase in the number of prescribed
analgesics from baseline to follow-up, was associated with higher levels
of both pain and depression. One explanation for this may be that the
prescribed treatment was insufficient to relieve pain effectively.
Another possibility is that use of one or more analgesics may increase
the total symptom burden due to adverse effects or interactions
between analgesics or other psychotropic drugs such as sedatives.
Known adverse effects of opioid analgesics in the elderly, such as
sedation or reduced appetite (Chau et al., 2008), may also have been
reported as symptoms of depression.
At baseline, 38% had depression and 31% received antidepressants.
A recent systematic review found that in Western nursing homes from
2004 to present, the use of antidepressants ranged from 18% to 48%,
and in the Nordic countries from 39% to 43% (Janus et al., 2016). In
the COSMOS sample, 40% used antidepressants, which is consistent
with these previous reports. Systematic reviews and meta-analyses have
not found clear benefit of antidepressants for moderate to severe
depression in people with dementia (Leong, 2014; Nelson and
Devanand, 2011), despite this the rate of antidepressant use in nursing
home patients appears to remain unchanged (Gulla et al., 2016; Janus
et al., 2016). We found that antidepressant use was associated with
Table 4
Results from mixed model analyses; unstratified.
Dependent variable Independent variable Model 1 Model 2 Model 3 Model 4 Model 5
C p C p C p C p C p
CSDD MOBID-2 .45 < .001* .48 < .001* .48 < .001* .44 < .001* .44 < .001*
Time (months) −.11 .002 −.10 .007* −.11 .002* −.11 .003* −.12 .001*
MMSE −.12 < .001* −.12 < .001* −.12 < .001* −.12 < .001*
Age −.10 < .001* −.09 < .001* −.11 < .001* −.09 < .001*
Sex −.08 .814 −.30 .381 −.13 .711 −.32 .336
Antidepressants 1.2 < .001* 1.2 < .001*
Analgesics .49 .006* .41 .023*
MOBID-2 CSDD .09 < .001* .10 < .001* .10 < .001* .09 < .001 .09 < .001*
Time (months) .01 .560 .01 .398 .01 .393 .00 .927 .00 .973
MMSE .00 .721 .00 .715 .00 .795 .00 .768
Age .02 .014* .02 .015* .02 .052 .02 .065
Sex .26 .069 .26 .068 .18 .180 .19 .153
Antidepressants −.02 .873 −.08 .440
Analgesics .65 < .001* .65 < .001*
Model 1: Association between pain and depression over time, unadjusted; Model 2: Association between pain and depression over time, adjusted for cognitive function, age, and sex;
Model 3: Association between pain and depression over time, adjusted for number of prescribed antidepressants, cognitive function, age, and sex; Model 4: Association between pain and
depression over time, adjusted for number of prescribed analgesics, cognitive function, age, and sex;Model 5: Association between pain and depression over time, adjusted for number of
prescribed antidepressants and analgesics, cognitive function, age, and sex. C, coefficient; CSDD, Cornell Scale for Depression in Dementia; MMSE, Mini-Mental State Examination;
MOBID-2, Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale. Analyses include all patients with valid assessments at any time point, and are adjusted for time to
follow-up (4/6 months) and intra-cluster effects at the nursing home level.
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MMSE 11-20 MMSE 0-10
Fig. 2. Mixed model; course of depressive symptoms by cognitive function.
Table 5
Mixed model, stratified for level of cognitive impairment.
Dependent
variable
Independent variable MMSE 0–10 (N=201) MMSE 11–20 (N=453) MMSE 21–25 (N=115) MMSE 26–30 (N=49) P-valuea
Coefficient p Coefficient p Coefficient p Coefficient p
CSDD MOBID-2 .24 .050 .62 < .001* .47 .005* .39 .232 .227
Time (months) −.08 .322 −.10 .042* −.13 .156 −.10 .436 .978
Sex .72 .392 −.45 .290 −.03 .967 .65 .706 .700
Age −.09 .086 −.09 .006* −.13 .019* −.11 .284 .830
MOBID-2 CSDD .06 .016* .12 < .001* .09 .008* .07 .229 .381
Time (months) −.06 .161 .04 .033* .02 .626 .00 .985 .165
Sex .49 .126 .09 .612 −.12 .751 1.5 .018* .024*
Age .04 .076 .02 .096 .00 .871 .01 .762 .417
CSDD, Cornell Scale for Depression in Dementia; MMSE, Mini-Mental State Examination; MOBID-2, Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale. Analyses
include all patients with valid assessments at any time point, adjusted for time to follow-up (4/6 months) and intra-cluster effects at the nursing home level.
* Significant association at p< .05 level.
a P for interaction is a test for difference in effect between the separate groups.
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higher levels of depression. Similar results have been reported pre-
viously, possibly due to inconclusive efficacy combined with increased
likelihood of prescribing to those with severe depressive symptoms
(Borza et al., 2015). While the efficacy of antidepressants for depression
in people with dementia is uncertain and may be difficult to assess,
elderly patients with dementia are also particularly susceptible to
adverse effects and drug interactions (Gulla et al., 2016). Increased
risks of seizures, falls, fractures, and mortality have been reported in
older patients receiving antidepressants (Bakken et al., 2013; Coupland
et al., 2011).
The therapeutic benefit of analgesic and antidepressant drugs
should be assessed regularly with validated tools, and weighed carefully
against potential adverse effects. Future advances should go towards
systematic symptom assessment in people with dementia, in order to
identify those in need of treatment, and to stop unnecessary or harmful
treatment.
4.2. Limitations
This study has its limitations. Due to the observational design of the
study, we cannot draw conclusions on causality from this material.
Furthermore, the REDIC and COSMOS trials had different inclusion
criteria. The REDIC trial, which contributed the majority of our
population, included patients at admission to nursing home care.
Thus our results may not be directly generalisable to other populations
with varying lengths of stay. Nursing home admission is associated with
increase of depressive symptoms, which may not be congruent with
depressive disorder (Achterberg et al., 2006). However, the persistence
rate of depression 6 months after admission has been estimated to 63%
(Smalbrugge et al., 2006), which is similar to that found in other studies
(Selbaek et al., 2013), and to our observed rate (67%). The proportion
of recently admitted patients could also strengthen our results, as the
length of stay in nursing home care is typically short. A UK study found
that 53% died within 6 months of admission, while a small number of
patients stayed much longer, increasing the average stay to 14 months
(Kelly et al., 2010). Though time to follow-up differed between the
REDIC and COSMOS trials, the mixed model analyses included a time
variable to ensure that this did not affect the results. The main analyses
(Table 4) were re-calculated separately for each group, with unchanged
results. The combined data set enabled us to include a high number of
patients, recruited from a wide network of research centres, controlling
for possible confounding factors to ensure robustness of results. Some
potential sources of confounding remain. The number of scheduled
prescriptions for any analgesic or antidepressant was recorded at each
time point, but we did not assess the duration of use, appropriateness of
the prescribed dose, or changes in the prescribed doses of individual
drugs. Nor did we assess any use of as-needed drugs. Furthermore, use
of nonpharmacological interventions for either pain or depression was
not assessed. While the CSDD scale includes some items that may
overlap with pain, such as “multiple physical complaints”, pain was
significantly associated with NPI depression, reducing the likelihood
that our results are due to symptom overlap.
5. Conclusion
We found highly significant, prospective associations between pain
and depression, irrespective of analgesic or antidepressant use. These
associations were replicated in groups with mild, moderate, and severe
cognitive impairment. Because a reduction in pain was associated with
less depressive symptoms, patients with dementia should be regularly
assessed for untreated pain. The benefit of analgesic or antidepressant
drugs should also be assessed regularly and weighed carefully against
the potential for adverse effects.
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Abstract
Background Chronic pain and depression often co-occur,
and pain may exacerbate depression in people with
dementia.
Objective The objective of this study was to assess the
efficacy and safety of analgesic treatment for depression in
nursing home patients with advanced dementia and clini-
cally significant depressive symptoms.
Methods We conducted a multicentre, parallel-group,
double-blind, placebo-controlled trial in 47 nursing homes,
including 162 nursing home patients aged C 60 years with
dementia (Mini-Mental State Examination B 20) and
depression (Cornell Scale for Depression in Demen-
tia C 8). Patients were randomised to receive active anal-
gesic treatment (paracetamol or buprenorphine transdermal
system) or identical placebo for 13 weeks. The main out-
come measure was the change in depression (Cornell Scale
for Depression in Dementia) from baseline to 13 weeks,
assessed using linear mixed models with fixed effects for
time, intervention and their interaction in the models.
Secondary outcomes were to assess whether any change in
depression was secondary to change in pain (Mobilisation-
Observation-Behaviour-Intensity-Dementia-2 Pain Scale)
and adverse events.
Results The mean depression change was - 0.66 (95%
confidence interval - 2.27 to 0.94) in the active group
(n = 80) and - 3.30 (- 4.68 to -1.92) in the placebo group
(n = 82). The estimated treatment effect was 2.64
(0.55–4.72, p = 0.013), indicating that analgesic treatment
had no effect on depressive symptoms from baseline to
13 weeks while placebo appeared to ameliorate depressive
symptoms. There was no significant reduction in pain in the
active treatment group (paracetamol and buprenorphine
combined) vs. placebo; however, a subgroup analysis
demonstrated a significant reduction in pain for paraceta-
mol vs. placebo [by - 1.11 (- 2.16 to - 0.06, p = 0.037)]
from week 6 to 13 without a change in depression.
Buprenorphine did not have significant effects on depres-
sion [3.04 (- 0.11 to 6.19), p = 0.059] or pain [0.47
(- 0.77 to 1.71), p = 0.456] from 0 to 13 weeks. Thirty-
five patients were withdrawn from the study because of
adverse reactions, deterioration or death: 25 (31.3%) dur-
ing active treatment [23 (52.3%) who received buprenor-
phine], and ten (12.2%) in the placebo group. The most
frequently occurring adverse events were psychiatric
(17 adverse reactions) and neurological (14 adverse
reactions).
Conclusion Analgesic treatment did not reduce depression
while placebo appeared to improve depressive symptoms
significantly by comparison, possibly owing to the adverse
effects of active buprenorphine. The risk of adverse events
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40266-018-0546-2) contains supple-
mentary material, which is available to authorized users.
& Ane Erdal
ane.erdal@uib.no
1 Department of Global Public Health and Primary Care,
Centre for Elderly and Nursing Home Medicine, University
of Bergen, Bergen, Norway
2 Department of Clinical Psychology, University of Bergen,
Bergen, Norway
3 Department of Old Age Psychiatry, Institute of Psychiatry,
Psychology and Neuroscience, King’s College London,
London, UK
4 University of Exeter, Exeter, UK




warrants caution when prescribing buprenorphine for
people with advanced dementia.
Trial registration ClinicalTrials.gov NCT02267057 (reg-
istered 7 July, 2014) and Norwegian Medicines Agency
EudraCT 2013-002226-23.
Key Points
Contrary to our hypothesis, patients who received
active analgesic treatment had more persistent
depressive symptoms
The buprenorphine transdermal system may
exacerbate neuropsychiatric symptoms in dementia
and should be used with caution in this group
1 Introduction
Approximately 40% of nursing home patients receive
antidepressants [1], and over 80% have dementia [2].
Although some studies suggest that antidepressants may be
beneficial for depression in people with dementia [3, 4],
several later studies have found negative results [5, 6]. The
most commonly prescribed antidepressants are selective
serotonin reuptake inhibitors such as sertraline, and nora-
drenergic and specific serotonergic antidepressants such as
mirtazapine [7]. Lyketsos et al. found that sertraline
reduced depression in Alzheimer’s disease compared with
placebo (n = 44) [4], this result was followed by a larger
study from the same group which found no benefit of
sertraline compared with placebo (n = 131) [6]. Banerjee
et al. found that sertraline or mirtazapine did not reduce
depression in dementia, and that participants who received
active treatment had significantly higher rates of adverse
events such as nausea and sedation compared with placebo
(n = 326) [5]. Updated systematic reviews and meta-anal-
yses conclude that the current evidence base for antide-
pressants in dementia is equivocal [8, 9].
More than 60% of nursing home patients experience
pain, often of moderate-to-severe intensity [10, 11]. Failure
to systematically assess and treat pain leads to the risk of
chronic pain, particularly in people with dementia who
gradually lose their ability to reliably describe symptom
severity [12]. Pain has been identified as a possible con-
tributing factor to depression in nursing homes, even in
patients with advanced dementia [13, 14]. Pain and
depression share a complex relationship, known as the
pain-depression dyad, implying that the conditions
commonly coexist, exacerbate each other, share common
signal pathways and neurotransmitters, and respond to
similar treatments [15]. A previous cluster randomised trial
suggests that a 12-week stepwise protocol for treating pain
with paracetamol, buprenorphine transdermal system
(TDS), morphine or pregabalin may reduce depressive
symptoms in people with advanced dementia and agitation
[16]. However, depression was not an inclusion criterion in
this study, and the pain intervention was not placebo
controlled.
Buprenorphine is currently recommended for opioid
analgesia in the elderly [17]. As a partial agonist/antago-
nist, it provides effective analgesia with a low potential for
serious adverse effects including respiratory depression
[17]. Because it undergoes hepatic metabolism and excre-
tion, it does not require dose adjustment in renal insuffi-
ciency [17]. Some evidence suggests that buprenorphine
may also have a potential for mood-elevating effects in
depression [18]. Paracetamol is the most widely used non-
opioid analgesic in the elderly, and may also exert an effect
in the central processing and response to emotional stimuli
[19].
Therefore, we wished to examine whether a stepwise
protocol for treating pain using paracetamol or buprenor-
phine ameliorated depressive symptoms in nursing home
patients with moderate-to-severe dementia and clinically
significant depressive symptoms, controlling for the choice
of analgesic, the presence of moderate-to-severe pain and
dementia severity. To assess whether any change in
depressive symptoms was secondary to an analgesic effect,
we also examined whether the intervention effectively
reduced pain compared with placebo.
2 Materials and Methods
2.1 Study Design
This was a 13-week, multicentre, parallel-group, double-
blind, randomised placebo-controlled trial conducted in
long-term and dementia wards in 47 nursing homes from
12 municipalities in Norway (Bergen, Baerum, Fjell,
Kvam, Meland, Os, Oslo, Sandnes, Stavanger, Sula, Sund
and Aalesund). Depending on ongoing medical treatment
and clinical investigation, participants were prescribed
either paracetamol tablets (maximum 3 g/day) or
buprenorphine TDS (maximum 10 lg/hour), and were
randomised to receive either active treatment or placebo.
2.2 Participants
We screened 2323 nursing home patients for inclusion
from 18 August, 2014 to 13 September, 2016. Data
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collection was completed by 20 December, 2016. Eligible
participants were elderly (C 60 years) long-term patients
(i.e. residents with permanent placement) who had been
living in the participating ward for at least 4 weeks prior to
screening, with dementia according to the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition cri-
teria for major neurocognitive disorders, Mini-Mental State
Examination (MMSE) score B 20 [20] and clinically sig-
nificant depression [Cornell Scale for Depression in
Dementia (CSDD) score C 8 at screening] of at least
4 weeks’ duration [21]. Exclusion criteria were: cognitive
impairment related to other diagnoses than Alzheimer’s
disease; frontotemporal dementia; vascular dementia;
dementia with Lewy bodies or mixed dementia (e.g. trau-
matic head injury, chronic alcohol abuse or Huntington’s
disease; assessed by a review of medical records); life
expectancy\ 6 months; severe pain [Mobilisation-Obser-
vation-Behaviour-Intensity-Dementia-2 (MOBID-2) Pain
Scale score C 8] [22]; severe aggression (with Neuropsy-
chiatric Inventory—Nursing Home version aggression
item C 8) [23]; suicide risk; severe hepatic or renal
insufficiency; anaemia (haemoglobin\ 8.5 mmol/L in
men,\ 7.5 mmol/L in women); severe disease or injury
that could interfere with study participation; comatose
state; participation in another experimental trial; having no
carer who was familiar with the patient; diagnosis of psy-
chosis or other severe mental disorder prior to dementia
diagnosis (e.g. schizophrenia, schizoaffective disorder and
bipolar disorder); severe psychiatric or neurological dis-
order; uncontrolled epilepsy; the clinician responsible for
care or study clinician considered that the patient had any
physical condition that would make participation in the
trial distressing or likely to increase patient discomfort;
contraindication, known allergy, adverse reaction or clini-
cally significant drug interaction to the assigned study
treatment; and scheduled prescriptions for any opioid
analgesic other than or exceeding buprenorphine 5 lg/
hour. When a patient at any point fulfilled any one exclu-
sion criterion, we conducted no further assessments and the
reason for exclusion was recorded.
At baseline, after a minimum of 4 weeks, we re-assessed
the eligible patients for depression. To avoid false nega-
tives at this point, we excluded patients who scored below
the cut-off for greatest sensitivity on the CSDD scale
(CSDD score C 6). The screening cut-off value of C 8 and
the re-assessment threshold for persistent depression of
C 6 on the CSDD scale correspond to the optimal cut-off
points for specificity and sensitivity, respectively, as sum-
marised in a recent meta-analysis [24].
2.3 Randomisation and Masking
The trial was double blinded, and participants were ran-
domly allocated to each arm in a 1:1 ratio according to
computer-generated random numbers in blocks of ten
(paracetamol) and 12 (buprenorphine) with no stratification
factors. Statisticians generated and sent the randomisation
lists directly to the production and packing facilities
without researcher involvement. Paracetamol and identical
inert placebo tablets were purchased from Kragero
Tablettproduksjon A/S, Norway. Mundipharma Research
Limited, UK provided buprenorphine TDS and identical
inert placebo. The patients, carers, clinicians, pharmacy,
researchers and study statistician were masked to group
identity until completion of the protocol.
2.4 Intervention
As shown in Table 1, participants without current sched-
uled analgesics or who received B 1 g/day of paracetamol
were allocated to step 1, oral paracetamol (increased to a
maximum of 3 g/day, active or placebo). Participants who
were already prescribed regular doses of[ 1 g/day of
paracetamol, buprenorphine 5 lg/hour or non-steroidal
anti-inflammatory drugs (except low-dose acetylsalicylic
acid) were allocated to step 2, buprenorphine TDS (maxi-
mum dose of 10 lg/hour, active or placebo). Patients with
dysphagia, to whom it was not deemed feasible to
administer oral tablets, were allocated to step 2 regardless
of whether they were already using paracetamol.
We used a fixed-dose regimen throughout the 13-week
treatment period: paracetamol 1 g tablet/placebo was
administered at breakfast, lunch and dinner (approximately
8:00 a.m., noon, 6:00 p.m.) for a total daily dose of 3 g in
the active group (corresponding to step 1; see Table 1). If
the patient was using paracetamol B 1 g/day prior to study
inclusion, the study treatment was prescribed in addition to
the basis dose, giving a maximum total dose of 1 g three
times daily (supplement active or placebo) [step 1b;
Table 1]. Buprenorphine/placebo TDS was changed
weekly for a total dose of 5 lg/hour in the active group
(step 2a; Table 1). However, if the patient was using
buprenorphine TDS 5 lg/hour prior to study inclusion, the
study treatment was administered as an additional 5 lg/
hour TDS (active or placebo) to yield a total dose of 10 lg/
hour in the active group (step 2b; Table 1). Patients who
were unable to tolerate study treatment were withdrawn
from the study and treated as clinically appropriate.
2.5 Concomitant Drugs
All participants continued their usual medical treatment
after inclusion in the study (including any regular or ‘as
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needed’ analgesic). The use of ‘as needed’ analgesics was
allowed and monitored during the study, ensuring that all
patients received adequate pain treatment irrespective of
group allocation. Ongoing treatment with antidepressants,
other psychotropic drugs and regular analgesics was
allowed if the dose had remained stable for 4 weeks prior
to study inclusion. Clinicians were advised to keep doses of
psychotropic and analgesic drugs unchanged during the
study period if possible. If lasting changes were made to
regular analgesic treatment or antidepressants, the patient
was withdrawn from the study. Lists of regular and ‘as
needed’ prescriptions and documentation of administered
doses were extracted from medical records at each visit.
2.6 Primary and Secondary Outcome Measures
Depressive symptoms were assessed using the CSDD scale,
which has been validated and used in clinical studies
including people with and without dementia [24]. Each of
the 19 items is rated from zero (no symptoms) to two
(severe symptoms), and yields a sum score of between zero
(no depression) and 38 (most severe depression). While the
CSDD scale alone cannot be used to accurately diagnose
depression in dementia, it is useful as a screening tool and
sufficiently precise to assess change in depressive symptom
burden over time. Pain was assessed using the MOBID-2
Pain Scale, a two-part staff-administered behavioural
instrument to assess pain in older persons with advanced
dementia (see the Electronic Supplementary Material 1)
[22]. The evaluation of inferred pain intensity is based on
the patient’s pain behaviours during standardised guided
movements of different body parts (Part 1), and pain
behaviours that might be related to internal organs, head
and skin are recorded on an anatomical figure along with
inferred pain intensity for each region to allow monitoring
over time (Part 2). Excellent interrater and test-retest reli-
ability, internal consistency and validity have been repor-
ted [22]. The tool has also demonstrated responsiveness to
treatment, as it is able to detect change in the total score
(range 0–10) after pain treatment has been initiated [22].
For subgroup analyses, mild/no pain was defined as
MOBID-2\ 3 and moderate/severe pain as MOBID-
2 C 3. To assess cognitive function at inclusion, we used
the MMSE as a screening tool, with MMSE scores of 0–10
defined as severe and MMSE scores of 11–20 defined as
moderate dementia [25]. Although the MMSE scale poorly
distinguishes between patients with no/questionable
dementia, it has shown high agreement with the Clinical
Dementia Rating scale for the staging of moderate and
severe dementia using these cut-off scores [25]. Assess-
ments of depression (CSDD) and pain (MOBID-2) were
made at baseline and 6 and 13 weeks. Adverse events and
tolerability were monitored and recorded at each visit. The
primary outcome was the effect of analgesic treatment on
change in depressive symptoms (CSDD) from baseline to
13 weeks. Secondary outcomes were the effect of analgesic
treatment (paracetamol or buprenorphine) on change in
pain (MOBID-2) from baseline to 13 weeks, and adverse
events and dropout from treatment.
2.7 Sample Size
As a preliminary sample size estimate, we used results
from Banerjee et al., who found in their updated power
analyses that approximately 260 participants would be
required to provide 90% power to detect a 2-point differ-
ence in the CSDD scale (standard deviation 5; standardised
effect size 0.4) between two groups (active and placebo
treatment), allowing for 15% dropouts [5]. This estimate
was used as a preliminary goal, when inclusion and dropout
rates were unknown, and was reviewed when the first 113
patients had completed our 13-week trial protocol (or
dropped out). We calculated our revised sample size using
a sample size formula for longitudinal data because we
have data with repeated measurements. We used a sample
size formula for a longitudinal continuous response, where
the correlation between repeated measurements (intra-
cluster correlation) is taken into account, with the purpose
to estimate the intervention effect on average over the total
follow-up period [26]. This formula applies for group
Table 1 Study treatment steps 1–2
Step Regular analgesic treatment Study
treatment
Dose
1 No analgesics (1a) or paracetamol B 1 g/day (1b) Paracetamol
tablets
Maximum 3 g/day
Placebo tablets Inert placebo
2 Non-opioid analgesics (paracetamol[ 1 g/day, and/or NSAID), or no analgesics, but with




10 lg/h in 2b)
Placebo TDS Inert placebo
NSAID non-steroidal anti-inflammatory drug, except low-dose acetylsalicylic acid, TDS transdermal system
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comparisons with longitudinal data, such as randomised
controlled trials. The same parameters (standard deviation
5, standardised effect size 0.4, 90% power, p\ 0.05) were
used in the revised calculation, but based on available data
from the first 113 patients, we were able to estimate the
correlation coefficient of repeated measurements within
individuals (intra-cluster correlation) with greater precision
in the revised sample size calculation (intra-cluster corre-
lation 0.25). The final estimate required 66 patients in each
group to obtain 90% power to detect a 2-point CSDD
difference. Adjusting for 20% dropouts, our final aim was
to include 165 participants in total.
2.8 Statistical Analysis
Baseline characteristics were described as mean (standard
deviation) for continuous variables, and with the number of
patients and percentages of the sample size for categorical
variables. Differences in adverse outcomes (deaths)
between active treatment and placebo were assessed using
the Pearson v2 test for categorical variables. Treatment
effects on both the primary outcome (depression assessed
by the CSDD) and the secondary outcome (pain assessed
by the MOBID-2 Pain Scale) were assessed separately
using linear mixed-effects models, which incorporated all
assessments at baseline, 6 and 13 weeks. We treated time
as a categorical variable, and included fixed effects for
time, intervention and their interaction in the models. To
account for clustering, the models were fitted with random
intercepts for nursing home units and patients. Treatment
effects were calculated for active treatment vs. placebo,
these analyses were repeated with the use of other anal-
gesics or antidepressants at baseline as covariates to control
for any impact of concomitant drug use. We also conducted
pre-planned subgroup analyses for paracetamol tablets
compared with placebo tablets, buprenorphine TDS com-
pared with placebo TDS, and to investigate treatment
effects stratified for level of cognitive function and for the
presence of moderate-to-severe pain. We regarded
p\ 0.05 as significant. All statistical analyses were con-
ducted with STATA/IC 14 (Stata Corp LP, College Station,
TX, USA).
3 Results
Figure 1 shows the trial profile, wherein each patient is
categorised by the first exclusion criterion that was ful-
filled, after which no further assessments were made.
Table 2 shows group allocation and characteristics of the
162 included patients at baseline. In total, 39 patients
(24.1%) reported adverse events (Table 3), most frequently
in the active buprenorphine group of whom 23 (52%)
withdrew because of adverse events. Thirteen patients
discontinued treatment owing to clinical deterioration or
death; one in the paracetamol group, two who received
placebo tablets, six in the buprenorphine group and four
who received placebo TDS. Between-group differences in
mortality were not statistically significant (Pearson v2 test;
p = 0.447).
From the linear mixed-model analysis (Table 4, Fig. 2),
we found that the placebo group had a significant reduction
in depressive symptoms (CSDD score) of -3.30 (95%
confidence interval -4.68 to -1.92) from baseline to the
13-week follow-up. The active treatment group did not
have a significant CSDD change in the same period [mean
change -0.66 (-2.27 to 0.94)]. The estimated treatment
effect from baseline to 13 weeks was 2.64 (0.55–4.72,
p = 0.013), thus receiving placebo was associated with a
significant reduction in depressive symptoms from baseline
to 13 weeks compared with those who received active
treatment. The observed treatment effects were not affected
by concomitant use of antidepressants or analgesics. Ana-
lysing patients in the different treatment groups separately,
we found that neither active paracetamol nor buprenor-
phine had significant treatment effects on depressive
symptoms from 0 to 13 weeks compared with placebo
(Table 4, Fig. 2). The estimated treatment effects were
1.98 (-0.79 to 4.74, p = 0.162) for paracetamol vs. pla-
cebo tablets, and 3.04 (-0.11 to 6.19, p = 0.059) for
buprenorphine vs. placebo TDS. Grouping patients
according to whether they had moderate-to-severe pain at
baseline did not yield significant treatment effects on
depression compared with placebo; nor did separate anal-
yses for patients with moderate and severe dementia
(Table 4, Fig. 2).
There was no significant reduction in pain in the com-
bined active treatment group (paracetamol and buprenor-
phine) compared with placebo (Table 5, Fig. 3). Active
paracetamol was associated with a significant decrease in
pain from 6- to 13-week assessments compared with pla-
cebo tablets, with an estimated treatment effect of -1.11
(-2.16 to -0.06, p = 0.037). This effect was not observed
for active buprenorphine [coefficient 0.26 (-1.06 to 1.59),
p = 0.697].
4 Discussion
This is the first placebo-controlled study investigating the
efficacy of analgesic treatment for depressive symptoms in
people with moderate-to-severe cognitive impairment and
dementia. We have found that a stepwise increase of
analgesic treatment, using either paracetamol tablets or
buprenorphine TDS, was not effective as a means of
reducing depressive symptoms in these patients. Contrary
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to our initial hypothesis, we found that the placebo group
had a significant decrease in depressive symptoms from
baseline to the 13-week follow-up compared with the
active treatment group. We did not find an overall benefit
of active treatment on pain compared with placebo, but
paracetamol reduced pain significantly from 6 to 13 weeks
compared with placebo tablets (Table 5). Despite this,
depressive symptoms did not decrease in the same group
(Table 4).
While our results appear to indicate the reverse effect: a
significant decrease in depressive symptoms in the placebo
group compared with the active treatment group, this result
must be interpreted with caution for several reasons. This
study includes people with severe dementia, in whom
symptoms of both pain and depression are difficult to
assess. We excluded patients in whom severe pain
(MOBID-2 C 8) was identified because it would be
unethical to risk prolonged untreated pain by randomising
these patients to receive active treatment or placebo, and
recommended instead that the responsible physician should
initiate appropriate analgesic treatment.
Therefore, our results may not be generalisable to
nursing home patients with dementia and severe pain. Most
of the included patients were unable to self-report pain
Fig. 1 Trial profile. Each patient was categorised by the first exclusion criterion that was fulfilled, after which no more assessments were made.
CSDD Cornell Scale for Depression in Dementia, MMSE Mini-Mental State Examination, NHs nursing homes
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reliably because of advanced cognitive impairment.
Although proxy-rated pain is the best available pain
assessment method in this group, we have no method to
ascertain the patients’ subjective pain experience. In
patients with very limited verbal and non-verbal expres-
sion, pain intensity may be underestimated by proxy rating.
Our initial hypothesis was therefore that undiagnosed and
therefore untreated painful symptoms may cause
exacerbated depressive symptoms in people with advanced
dementia.
The CSDD scale has been developed for use in people
with dementia, and has shown good sensitivity and speci-
ficity. However, as noted in a recent systematic review and
meta-analysis, most studies that have tested the scale have
excluded people with severe dementia or communication
deficits, thus limiting the majority of the evidence to people
Table 2 Demographic and
clinical characteristics of
included patients at baseline
Total (n = 162) Placebo (n = 82) Active (n = 80)
Age (y) 85.6 ± 7.4 86.2 ± 6.0 85.0 ± 8.7
Sex (female) 122 (75.3) 63 (76.8) 59 (73.8)
MMSE 7.8 ± 5.8 7.6 ± 5.7 8.0 ± 5.9
MOBID-2 2.7 ± 2.1 3.0 ± 2.3 2.4 ± 1.9
CSDD 11.2 ± 3.7 11.7 ± 4.1 10.8 ± 3.1
NPI-NH total score 32.1 ± 19.8 31.0 ± 20.1 32.8 ± 19.4
NPI-NH depression 4.4 ± 3.8 4.0 ± 3.7 5.0 ± 4.0
Analgesic 81 (50.0) 41 (50.0) 40 (50.0)
Antidepressant 81 (50.0) 50 (61.0) 31 (38.8)
Step 1aa 68 37 31
Step 1bb 5 0 5
Step 2ac 74 38 36
Step 2bd 15 7 8
Numbers represent mean ± standard deviation or number of patients (%)
CSDD Cornell Scale for Depression in Dementia, MMSE Mini-Mental State Examination, MOBID-2
Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale, NPI-NH Neuropsychiatric Inven-
tory-Nursing Home version
aStudy treatment: paracetamol 1 g/placebo tablet three times daily
bStudy treatment: paracetamol 1 g/placebo tablet two times daily ? usual treatment:
paracetamol B 1 g/day
cStudy treatment: buprenorphine 5 lg/h/placebo transdermal system
dStudy treatment: buprenorphine 5 lg/h/placebo transdermal system ? usual treatment: buprenorphine
5 lg/h transdermal system











Patients with adverse reactionsa 4 (10.8%) 2 (5.6%) 8 (17.8%) 25 (56.8%) 39 (24.1%)
Gastrointestinal 0 0 0 7 6
Neurological 0 0 2 12 14
Dermatological 0 0 1 0 1
Psychiatric 0 0 0 17 17
Infection 1 0 0 1 2
Falls/fractures 1 1 1 4 7
Major clinical changes, including
hospitalisation/death
2 1 4 7 14
TDS transdermal system
aEach patient may have had several reported reactions
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with mild-to-moderate dementia [24]. In cognitively intact
populations, the efficacy of pharmaceutical therapies for
both depression and pain is difficult to isolate from
expectation effects, including both placebo and nocebo
effects [27]. Although people with advanced dementia may
have a diminished or absent placebo response [28], the
proxy raters are prone to observer bias such as the Haw-
thorne effect, which could potentially skew the observed
difference between the treatment groups. Furthermore, we
did not assess raters’ expectation of group allocation, a
factor that has been shown to interfere strongly with
observed effects in placebo-controlled trials [27]. As
shown in the first graph of Fig. 2, all patients had a trend
towards decreasing severity of depressive symptoms from
baseline to the 6-week follow-up. Similarly, Fig. 3 shows
that pain tended to decrease from baseline to the 6-week
follow-up, regardless of group allocation. This initial
improvement across all groups exaggerates the apparent
benefit of placebo on depressive symptoms, and may be
caused by observer bias. Similar trends have been shown in
other studies [5, 16].
The high dropout rate observed in the group receiving
active buprenorphine may reduce comparability between
active treatment and placebo conditions, but represents an
important finding as it suggests lower than expected tol-
erability in this population, which warrants further inves-
tigation. In active treatment, only 44 of the 66 planned for
in the final power analysis completed 13-week assess-
ments. This may further limit our ability to detect a positive
effect of treatment compared with placebo. However, our
data are significantly in favour of the placebo condition
(p = 0.013), probably because the obtained mean CSDD
difference of 2.64 at 13 weeks was larger than the thresh-
old for a clinically relevant difference of 2.0 (standardized
effect size 0.4) used in the power analysis. This means that
the sample size was sufficient to explore our primary aim,
and may indicate that adverse effects of active treatment
led to apparent worsening of depressive symptoms. Known
adverse effects of buprenorphine include symptoms such as
sedation, reduced appetite and anxiety, which may overlap
with items assessed by the CSDD scale and possibly be
interpreted as increased depression. Secondary analyses, in
Table 4 Estimated effect of active analgesic treatment on primary outcome (Cornell Scale for Depression in Dementia depressive symptoms)
compared with placebo; mixed-model analysis including exploratory subgroup analyses
N From baseline to 13 wk From baseline to 6 wk From 6 to 13 wk
C (95% CI) P value C (95% CI) P value C (95% CI) P value
Primary analysis
All patients 160 2.64 (0.55–4.72) 0.013 0.74 (- 1.03 to
2.52)




MMSE 11–20 49 2.24 (- 1.24 to
5.72)
0.207 0.33 (- 2.50 to
3.16)
0.818 1.91 (- 2.05 to
5.86)
0.344
MMSE 0–10 92 1.10 (- 1.49 to
3.69)
0.405 0.56 (- 1.75 to
2.86)
0.635 0.54 (- 2.27 to
3.35)
0.705
Stratified on drug type
Paracetamol/placebo tablets 73 1.98 (- 0.79 to
4.74)
0.162 0.40 (- 2.39 to
3.18)
0.780 1.58 (- 1.49 to
4.64)
0.313
Buprenorphine/placebo TDS 89 3.04 (- 0.11 to
6.19)
0.059 0.96 (- 1.45 to
3.37)
0.433 2.07 (- 1.06 to
5.20)
0.194
Stratified on pain level
MOBID-2\ 3 57 2.65 (- 0.49 to
5.80)
0.098 1.42 (- 1.00 to
3.83)
0.251 1.24 (- 1.40 to
3.87)
0.357
MOBID-2 C 3 103 2.25 (- 0.55 to
5.04)
0.115 0.47 (- 1.98 to
2.91)
0.709 1.78 (- 1.31 to
4.88)
0.260
MOBID-2 C 3 and
paracetamol
47 1.63 (- 2.68 to
5.94)
0.459 - 0.38 (- 4.51 to
3.76)
0.858 2.01 (- 2.52 to
6.53)
0.385
MOBID-2 C 3 and
buprenorphine
61 2.19 (- 1.35 to
5.73)
0.226 1.32 (- 1.87 to
4.51)
0.418 0.87 (- 2.84 to
4.58)
0.646
C coefficient for time 9 treatment interaction, CI confidence interval, MMSE Mini-Mental State Examination, MOBID-2 Mobilisation-Obser-
vation-Behaviour-Intensity-Dementia-2 Pain Scale, N number of patients with at least one valid assessment, TDS transdermal system. See also
the Electronic Supplementary Material 2, which reports all corresponding coefficients for change
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which patients were grouped based on the presence of
moderate-to-severe pain, cognitive status and choice of
analgesic treatment all show a similar trend in favour of the
placebo condition, although these associations did not
reach significance, probably because the sample size did
not provide sufficient power for subgroup analyses.
An important limitation to the interpretation of our
results is therefore that we do not have a sufficient sample
size to determine whether there was a significant differ-
ential effect between paracetamol and buprenorphine on
depressive symptoms. Furthermore, the extensive list of
exclusion criteria was necessary to include this frail pop-
ulation in the current trial, but also limits the generalis-
ability of our results to a more heterogeneous group of
nursing home patients. A recent study found that patients
with depression were more likely to be prescribed anal-
gesic treatments [29]. This means that an unknown pro-
portion of patients who theoretically may have benefited
from the intervention were excluded from our study: 562
patients (38% of the 2323 patients screened) were excluded
because of opioid analgesic use, without any further
assessments of eligibility. This choice was made inten-
tionally to assess treatment effects in patients who were not
already using high doses of the study drugs, and in whom
untreated pain was not identified as a primary clinical
issue.
Several previous studies have suggested that depression
in nursing home patients with cognitive impairment may be
related to untreated pain. The association between pain and
depression, also known as the pain-depression dyad, has
been observed in nursing home patients at all stages of
cognitive impairment [13, 14]. Secondary analyses from a
previous cluster-randomised study, which assessed the
efficacy of a stepwise increase in analgesic treatment for
depressive symptoms in 175 nursing home patients with
dementia and agitation, found a significant but small ben-
efit on the mood syndrome cluster assessed with the Neu-
ropsychiatric Inventory – Nursing Home version [16].
They included patients with agitation, whereas in our study
depression was an inclusion criterion. Furthermore, a
higher proportion of patients were allocated to receive
paracetamol relative to our study [120 (69%) and 36 (45%),
respectively]. They had an open-label design with the
control group receiving usual care, consequently their
results may have been biased owing to a Hawthorne effect.
These methodological differences may in part explain our
apparently opposing result.
Nonetheless, our rigorous placebo-controlled design
justifies our conclusion that analgesic treatment alone is not
sufficient to improve depressive symptoms in nursing home
patients with dementia and depression in the absence of
severe pain. By excluding patients with severe pain from
the trial, we may have limited the potential to find
beneficial effects of analgesic treatment for depression.
However, subgroup analyses stratified on pain level did not
indicate that patients with moderate-to-severe pain had a
more beneficial effect of active treatment on depressive
symptoms. Although the group that received active
paracetamol had a significant decrease in pain compared
with those who received placebo tablets, there was a trend
towards more persistent depressive symptoms in this group
during the same period. While the latter result was not
statistically significant, it indicates that the negative result
on the main outcome of the current trial cannot be
explained by the absence of pain at baseline.
Importantly, no clear causal relationship between pain
and increased depression, or between depression and
increased pain, has been established. Pain and depression
are known to mutually exacerbate each other, a relationship
that may be most accurately characterised as multifactorial.
Although many nursing home patients with depression
have comorbid chronic pain, other associated problems
such as isolation and lack of social contact or meaningful
activity may be equally important [30]. In this perspective,
it may not be surprising that an isolated pain intervention is
insufficient to improve depressive symptoms. Rather, our
results show that careful assessment of painful symptoms,
followed by the implementation and continuous re-evalu-
ation of appropriate interventions, is an absolute require-
ment for adequate care in this population, as both untreated
pain and use of unnecessary analgesics may lead to harm.
Patients with cognitive impairment are particularly sus-
ceptible to the adverse effects of analgesics and antide-
pressants, and may be unable to communicate verbally the
severity of their symptoms. This makes it particularly
challenging to ensure that the benefit of pharmacological
treatment outweighs any potential harm.
A 2011 study found that physicians in Norwegian
nursing homes rarely diagnosed depression before pre-
scribing antidepressants, and that treatment with antide-
pressants often was continued despite great uncertainty of
their effectiveness [31]. Forty percent of nursing home
patients in Norway use antidepressants [32]. This is in line
with the pooled percentage of antidepressant use in Wes-
tern European nursing homes [1], and indicates that the
need for improved prescribing practice is not exclusive to
Norway. Future advances should go towards more com-
prehensive treatment strategies that include both pharma-
cological and non-pharmacological interventions, as
exemplified by Chen and Lin [33]. Non-pharmacological
interventions that have been shown to reduce depressive
symptoms in dementia include caregiver education and
engagement in physical activity and pleasant events, but
more evidence is needed to determine which strategies are
most effective [34, 35].
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Buprenorphine elicits its pharmacological effects on the
opioidergic system, but has previously been suggested as a
potential agent for treatment-resistant depression as some
patients have had promising results [18]. However, based
on the high rate of adverse events and absence of benefit on
depressive symptoms, it is unlikely that buprenorphine has
any potential as a treatment for depression in nursing home
patients with dementia. The efficacy and tolerability of
buprenorphine TDS have not previously been investigated
in people with dementia in a placebo-controlled study.
Buprenorphine has similar pharmacokinetic properties and
does not require dose adjustment in the elderly compared
with younger patients [36]. In a study comparing healthy
elderly people aged C 75 years to those aged 50–60 years,
buprenorphine TDS was found to have a slightly lower
steady-state concentration with higher variability in the
elderly group [37]. The same study found a lower rate of
adverse events in the elderly subjects compared with the
younger controls [37].
In the current study, the dropout rate owing to adverse
events of buprenorphine exceeded that reported in a pre-
vious study of buprenorphine in patients with dementia
[16], and is more than twice that reported in a study of
opioid-naı̈ve, cognitively intact elderly patients (aged
C 75 years), which found that 21% dropped out because of
adverse events of buprenorphine [38]. This suggests that
people with dementia may be more susceptible to adverse
events of buprenorphine compared with elderly patients
without cognitive impairment.
Because few large-scale safety studies of opioid anal-
gesics in elderly patients exist, and none have included
people with advanced dementia, we do not know whether
this may represent a class effect of opioid analgesics or
whether buprenorphine may be more poorly tolerated in
frail elderly people and people with dementia compared
with other opioid analgesics. In light of the widespread use
of buprenorphine TDS and other opioid analgesics in
nursing home patients, particularly in the oldest patients
[39, 40], there is an urgent need for high-powered studies
investigating the safety and efficacy of buprenorphine and
other opioid analgesics for treating pain in people with
advanced dementia.
bFig. 2 Change in depressive symptoms (Cornell Scale for Depression
in Dementia) throughout the study period. CI confidence interval,
MMSE Mini-Mental State Examination, MOBID-2 Mobilisation-
Observation-Behaviour-Intensity-Dementia-2 Pain Scale
Table 5 Estimated effect of active analgesic treatment on secondary outcome [Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain
Scale (MOBID-2) pain intensity] compared with placebo; mixed-model analysis including exploratory subgroup analyses
N From baseline to 13 wk From baseline to 6 wk From 6 to 13 wk
C (95% CI) P value C (95% CI) P value C (95% CI) P value
Secondary analysis
All patients 147 - 0.19 (- 1.02 to
0.64)
0.652 0.19 (- 0.59 to
0.97)




MMSE 11–20 44 - 1.01 (- 2.44 to
0.41)
0.162 0.39 (- 0.94 to
1.73)
0.563 - 1.41 (- 2.83 to
0.01)
0.051
MMSE 0–10 87 0.12 (- 1.02 to
1.26)
0.838 0.03 (- 1.05 to
1.11)
0.960 0.09 (- 1.13 to
1.32)
0.884
Stratified on drug type
Paracetamol/placebo tablets 69 - 0.98 (- 2.00 to
0.05)
0.061 0.14 (- 0.83 to
1.10)
0.779 - 1.11 (- 2.16 to
-0.06)
0.037
Buprenorphine/placebo TDS 78 0.47 (- 0.77 to
1.71)
0.456 0.21 (- 0.98 to
1.39)
0.733 0.26 (- 1.06 to
1.59)
0.697
Stratified on pain level
MOBID-2 C 3 90 - 0.57 (- 1.77 to
0.62)
0.347 -0.16 (- 1.24 to
0.93)
0.779 - 0.42 (- 1.63 to
0.79)
0.498
MOBID-2 C 3 and
paracetamol
38 - 1.36 (- 3.27 to
0.55)
0.164 0.07 (- 1.67 to
1.82)
0.933 - 1.43 (- 3.25 to
0.39)
0.123
MOBID-2 C 3 and
buprenorphine
52 0.23 (- 1.32 to
1.77)
0.775 -0.38 (- 1.81 to
1.05)
0.607 0.60 (- 1.04 to
2.25)
0.474
C coefficient for time 9 treatment interaction, CI confidence interval, CSDD Cornell Scale for Depression in Dementia, MMSE Mini-Mental
State Examination, N number of patients with at least one valid assessment, TDS transdermal system. See also the Electronic Supplementary
Material 3, which reports all corresponding coefficients for change
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5 Conclusion
Analgesic treatment did not reduce depression in patients
with cognitive impairment and depressive symptoms.
Patients who received active treatment had more persistent
depressive symptoms than those who received placebo,
possibly owing to adverse effects. These results point to
the importance of continuous symptom assessment when
caring for people with dementia, ensuring that analgesics
are given based on the correct indications with a minimal
risk of harm, and using both pharmacological and non-
pharmacological interventions as appropriate. Active
buprenorphine was associated with high rates of adverse
events, and should be prescribed cautiously in people with
dementia.
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understand the purpose and implications of study participation. We
included a verbal and written statement assuring that their decision to
give consent would not affect the quality of the medical care provided
to the patient. Even though informed consent had been given, all
participants were free to decline drug administration and other pro-
cedures at any time during the trial, irrespective of cognitive state.
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Purpose: Buprenorphine transdermal system is increasingly prescribed in people with advanced 
dementia, but no clinical trial has investigated the safety and factors associated with discontinu-
ation due to adverse events in this population.
Patients and methods: One hundred sixty-two people with advanced dementia and significant 
depression from 47 nursing homes were included and randomized to active analgesic treatment 
(acetaminophen/buprenorphine) or identical placebo for 13 weeks. In this secondary analysis, 
the main outcomes were time to and reasons for discontinuation of buprenorphine due to adverse 
events. Change in daytime activity as measured by actigraphy was a secondary outcome.
Results: Of the 44 patients who received active buprenorphine 5 µg/hour, 52.3% (n=23) dis-
continued treatment due to adverse events compared to 13.3% (6 of 45) in the placebo group 
(p,0.001). Psychiatric and neurological adverse events were the most frequently reported 
causes of discontinuation (69.6%, n=16). Concomitant use of antidepressants significantly 
increased the risk of discontinuation (HR 23.2, 95% CI: 2.95–182, p=0.003). Adjusted for age, 
sex, cognitive function, pain and depression at baseline, active buprenorphine was associated 
with 24.0 times increased risk of discontinuation (Cox model, 95% CI: 2.45–235, p=0.006). 
Daytime activity dropped significantly during the second day of active treatment (−21.4%, 
p=0.005) and decreased by 12.9% during the first week (p=0.053).
Conclusion: Active buprenorphine had significantly higher risk of discontinuation compared 
with placebo in people with advanced dementia and depression, mainly due to psychiatric and 
neurological adverse events. Daytime activity dropped significantly during the first week of treat-
ment. Concomitant use of antidepressants further reduced the tolerability of buprenorphine.
Keywords: opioids, analgesics, dementia, drug safety, adverse drug reactions
Introduction
More than 80% of elderly people in long-term residential care have dementia.1 
Approximately 50% of these individuals suffer from pain of clinically significant 
intensity.2 Cognitive impairment leads to difficulty in verbally expressing painful 
symptoms and complicates the assessment and treatment of pain.3 This may increase 
the risk of untreated chronic pain in people with dementia compared with cognitively 
intact patients.4 In the past few decades, systematic reviews have expressed concern 
that nursing home patients with dementia receive less analgesic treatment than those 
without dementia, despite comparable diagnoses of pain.5,6
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Data from the entire population of Denmark in 2010 
showed that 41% of the country’s 42,291 nursing home 
patients used opioids, and that patients without dementia 
received significantly more opioid analgesics compared with 
those with dementia (43% and 38%, respectively).7 A study 
including 425 patients from 12 nursing homes in Austria 
in 2011–2012 found that despite having more pain, fewer 
cognitively impaired patients received scheduled analgesic 
prescriptions compared with patients without cognitive 
impairment (36% and 58%, respectively).8 Several studies 
have reported similar rates of analgesic use in nursing home 
patients with and without dementia,9,10 with an overall 
increase in total analgesic use irrespective of cognitive 
state and a shift toward increased use of opioid analgesics.9 
In Norway, the use of opioid analgesics in nursing home 
patients increased from 11% in 2000 to 24% in 2011, with a 
substantial increase in the use of strong opioids from 1.9% 
to 17.9%.9 In 2011, the odds ratio for the use of strong opioids 
in nursing home patients with dementia did not differ signifi-
cantly compared with those without dementia.9
Buprenorphine transdermal system (TDS) has been 
recommended for elderly patients because of its favorable 
pharmacodynamic and pharmacokinetic profile, with low 
risk of serious adverse events.11 Buprenorphine, a strong 
opioid, is a partial mu receptor agonist and a kappa receptor 
antagonist. This pattern of activity gives a ceiling effect for 
respiratory depression, without a clinically relevant ceiling 
effect on analgesia.12 As one of few opioids, it does not 
require dose adjustment in renal insufficiency due to hepatic 
clearance.13 Buprenorphine TDS is prescribed to over 10% 
of nursing home patients in countries where it is marketed, 
with estimated use in people with dementia ranging from 
10.5% to 14.8%.7,9,10 While buprenorphine TDS has shown 
high persistence rates in the general population, the rate of 
common adverse events such as nausea, dizziness, or sedation 
is higher than that of comparator opioids.14,15 Dementia, age-
related physiological changes, multimorbidity, frailty, and 
interactions with psychotropic drugs may impact the safety 
and tolerability of buprenorphine TDS.16
There is a well-documented association between pain and 
increased depressive symptoms in people with dementia,17 
and antidepressants have questionable efficacy for depression 
in these patients.18 In a recent study, we investigated whether 
analgesic treatment with acetaminophen or buprenorphine 
TDS could improve depression in people with dementia. 
Contrary to our hypothesis, we found that active treatment 
was associated with more persistent depressive symptoms, 
and 52% of patients who received active buprenorphine 
were withdrawn from the study due to adverse events dur-
ing treatment.39 Few studies have assessed the tolerability 
and adverse effects of buprenorphine TDS in nursing home 
patients with dementia, and none with a placebo-controlled 
design. Furthermore, buprenorphine may have additive or 
synergistic interaction effects with other drugs that have seda-
tive effects. Elderly patients and people with dementia are 
particularly vulnerable to adverse effects such as sedation, but 
interactions between opioids and other commonly prescribed 
psychotropic drugs such as antidepressants have not been 
studied in this population. Similarly, anticholinergic drugs 
may negatively impact cognition in people with dementia, but 
we do not know whether high anticholinergic drug burden is 
associated with poorer tolerability of buprenorphine. There 
is a need to investigate clinically significant interactions 
between opioids and anticholinergic and psychotropic drugs 
in people with dementia.
In these secondary analyses of our study, the primary 
aim was to assess the tolerability of buprenorphine TDS in 
nursing home patients with moderate to severe dementia, 
controlling for pain intensity, depressive symptoms, cogni-
tive state, and concomitant use of psychotropic and anti-
cholinergic drugs. Secondary aims were to assess which 
adverse effects most frequently caused discontinuation and 
to determine how daytime activity changed during the first 
week of treatment.
Patients and methods
study design and population
The current study comprises secondary analyses of data 
collected in the randomized, placebo-controlled trial 
“Efficacy of analgesic treatment for depression in nursing 
home patients with dementia (DEP.PAIN.DEM),” which 
was conducted in 47 nursing homes in 10 municipalities of 
Norway, including people with dementia (Mini-Mental State 
Examination [MMSE] #20) and depression (Cornell Scale 
for Depression in Dementia [CSDD] $8; full inclusion and 
exclusion criteria are presented in Table 1). The intervention 
consisted of a stepwise increase in analgesic treatment, and 
patients who did not use scheduled analgesics at baseline or 
used acetaminophen #1 g/day were prescribed acetamino-
phen in a total dose of 1 g three times daily. Patients who 
already used acetaminophen .1 g daily, nonsteroidal antiin-
flammatory drugs (except low-dose acetylsalicylic acid), or 
buprenorphine 5 µg/hour, or who had difficulty swallowing 
tablets, were prescribed buprenorphine TDS 5 µg/hour in 
addition to their regular treatment and randomized to receive 
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adjustment.39 Patients who received buprenorphine/placebo 
TDS are included in the current analyses.
Procedures
Clinicians were advised to keep doses of psychotropic 
and analgesic drugs unchanged during the study period, if 
possible. If lasting changes were made to regular analgesic 
treatment or antidepressants, the patient was withdrawn 
from the study. The study treatment was prescribed in 
addition to any regular or as-needed analgesics. In mild to 
moderate acute pain, patients were given as-needed analge-
sics in addition to study treatment, and the number of doses 
given during the study period was recorded. Patients with 
severe pain at baseline were excluded because it would be 
unethical to risk treating them with a placebo. We there-
fore ensured that the included patients would not suffer 
from prolonged or unnecessary untreated pain because of 
the study protocol. Furthermore, the physician who was 
responsible for the patient had full authority to discontinue 
study treatment promptly if clinical changes necessitated 
treatment with a known dose of active analgesic. Written 
informed consent was obtained from patients with medical 
decision-making capacity, or written presumed consent 
was obtained from a legally authorized representative in 
those with reduced capacity to consent in accordance with 
ethics committee requirements and current Norwegian 
legislation. The trial was approved by the Regional Com-
mittee for Medical and Health Research Ethics (REC-
West 2013/1474) and the Norwegian Medicines Agency 
(EudraCT 2013-002226-23), and registered at ClinicalTri-
als.gov (NCT02267057).
randomization and masking
The trial was double blinded, and participants were ran-
domly allocated to each arm in a 1:1 ratio according to 
computer-generated random numbers in blocks of 12 with 
no stratification factors. Buprenorphine TDS and identical, 
inert placebo (Mundipharma Research Limited, Cambridge, 
UK) were packed and marked indiscernibly, identifiable only 
by pack number. Patients, nursing home staff, physicians, 
pharmacy, researchers, and statisticians were all masked to 
group identity until completion of the analyses.
Assessments
Assessments were made by the researchers in collabora-
tion with the nursing home staff and included scheduled 
assessments at baseline, 6 and 13 weeks in addition to any 
spontaneous reports during the whole 13-week period. The 
tolerability of buprenorphine TDS was operationalized by 
assessing how many patients discontinued treatment due to 
adverse events (defined as suspected adverse event, clinical 
deterioration, or death) and how long treatment lasted before 
such discontinuation. Discontinuation for other reasons, such 
as protocol violation, was not included in the analysis, and 
in the following, “discontinuation” refers only to those cases 
defined here as caused by adverse events. To ensure that 
all suspected adverse events were reported, the proxy rater 
received standardized detailed verbal and written information 
Table 1 Inclusion and exclusion criteria
Type of criterion Patient characteristics
Inclusion criteria Age $60 years
long-term nursing home placement with .4 weeks’ stay
Dementia (MMse #20)
Depression (CsDD $8, .3 weeks’ duration)
exclusion criteria life expectancy ,6 months
severe medical disease that could interfere with study participation
Impaired liver function, assessed by elevated serum alanine aminotransferase
severe renal impairment with serum creatinine indicative of egFr #30 (Cockcroft–gault equation)
Anemia (hb ,8.5 mmol/l for men, ,7.5 mmol/l for women) or electrolyte imbalance (na+, K+)
history of severe psychiatric disease prior to dementia onset
suicide risk (any attempts during the last year)
severe aggression (nPI-nh aggression item score $8, with aggression as the predominant symptom)
severe pain (MOBID-2 $8)
Uncontrolled epilepsy
Contraindication or clinically significant drug interaction to the assigned study treatment
regular use of any opioid analgesic other than or exceeding buprenorphine 5 µg/hour
Cognitive impairment related to diagnoses other than Alzheimer’s disease, frontotemporal dementia, 
vascular dementia, dementia with lewy bodies, or mixed dementia
Abbreviations: CSDD, Cornell Scale for Depression in Dementia; eGFR, estimated glomerular filtration rate; MMSE, Mini-Mental State Examination; MOBID-2, Mobilization-
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about known possible adverse effects of buprenorphine. They 
were instructed to pay attention to and report changes in any 
of the symptoms listed as potential adverse events, as well 
as any other clinical changes that occurred during treatment. 
If any clinical changes were observed during treatment, the 
raters were instructed to contact the researchers by phone 
immediately to report the symptoms. This information was 
distributed to other staff members, along with instructions 
to contact the researchers by phone immediately upon 
suspicion of any adverse event. In addition, the research-
ers asked specifically whether any adverse events were 
suspected at other contacts with the nursing home staff and 
during scheduled follow-up at 6 and 13 weeks of treatment. 
All suspected adverse events, irrespective of whether the 
patient discontinued treatment, were recorded verbatim as 
reported by nursing home staff, in as much detail as possible, 
including information about time from initiation to presenting 
symptoms and discontinuation of treatment.
Demographic information and a complete list of sched-
uled drug prescriptions (excluding prescriptions given pro re 
nata, ie, “as needed”) were extracted from the patients’ 
medical records at baseline. The total number of scheduled 
drug prescriptions was counted. Analgesic use was assessed 
by counting the number of prescriptions for drugs classified as 
systemic analgesics (Anatomical Therapeutic Chemical 
[ATC] code N02 or M01A). In addition, the individual 
and total numbers of scheduled psychotropic drugs were 
counted (antidepressants [N06A], anti-dementia [N06D], 
antipsychotic [N05A], anxiolytic [N05B], hypnotic and 
sedative [N05C], and antiepileptic [N03A] drugs). The total 
anticholinergic cognitive burden (ACB) was calculated by 
assigning 1 point for each prescribed drug with mild anti-
cholinergic properties, 2 points for each drug with moderate 
anticholinergic effects, and 3 points for each drug with strong 
anticholinergic properties.19,20 Between-group differences 
in drug use and morbidity at baseline were assessed by 
counting the number of prescriptions for drugs within each 
ATC group (A–V).
Activity was assessed by actigraphy registration using 
the Philips Actiwatch Spectrum, which was worn on the 
patients’ dominant or mobile wrist continuously for 14 days 
(7 days before and 7 days after treatment was started).21,22 
Total activity counts per day (Total AC) and mean intensity 
of activity per minute (AC/minute) for daily 12-hour intervals 
(09:00–21:00) were extracted from the Respironics Actiware 
6.0.9 software. Mean activity counts for Total AC and 
AC/minute were calculated for both 7-day periods in all patients 
with at least 5 valid days of actigraphy recording per week.
Cognitive function was assessed using the MMSE, a 
30-item questionnaire administered directly to the patient cov-
ering 11 domains (registration, orientation to time and place, 
short-term recall, attention, calculation, long-term recall, 
naming, repetition, comprehension [verbal and written], 
writing, and visuospatial construction) to yield a sum score 
from 0 (most severe impairment) to 30 (no impairment).23,24
Pain was assessed using the Mobilization-Observation-
Behavior-Intensity-Dementia-2 Pain Scale (MOBID-2), 
a two-part staff-administered instrument to assess pain in 
people with advanced dementia.25 The proxy evaluation of 
inferred pain intensity is based on the patient’s pain behaviors 
during standardized, guided movements of different body 
parts (Part 1), and pain behaviors that might be related to 
internal organs, head, and skin are recorded on an anatomical 
figure along with the inferred pain intensity for each region to 
allow monitoring over time (Part 2). The scale yields a final 
score from 0 (no pain) to 10 (worst pain imaginable). Good 
interrater and test–retest reliability, internal consistency, and 
validity have been shown, and the MOBID-2 scale has also 
demonstrated responsiveness to change.25
Depressive symptoms were assessed using the CSDD, 
which is a validated and widely used screening tool for depres-
sion in people with dementia.26 It is administered by an inter-
view with a proxy rater who is familiar with the patient, and 
it contains 19 items in five domains (mood-related signs, 
behavioral disturbance, physical signs, cyclic functions, and 
ideational disturbance). Each item is rated from 0 (no symp-
tom) to 2 (severe symptoms) to yield a sum score of between 
0 (no depression) and 38 (most severe depression).26
The main outcome measure was time to discontinuation 
of treatment due to adverse events. Secondary outcome 
measures were reasons for discontinuation, and change in 
total daytime activity and mean intensity of daily activity as 
measured by actigraphy recording.
sample size calculation
The DEP.PAIN.DEM trial was designed to obtain 90% power 
to detect a 2-point CSDD difference between active treatment 
(acetaminophen or buprenorphine) and identical placebo, 
with an SD of 5, a standardized effect size of 0.4, p,0.05. 
The sample size was calculated using a sample size formula 
for longitudinal continuous response, adjusted for within-
subject correlation between repeated measurements which 
was estimated to be 0.25 using data from the first 113 patients. 
One hundred thirty-two participants (66 in each group) were 
required, and adjusting for 20% dropouts, our final aim was 
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Baseline characteristics were described as mean and standard 
deviation for continuous variables, and with the number of 
patients and percentages of the sample size for categorical 
variables. Between-group differences were tested using 
independent-samples t-test for continuous variables with 
normal distribution; Mann-Whitney U-test for continuous 
variables with non-normal distribution; and Pearson’s χ2 test 
for categorical variables. We used a Kaplan–Meier survival 
plot and Cox regression models to determine whether patients 
who were randomized to receive active buprenorphine had a 
higher risk of discontinuation compared to those who received 
placebo. Cox regression analyses were repeated with age, sex, 
and MOBID-2, CSDD, and MMSE as covariates to determine 
which variables should be included in the adjusted analyses. 
To further assess whether the risk of discontinuation of active 
buprenorphine was modified by drug use, we tested the interac-
tion between the treatment effect and each of the drug variables 
(total number of prescribed drugs, ACB score, total number of 
psychotropic drugs, and use of each class of psychotropic drugs 
[N06A, N06D, N05A, N05B, N05C, N03A]) on discontinua-
tion, both unadjusted and adjusted for age, sex, and MOBID-2, 
CSDD, and/or MMSE at baseline if these covariates impacted 
discontinuation risk. We used cluster-robust variance estimates 
to account for dependence within nursing homes. To assess 
immediate changes in daytime activity during the early days 
of treatment, we used linear mixed-effects models for Total 
AC and AC/minute/day using the mean recording from the 
7 days before treatment was initiated as baseline. Time was 
included as a categorical variable, with fixed effects for time, 
intervention, and their interaction in the models. The models 
were fitted with random intercepts for patients to account for 
correlation between longitudinal measurements, random slope 
for time, and residual error structure specified as independent 
by day. We regarded p,0.05 as significant. All statistical 
analyses were conducted with STATA/IC 15 (Stata Corp LP, 
College Station, TX, USA).
Results
In total, 162 patients were included in the DEP.PAIN.DEM 
trial: 73 were prescribed acetaminophen/placebo tablets, and 
89 patients were prescribed buprenorphine/placebo TDS and 
included in the current study. In the latter group, 44 were 
allocated to active treatment (hereafter, “active group”), and 
45 to placebo (hereafter, “placebo group”; see Figure 1). 
Characteristics of the included patients at baseline are shown in 
Table 2. The groups were comparable at baseline on all tested 
variables except that the active group received more drugs 
in ATC group M (seven patients in active treatment and one 
patient in placebo; p=0.025), and the placebo group received 
more drugs in ATC group N (mean number of prescriptions 
2.2 [SD 1.6] in the active group and 3.2 [SD 1.7] in the placebo 
group; p=0.001). From the latter ATC group, use of antidepres-
sants and total number of psychotropic drugs were significantly 
higher in the placebo group; we also found significantly higher 
ACB in the placebo group (Table 2). Fifteen patients used 
buprenorphine TDS 5 µg/hour prior to inclusion, eight of 
whom were allocated to receive active treatment.
Frequency and types of adverse events
All adverse events recorded are presented in Table 3. Because 
each patient may have had more than one adverse event of 
each type, the number of adverse events may not correspond 
to the number of patients affected unless specified. Psychiatric 
adverse events were reported most frequently, with 17 sepa-
rate adverse effects recorded in the active treatment group 
and none in the placebo group (p=0.003). Of psychiatric 
symptoms, personality changes (ie, changed emotional labil-
ity or other behavioral changes described as such) were the 
most frequent, reported in eight patients (18.2%), followed 
by confusion reported in five patients (11.4%). Neurological 
adverse events were the second most commonly reported, 
with 11 adverse effects recorded in the active treatment group 
and 2 in the placebo group (p=0.039). The most frequent neu-
rological adverse event and the single most frequent adverse 
symptom was sedation/somnolence, which was reported in 
nine patients (20.5%) receiving active treatment and two 
patients receiving placebo (4.4%, p=0.022).
rates and causes of discontinuation
Buprenorphine TDS active treatment was discontinued in 
23 patients (52.3%) due to adverse events, compared with 
6 patients (13.3%) in the placebo group (p,0.001). Mean 
time to discontinuation was 61 days (SD 36) in the active 
treatment group and 82 days (SD 24) in the placebo group. 
Within the first 14 days, nine patients (20.5%) discontinued 
active treatment, and two patients (4.4%) discontinued 
placebo. Nearly half of patients who did not tolerate active 
treatment reported several types of adverse events (Table 4). 
Psychiatric adverse events were the most frequent cause of 
discontinuation reported in 12 of 23 patients (52%). Neuro-
logical adverse events were the second most frequent cause 
of discontinuation reported in nine patients (39%), five of 
whom also had psychiatric symptoms.
Kaplan–Meier estimates of time to discontinuation are 
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to receive active buprenorphine
45 randomly allocated

























2,015 did not meet primary eligibility criteria
562 used opioid analgesics
895 did not have depression (CSDD <8)
139 did not have dementia (MMSE >20)
14 had changes in analgesic or antidepressant treatment
56 had life expectancy <6 months
14 had contraindication or allergy to study treatment
65 had psychiatric disorder which warranted exclusion
99 had blood test indicative of renal/hepatic failure and/or electrolyte imbalance/anemia
54 died prior to enrolment
87 had short-term placement or moved
30 aged <60 years
137 did not consent
9 were excluded for other reasons/reasons not recorded
Figure 1 Trial profile.
Abbreviations: CsDD, Cornell scale for Depression in Dementia; MMse, Mini-Mental state examination; nh, nursing home; TDs, transdermal system.








Agea 85.8 (7.2) 85.6 (8.5) 86.0 (5.9) 0.782
sex (female)b 67 (75.3%) 33 (75.0%) 34 (75.6%) 0.952
MMsea 7.0 (6.1) 6.8 (5.6) 7.3 (6.5) 0.737
MOBID-2a 3.1 (1.9) 2.7 (1.8) 3.5 (2.0) 0.095
CsDDa 10.9 (3.4) 10.3 (2.4) 11.5 (4.1) 0.099
Analgesicsb (n02/M01A) 78 (87.6%) 37 (84.1%) 41 (91.1%) 0.314
Antidepressantsb (n06A) 41 (46.1%) 14 (31.8%) 27 (60.0%) 0.008
Antipsychoticsb (n05A) 20 (22.5%) 8 (18.2%) 12 (26.7%) 0.338
Anti-dementia drugsb (n06D) 17 (19.1%) 5 (11.4%) 12 (26.7%) 0.066
Anxiolyticsb (n05B) 24 (27.0%) 9 (20.5%) 15 (33.3%) 0.171
Antiepilepticsb (n03A) 9 (10.1%) 5 (11.4%) 4 (8.9%) 0.699
sedatives/hypnoticsb (n05C) 26 (29.2%) 9 (20.5%) 17 (37.8%) 0.072
Total number of psychotropicsc 1.6 (1.3) 1.2 (1.1) 1.9 (1.3) 0.007
Anticholinergic drugsc (ACB) 1.4 (1.5) 0.9 (1.3) 1.8 (2.8) 0.014
Total number of drugsa 6.7 (3.0) 6.4 (3.5) 7.1 (2.5) 0.262
Notes: numbers represent mean (sD) or number of patients (%). aIndependent samples t-test. bPearson’s χ2-test. cMann–Whitney U-test.
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Patients with reported 
adverse reactionsb
25 (56.8%) 8 (17.8%) ,0.001
Patients who 
discontinued treatment
23 (52.3%) 6 (13.3%) ,0.001
neurological 11 2 0.039
sedation/somnolence 9 (20.5%) 2 (4.4%) 0.022
seizure 1 (2.3%) – 0.309
loss of coordination 1 (2.3%) – 0.309
Psychiatric 17 – 0.003
Personality changes 8 (18.2%) – 0.003
Anxiety 1 (2.3%) – 0.309
Agitation 2 (4.5%) – 0.148
Confusion 5 (11.4%) – 0.020
hallucinations 1 (2.3%) – 0.309
gastrointestinal 6 – 0.117
Dry mouth 1 (2.3%) – 0.309
nausea 3 (6.8%) – 0.075
Vomiting 1 (2.3%) – 0.309
Anorexia 1 (2.3%) – 0.309
Dermatological
Application site rash – 1 (2.2%) 0.320
Other 8 2 0.204
Fall 4 (9.1%) 1 (2.2%) 0.159
Fracture 1 (2.3%) 1 (2.2%) 0.987
respiratory tract 
infection
1 (2.3%) – 0.309
hospitalization 2 (4.5%) – 0.148
Deterioration/death 6 (13.6%) 4 (8.9%) 0.478
Notes: Bold figures indicate significantly different prevalence rates (p,0.05). 
aPearson’s χ2-test. beach patient may have had more than one reaction.
Table 4 symptom combinations reported in the 23 patients who discontinued active buprenorphine due to adverse events
























received active treatment had 4.7 times higher risk of dis-
continuation compared with those who received placebo 
(Table 5; Cox proportional hazards model, unadjusted 
HR, 95% CI: 1.66–13.3, p=0.004). Adjusted for age, sex, 
MOBID-2, CSDD, and MMSE at baseline, active treatment 
was associated with 24.0 times higher risk of discontinuation 
(95% CI: 2.45–235, p=0.006). In this model, age, sex, depres-
sive symptoms, and pain were not significantly associated 
with discontinuation (age: HR 1.0, 95% CI: 0.99–1.11, 
p=0.133; sex: HR 0.32, 95% CI: 0.10–1.58, p=0.149; CSDD: 
HR 1.1, 95% CI: 0.90–1.34, p=0.343; MOBID-2: HR 1.1, 
95% CI: 0.91–1.45, p=0.246). Lower MMSE scores were 
associated with increased risk of discontinuation (HR 0.82, 
95% CI: 0.71–0.94, p=0.005), but interaction effects of 
MMSE score were tested in a new model and were not signifi-
cant, that is, patients who received active treatment were not 
at increased risk of discontinuation if they had lower MMSE 
scores (HR 1.04, 95% CI: 0.82–1.31, p=0.767).
Drug use and rates of discontinuation
Total number of prescribed drugs, ACB score, total 
number of psychotropic drugs, and use of any individual 
psychotropic drug (N06A, N06D, N05A, N05B, N05C, or 
N03A; dichotomized) were all not independently associ-
ated with discontinuation of the study treatment (active or 
placebo). However, patients who received active treatment 
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discontinuation compared with patients who used antidepres-
sants and received placebo (95% CI: 2.75–170, p=0.003; 
Table 5). The interaction between active buprenorphine 
and antidepressant use remained unchanged when adjusting 
for age, sex, and MMSE (HR 23.2, 95% CI: 2.95–182, 
p=0.003). In this model, active buprenorphine was not sig-
nificantly associated with increased risk of discontinuation in 
patients who did not use antidepressants (HR 2.95, 95% CI: 
0.53–16.6, p=0.218), as shown in Figure 3 (Table 5). Interac-
tion effects were calculated separately for each variable for 
drug use, and none except antidepressant use had significant 
interactions with active buprenorphine.
Although patients who used antidepressants and received 
active treatment had significantly increased risk of discon-
tinuation, we were not able to detect any significant differ-
ence in the total number of adverse events and treatment 
discontinuations compared with those who did not use anti-
depressants. Nine of the 14 patients (64.3%) who received 
active treatment and used antidepressants reported adverse 
events and discontinued treatment. Of the 30 patients who 
received active treatment and did not use antidepressants, 16 
(53.3%) reported adverse events and 14 (46.7%) discontinued 
treatment. Using χ2-tests, the rates of adverse events and 
discontinuation in patients who received active treatment and 
used antidepressants were compared to those who did not 
use antidepressants (groups defined by the number of pre-
scriptions for antidepressants at baseline), but no significant 
differences were found (p=0.599 and 0.419, respectively). 
We did not find that patients who used antidepressants 
reported any single type of adverse event more frequently, 
except confusion which was reported in three patients who 
used antidepressants (21.4%) and two patients who did not 
use antidepressants (6.7%, p=0.013, χ2-test).
Changes in activity during the first week 
of treatment
Day-to-day activity counts in the first week of treatment, 
measured by actigraphy, are shown in Figure 4 with the 
Figure 2 Kaplan–Meier survival plot: duration of study treatment.
Table 5 estimated treatment effect of buprenorphine versus 
placebo on discontinuation (Cox regression)
N HR (95% CI) p-value
Unadjusted 89 4.70 (1.66–13.3) 0.004
Model 1a 76 7.19 (1.65–31.3) 0.009
Model 2b 65 24.0 (2.45–235) 0.006
Modified by antidepressantsc
no antidepressants 89 1.88 (0.63–5.64) 0.257
Antidepressants 89 21.6 (2.75–170) 0.003
Modified by antidepressantsa
no antidepressants 76 2.95 (0.53–16.6) 0.218
Antidepressants 76 23.2 (2.95–182) 0.003
Notes: Modified analyses include interaction effects. aAdjusted for age, sex, and 
cognition (MMse). bAdjusted for age, sex, cognition (MMse), pain (MOBID-2), and 
depression (CsDD). cUnadjusted.
Abbreviations: CsDD, Cornell scale for Depression in Dementia; MMse, Mini-
Mental state examination; MOBID-2, Mobilization-Observation-Behavior-Intensity-
Dementia-2 Pain scale.
Figure 3 Cox proportional hazard plot: discontinuation risk stratified on treatment 
allocation and antidepressant use.
Abbreviation: n06A, Antidepressant.
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Placebo Buprenorphine
Figure 4 Daytime activity during the first week of study treatment.
Notes: Actigraphy recording of total activity from 09:00 to 21:00 hours daily. 
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mean activity counts during the week before treatment 
started as the baseline activity score. Patients who received 
active treatment had significantly reduced daytime activity 
on day 2 of treatment compared with placebo (mixed model; 
Total AC: −16,967, p=0.005). This corresponds to a 21.4% 
decrease in total daytime activity in those who received 
active treatment. Comparing the mean daytime activity in 
the first week of treatment with baseline activity, we found 
that active treatment was associated with a 12.9% decrease in 
mean Total AC, but this effect was not statistically significant 
(mixed model; p=0.053).
Discussion
To our knowledge, this is the first placebo-controlled study 
investigating the tolerability and observed adverse events of 
buprenorphine TDS in nursing home patients with moder-
ate to severe dementia. Patients who used antidepressants 
and received active treatment had the highest risk of dis-
continuation; this suggests a clinically relevant interaction 
between antidepressants and buprenorphine in people with 
dementia. Buprenorphine significantly reduced daytime 
activity as measured by actigraphy on the second day of 
treatment compared with placebo, supporting reports from 
nursing home staff of increased sedation/somnolence as 
the most frequent adverse effect. The poor tolerability of 
buprenorphine TDS due to the high risk of neurological and 
psychiatric adverse events should be considered carefully by 
clinicians before prescribing to people with dementia, and 
particularly to patients who are also using antidepressants, 
which may further reduce tolerability. This study does not 
assess the efficacy of buprenorphine TDS for treating dif-
ferent types of pain in dementia, which should be addressed 
in future research.
In the active treatment group, 57% had reported adverse 
events. A recent meta-analysis of six randomized controlled 
studies (five were placebo controlled) found that 82% of 
elderly patients ($65) had adverse events of buprenorphine 
TDS.27 The lower rate of reported adverse events in our 
study can most likely be attributed to our reliance on proxy 
observations of adverse events. Although self-report of symp-
toms is considered the gold standard, people with advanced 
dementia often have impaired ability to reliably report their 
symptom burden. For example, less than half of patients 
with MMSE #6 are able to comprehend any assessment 
scale used to self-report painful symptoms.28 In our study, 
mean MMSE was 7 at baseline; therefore, many could not 
self-report adverse effects of buprenorphine TDS. Mild 
adverse effects of buprenorphine are subjective, they may 
not be easily observable, and subtle changes such as reduced 
appetite, confusion, or agitation could be misinterpreted as 
neuropsychiatric symptoms in dementia which may not be 
attributed to study treatment by the proxy raters. Because 
people with communication difficulty due to advanced 
dementia cannot be expected to reliably self-report mild 
adverse events, the true prevalence of adverse events is likely 
to have been underestimated in our study due to observer bias. 
Therefore, this should be interpreted as a tolerability study 
presenting adverse events associated with discontinuation 
of treatment, rather than the absolute frequency of adverse 
events in people with dementia.
Although very frail patients with short life expectancy 
were not included in the trial, sudden clinical deterioration 
is difficult to predict and must be expected to occur during 
an extended follow-up period in nursing home patients with 
advanced dementia, regardless of exposure to a clinical 
intervention. The number of patients who were withdrawn 
from the study because of severe clinical deterioration with 
short life expectancy did not differ significantly between 
the active treatment and placebo groups, and our sample 
size and follow-up period were not designed to investigate 
whether buprenorphine use may be associated with increased 
mortality. Adverse events were registered on suspicion, based 
on detailed reports of clinical changes from nursing home 
staff. Even though we did not assess the likelihood of causality 
between the study treatment and each reported adverse event, 
we conclude that the difference in the total number of adverse 
events between active treatment and placebo can likely be 
attributed to adverse effects of buprenorphine.
Previous studies indicate that buprenorphine TDS is 
well tolerated in elderly patients, with studies reporting 
similar or lower rates of adverse events in healthy elderly 
patients compared with younger controls.29–31 In elderly 
patients without dementia, the most common adverse events 
associated with discontinuation of buprenorphine treatment 
are gastrointestinal – nausea (8.2%), vomiting (3.9%), and 
constipation (2.0%) – followed by neurological symptoms – 
dizziness (5.1%), somnolence (2.0%), and headache (2.0%).27 
In our study, psychiatric and neurological adverse effects 
were frequent, reported in 16 of patients who discontinued 
treatment (36.4%). Four patients (9.1%) who discontinued 
treatment had gastrointestinal symptoms. This indicates that 
psychiatric adverse events of buprenorphine may occur more 
frequently in people with dementia compared with cogni-
tively intact elderly patients. As buprenorphine has similar 
pharmacokinetic properties in elderly patients including those 
with renal impairment,29,32 this reduced tolerability is most 
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Buprenorphine TDS is absorbed slowly, and it reaches 
active concentration after ~24 hours and steady state during 
the first 72 hours in young healthy patients.35 Although phar-
macokinetics have not been investigated in the very old and 
frail, buprenorphine TDS appears to be absorbed at a similar 
rate in people aged $75 years compared to a younger con-
trol group.29 The largest drop in daytime activity observed 
in our study (recorded ~24–36 hours after administration) 
may therefore correspond to the first systemic exposure 
to buprenorphine. While the reduction in daytime activity 
during the first week of active treatment was not statistically 
significant, this was probably due to low sample size.
Depression is associated with the use of antidepressants 
in nursing home patients with dementia.17 Because depression 
was an inclusion criterion, we may have selected patients 
who used more antidepressants relative to other psycho-
tropic drugs. This may have enabled us to find a significant 
interaction between antidepressant use and buprenorphine 
discontinuation, while potential interactions between 
buprenorphine and other psychotropic drugs may have gone 
unnoticed. However, patients in the active treatment group 
generally used less psychotropic drugs compared with the 
placebo group and had a lower prevalence of antidepressant 
use (31.8%) than that expected from recent reports in people 
with dementia (~40%).36,37 Thus, the observed interaction 
between antidepressants and buprenorphine is likely to be 
of clinical relevance. While we did not find significant inter-
action effects between other psychotropic drugs and active 
buprenorphine, this may be due to insufficient power rather 
than the absence of such effects.
As shown in two recent studies, the use of opioid anal-
gesics in the oldest nursing home patients with dementia is 
increasing.7,9 Age is associated with increased pain, frailty, 
and dementia. In patients with severe pain, or very frail 
patients, it may be difficult to achieve full analgesic effect 
as the type or dose of analgesics required may not be toler-
ated by the patient. Because patients with dementia have not 
been included in safety studies, the evidence base to ensure 
appropriate prescribing is lacking. In the DEP.PAIN.DEM 
trial, neither did we find a significant change in pain intensity 
in either of the buprenorphine or placebo TDS groups dur-
ing follow-up, nor did we find a significant treatment effect 
on pain between these groups.39 However, this may be due 
to insufficient sample size as the DEP.PAIN.DEM trial was 
not powered to assess the effect of buprenorphine on pain. 
Further studies should investigate the efficacy and tolerability 
of buprenorphine and other opioid analgesics for pain in 
nursing home patients with dementia and painful symptoms. 
Use of opioids in people with dementia should be based on a 
careful risk–benefit evaluation, including regular assessments 
of pain and potential adverse effects, in combination with 
nonpharmacological strategies as appropriate.34
This study has limitations. The included patients had clini-
cally significant depressive symptoms at baseline, but not all 
had pain. Therefore, our results may not be generalizable to 
patients who receive buprenorphine for pain. Prescribers may 
have had a lower threshold for discontinuation upon adverse 
events in this study, for instance, the risk–benefit consider-
ation may have been shifted toward a greater awareness of 
adverse events as the treatment was prescribed off-label. 
The patients’ level of vulnerability to adverse events, and 
the relative prevalence of different types of adverse events, 
may also be different in people with advanced dementia 
and severe pain as opposed to the current sample which 
consisted of people with advanced dementia and depres-
sion without severe pain. Similarly, the adverse effects of 
buprenorphine TDS may differ between subgroups of pain 
patients (neuropathic/nociceptive; acute/chronic pain). Since 
the focus of the DEP.PAIN.DEM trial was to investigate the 
efficacy of pain treatment on depression, we did not diag-
nose the type and duration of pain. Therefore, future studies 
should investigate the safety and efficacy of buprenorphine 
TDS in people with dementia and different types of pain. 
Patients who were prescribed buprenorphine rather than acet-
aminophen used more regular analgesics and/or had difficulty 
swallowing tablets. This means that we may have selected 
more frail/multimorbid patients to receive buprenorphine/
placebo as opposed to acetaminophen/placebo in the DEP.
PAIN.DEM trial. However, this prescribing strategy mirrors 
clinical practice with a stepwise increase from non-opioid 
to opioid analgesics and the choice of transdermal formu-
lation for patients who cannot swallow tablets; therefore, 
our sample should be similar to nursing home patients with 
dementia who receive buprenorphine TDS. We included a 
mixture of opioid-naïve patients, patients who had previously 
discontinued or received sporadic as-needed treatment with 
an opioid, and patients who received ongoing buprenorphine 
treatment; this is likely to have affected the observed pattern 
of adverse events which is not representative of an opioid-
naïve population. Despite randomization, we found that 
patients who received active treatment used significantly 
less psychotropic and anticholinergic drugs, and fewer used 
antidepressants. This could potentially influence the results, 
as these drugs are associated with adverse outcomes in 
people with dementia.38 However, because these drugs were 
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adverse events in the active treatment group is likely caused 
by buprenorphine. We have not controlled for changes in 
concomitant drug use during study treatment. Physicians 
were instructed to avoid changes, particularly to psychotropic 
and analgesic drugs, but drug changes were not assessed in 
the 17 patients who discontinued treatment before week 6 
assessment. The DEP.PAIN.DEM trial was designed with 
90% power to detect a 2-point difference in depression 
(CSDD) from baseline to 13-week follow-up between active 
treatment (acetaminophen or buprenorphine) and placebo.39 
For the secondary outcomes reported in the present study, 
no a priori power analyses have been conducted. This is an 
important limitation, and the findings from the current analy-
ses should therefore be interpreted with caution, in particular 
for the subgroup analyses with lower sample sizes. Because 
the estimated effect sizes have very wide CIs, the exact 
magnitude of increased risk remains uncertain. However, 
we have identified significant between-group differences in 
reported adverse events and discontinuation risk. Although 
adverse events were assessed by proxy, and are therefore 
likely to be affected by observer bias, the placebo-controlled 
design provides strong evidence that the difference in adverse 
events is caused by the active drug rather than observer bias. 
Therefore, we find it important to share the presented results. 
Further studies are needed to provide evidence of the safety 
and efficacy of transdermal buprenorphine for different types 
of pain in people with dementia.
Conclusion
Buprenorphine appears to be poorly tolerated in people with 
dementia, with a higher prevalence of psychiatric adverse 
events compared with previous studies in cognitively 
intact elderly patients. Initiation of buprenorphine therapy 
is associated with reduced daytime activity. Although no 
dose adjustment is recommended for buprenorphine in 
elderly patients, our data suggest that people with dementia 
are susceptible to adverse events even at the lowest initial 
dose. When buprenorphine is administered to people with 
dementia, the patients’ general condition pre- and posttreat-
ment should therefore be monitored carefully, including 
assessments of intended and adverse treatment effects, 
particularly in patients using antidepressants.
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